

CITATION REPORT

List of articles citing

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

DOI: 10.1056/nejmoa1615664

New England Journal of Medicine, 2017, 376, 1713-1722.

Source: <https://exaly.com/paper-pdf/66680864/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2269	Atherosclerosis: PCSK9 inhibition reduces cardiovascular events in high-risk patients. 2017 , 14, 251		1
2268	Targeting low-density lipoprotein cholesterol with PCSK9 inhibitors. 2017 , 47, 856-865		17
2267	Editorial commentary: Importance of triglycerides. 2017 , 27, 433-434		
2266	Genetics of Dyslipidemia and Ischemic Heart Disease. 2017 , 19, 46		13
2265	Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. 2017 , 38, 2459-2472		1267
2264	Phase 2 clinical trials with K-877 (pemafibrate): A promising selective PPAR- α modulator for treatment of combined dyslipidemia. 2017 , 261, 163-164		11
2263	Role of Non-Statins, LDL-C Thresholds, and Special Population Considerations: A Look at the Updated 2016 ACC Consensus Committee Recommendations. 2017 , 19, 29		11
2262	Protein-Truncating Variants at the Cholesteryl Ester Transfer Protein Gene and Risk for Coronary Heart Disease. 2017 , 121, 81-88		48
2261	AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE. 2017 , 23, 1-87		535
2260	PCSK9 inhibitors: smooth sailing or a little turbulence ahead?. 2017 , 5, 490-492		1
2259	New data on familial hypercholesterolaemia and acute coronary syndromes: The promise of PCSK9 monoclonal antibodies in the light of recent clinical trials. 2017 , 24, 1200-1205		10
2258	The Role of Emerging Risk Factors in Cardiovascular Outcomes. 2017 , 19, 28		28
2257	Why published studies of the cost-effectiveness of PCSK-9 inhibitors yielded such markedly different results. 2017 , 20, 749-751		5
2256	Do triglyceride-lowering drugs decrease risk of cardiovascular disease?. 2017 , 28, 374-379		9
2255	Dyslipidaemia: PCSK9 inhibitors and foamy monocytes in familial hypercholesterolaemia. 2017 , 14, 385-386		16
2254	Physiological and therapeutic regulation of PCSK9 activity in cardiovascular disease. 2017 , 112, 32		45
2253	High Serum PCSK9 Is Associated With Increased Risk of New-Onset Diabetes After Transplantation in Renal Transplant Recipients. 2017 , 40, 894-901		22

2252	Estimation of Eligibility for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Associated Costs Based on the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk): Insights From the Department of Veterans Affairs. 2017 , 135, 2572-2574	37
2251	Dyslipidaemia: The PCSK9 adventure - humanizing extreme LDL lowering. 2017 , 14, 319-320	2
2250	. 2017 , 159, 10-11	
2249	PCSK9 Inhibitors in Hyperlipidemia: Current Status and Clinical Outlook. 2017 , 31, 167-174	11
2248	Can iPCSK9-induced hypocholesterolemia starve cancer cells?. 2017 , 11, 600-601	3
2247	Access to Nonstatin Lipid-Lowering Therapies in Patients at High Risk of Atherosclerotic Cardiovascular Disease. 2017 , 135, 2204-2206	28
2246	Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors: Shaping the future after the further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER) trial. 2017 , 74, 43-46	16
2245	PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. 2017 , 4, CD011748	57
2244	Reduction of LDL-C-related residual cardiovascular risk with ezetimibe: are mechanistic considerations warranted in practice?. 2017 , 38, 2276-2278	1
2243	The economics of PCSK-9 inhibitors. 2017 , 189, 200-201	5
2242	Emerging biologic therapies for hypercholesterolaemia. 2017 , 17, 1077-1087	9
2241	Detection of atherosclerotic cardiovascular disease influences the perceived need for aggressive lipid management. 2017 , 263, 112-118	3
2240	Platelet lipidomics: a window of opportunity to assess cardiovascular risk?. 2017 , 38, 2006-2008	8
2239	2017 Position Paper of the Italian Society for Cardiovascular Prevention (SIPREC) for an Updated Clinical Management of Hypercholesterolemia and Cardiovascular Risk: Executive Document. 2017 , 24, 313-329	7
2238	Vaccination to prevent atherosclerotic cardiovascular diseases. 2017 , 38, 2508-2510	5
2237	PCSK9 Inhibitors Show Value for Patients and the US Health Care System. 2017 , 20, 1270-1278	4
2236	Translating Guidelines Into Practice: Interpreting the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statins Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk. 2017 , 51, 914-920	3
2235	Response letter: Management of statin-induced myopathies: Much demands and still (almost) empty hands!. 2017 , 8, 514-515	2

2234	Treatment of Dyslipidemia Using CRISPR/Cas9 Genome Editing. 2017 , 19, 32	6
2233	Pharmacologic approaches for the management of patients with moderately elevated triglycerides (150-499 mg/dL). 2017 , 11, 872-879	7
2232	Update on the use of PCSK9 inhibitors in adults: Recommendations from an Expert Panel of the National Lipid Association. 2017 , 11, 880-890	73
2231	Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides. <i>New England Journal of Medicine</i> , 2017 , 377, 222-232	59.2 345
2230	Barriers to PCSK9 inhibitor prescriptions for patients with high cardiovascular risk: Results of a healthcare provider survey conducted by the National Lipid Association. 2017 , 11, 891-900	34
2229	Interventions in type 2 diabetes mellitus and cardiovascular mortality-An overview of clinical trials. 2017 , 42, 1-15	6
2228	Beyond Statins: New Therapeutic Frontiers for Cardiovascular Disease. 2017 , 169, 971-973	4
2227	Mendelian randomization in cardiometabolic disease: challenges in evaluating causality. 2017 , 14, 577-590	245
2226	Prognostic impact of subclinical or manifest extracoronary artery diseases after acute myocardial infarction. 2017 , 263, 53-59	7
2225	Inhibition of PCSK9 does not improve lipopolysaccharide-induced mortality in mice. 2017 , 58, 1661-1669	30
2224	EAS 2017 Congress Prague highlights. 2017 , 263, 322-324	
2223	[Genetic testing in polygenic diseases : Atrial fibrillation, arterial hypertension and coronary artery disease]. 2017 , 42, 440-448	
2222	Vascular inflammation and low-density lipoproteins: is cholesterol the link? A lesson from the clinical trials. 2017 , 174, 3973-3985	80
2221	Attitudes and actions: A survey to assess statin use among Finnish patients with increased risk for cardiovascular events. 2017 , 11, 485-494	8
2220	Can LDL cholesterol be too low? Possible risks of extremely low levels. 2017 , 281, 534-553	41
2219	PCSK9 Inhibition to Reduce Cardiovascular Events. <i>New England Journal of Medicine</i> , 2017 , 376, 1790-1797	59.2 23
2218	Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol. <i>New England Journal of Medicine</i> , 2017 , 376, 1430-1440	59.2 507
2217	Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. A new drug class for the treatment of hypercholesterolemia. 2017 , 64, 341-344	

2216	The challenges of proprotein convertase subtilisin-kexin-9 inhibitors for lipid guidelines and models of care. 2017 , 28, 470-476	1
2215	Precision medicine to change the landscape of cardiovascular drug development. 2017 , 2, 337-343	
2214	Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy: Payer Approvals and Rejections, and Patient Characteristics for Successful Prescribing. 2017 , 136, 2210-2219	33
2213	The continuing challenge of familial hypercholesterolaemia. 2017 , 3, 253-255	1
2212	Long-term safety, tolerability, and efficacy of evolocumab in patients with heterozygous familial hypercholesterolemia. 2017 , 11, 1448-1457	32
2211	Triglyceride-lowering trials. 2017 , 28, 477-487	11
2210	Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). 2017 , 136, 2440-2450	67
2209	PCSK9 deficiency: A double-edged sword?. 2017 , 24, 1867-1869	0
2208	Association of Prior Authorization and Out-of-pocket Costs With Patient Access to PCSK9 Inhibitor Therapy. 2017 , 2, 1217-1225	61
2207	Insights into a PCSK9 structural groove: a harbinger of new drugs to reduce LDL-cholesterol. 2017 , 24, 785-786	5
2206	Genetics and molecular biology controversies on Mendelian randomization and proprotein convertase subtilisin-kexin type 9 inhibitor clinical trials: more data still necessary. 2017 , 28, 522-523	2
2205	Après l'étude FOURIER, quelle prise en charge de l'hypercholestérolémie?. 2017 , 2017, 9-13	
2204	L'hypercholestérolémie familiale : un diagnostic à ne pas manquer en cardiologie. 2017 , 2017, 14-18	
2203	Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition with Bococizumab on Lipoprotein Particles in Hypercholesterolemic Subjects. 2017 , 39, 2243-2259.e5	10
2202	Can pleiotropic effects of eicosapentaenoic acid (EPA) impact residual cardiovascular risk?. 2017 , 129, 822-827	19
2201	CETP Inhibitors - A New Inning?. <i>New England Journal of Medicine</i> , 2017 , 377, 1284-1285	59.2 22
2200	Treatment of Dyslipidemia in Diabetes: Recent Advances and Remaining Questions. 2017 , 17, 112	18
2199	Statin Discontinuation, Reinitiation, and Persistence Patterns Among Medicare Beneficiaries After Myocardial Infarction: A Cohort Study. 2017 , 10,	26

2198	Coronary Artery Calcium Scoring in Current Clinical Practice: How to Define Its Value?. 2017 , 19, 85	8
2197	Heterogeneity of atherosclerotic plaque macrophage origin, phenotype and functions: Implications for treatment. 2017 , 816, 14-24	21
2196	Targeting ATP-Citrate Lyase in Hyperlipidemia and Metabolic Disorders. 2017 , 23, 1047-1063	41
2195	Do Oxidized Lipoproteins Cause Atherosclerotic Cardiovascular Diseases?. 2017 , 33, 1513-1516	1
2194	The PCSK9-LDL Receptor Axis and Outcomes in Heart Failure: BIOSTAT-CHF Subanalysis. 2017 , 70, 2128-2136	24
2193	How Low to Go With Glucose, Cholesterol, and Blood Pressure in Primary Prevention of CVD. 2017 , 70, 2171-2185	39
2192	Relation of Low-Density Lipoprotein Cholesterol With Microvascular Injury and Clinical Outcome in Revascularized ST-Elevation Myocardial Infarction. 2017 , 6,	22
2191	PCSK9 Mutations in Familial Hypercholesterolemia: from a Groundbreaking Discovery to Anti-PCSK9 Therapies. 2017 , 19, 49	19
2190	The shape of things to come in lipid management: a feast of reason. 2017 , 28, 449-451	
2189	Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers: Insights Derived From the FOURIER Trial. 2017 , 2, 1369-1374	65
2188	Interleukin-1 Beta as a Target for Atherosclerosis Therapy: Biological Basis of CANTOS and Beyond. 2017 , 70, 2278-2289	293
2187	Functional diversity of macrophages in vascular biology and disease. 2017 , 99, 13-22	10
2186	Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial. 2017 , 318, 748-750	94
2185	Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease. 2017 , 2, 1069-1078	91
2184	Discovery of a cryptic peptide-binding site on PCSK9 and design of antagonists. 2017 , 24, 848-856	42
2183	Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. <i>New England Journal of Medicine</i> , 2017 , 377, 1119-1131	59.2 3877
2182	Carotid Artery Stenosis: Medical Therapy, Surgery, and Stenting. 2017 , 17, 77	38
2181	Heart disease: Putative medicines that mimic mutations. 2017 , 548, 530-531	3

2180	Evolocumab in Patients with Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2017 , 377, 787-8	59.2	21
2179	New perspectives on CKD-induced dyslipidemia. 2017 , 21, 967-976		21
2178	Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease. <i>New England Journal of Medicine</i> , 2017 , 377, 1217-1227	59.2	562
2177	Impact of protease inhibitors on circulating PCSK9 levels in HIV-infected antiretroviral-naive patients from an ongoing prospective cohort. 2017 , 31, 2367-2376		14
2176	Strategies for the use of nonstatin therapies. 2017 , 28, 458-464		2
2175	Inflammation and Atherosclerosis: The End of a Controversy. 2017 , 136, 1875-1877		71
2174	New insights into the role of glycosylation in lipoprotein metabolism. 2017 , 28, 502-506		10
2173	Impact of evolocumab treatment on low-density lipoprotein cholesterol levels in heterozygous familial hypercholesterolemic patients withdrawing from regular apheresis. 2017 , 265, 225-230		16
2172	Incorporation of PCSK9 inhibitors into prevention of atherosclerotic cardiovascular disease. 2017 , 129, 801-810		1
2171	Novel treatment options for the management of heterozygous familial hypercholesterolemia. 2017 , 10, 1375-1381		12
2170	Exploration of PCSK9 as a Cardiovascular Risk Factor: Is There a Link to the Platelet?. 2017 , 70, 1463-1466		8
2169	The renaissance of lipoprotein(a): Brave new world for preventive cardiology?. 2017 , 68, 57-82		46
2168	Nationwide Coverage and Cost-Sharing for PCSK9 Inhibitors Among Medicare Part D Plans. 2017 , 2, 1164-1166		14
2167	Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. 2017 , 5, 941-950		330
2166	PCSK9 inhibition and type 2 diabetes. 2017 , 5, 926-927		1
2165	Dyslipidemia. 2017 , 2, 633-650		2
2164	Circulating PCSK9 levels in acute coronary syndrome: Results from the PC-SCA-9 prospective study. 2017 , 43, 529-535		16
2163	New approaches to address dyslipidemia. 2017 , 28, 452-457		15

2162	The maturation of a 'neural-hematopoietic' inflammatory axis in cardiovascular disease. 2017 , 28, 507-512	6
2161	Implications of GLAGOV study. 2017 , 28, 465-469	6
2160	Optimal Target Level of Low-density Lipoprotein Cholesterol for Vascular Function in Statin Naïve Individuals. 2017 , 7, 8422	9
2159	Is atherosclerosis imaging the most sensitive way to assess patients' risk and the best way to conduct future drug trials? A pros-and-cons debate. 2017 , 266, 229-233	3
2158	Reducing the Global Burden of Cardiovascular Disease, Part 1: The Epidemiology and Risk Factors. 2017 , 121, 677-694	365
2157	Reducing the Global Burden of Cardiovascular Disease, Part 2: Prevention and Treatment of Cardiovascular Disease. 2017 , 121, 695-710	134
2156	Potential Role of Thyroid Receptor Agonists in the Treatment of Hyperlipidemia. 2017 , 77, 1613-1621	11
2155	Recent perspectives on the role of nutraceuticals as cholesterol-lowering agents. 2017 , 28, 495-501	27
2154	2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. 2017 , 70, 1785-1822	247
2153	Time for new low density lipoprotein cholesterol (LDL-C) targets?. 2017 , 18, 1539-1541	2
2152	Recent Insights into Pharmacologic Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus. 2017 , 31, 459-470	2
2151	Practical Considerations for the Use of Subcutaneous Treatment in the Management of Dyslipidaemia. 2017 , 34, 1876-1896	8
2150	Hepatitis C virus and proprotein convertase subtilisin/kexin type 9: a detrimental interaction to increase viral infectivity and disrupt lipid metabolism. 2017 , 21, 3150-3161	13
2149	The evolving model of care for familial hypercholesterolaemia. 2017 , 24, 1729-1732	3
2148	Prognostic value of electrocardiogram exercise testing for risk stratification in asymptomatic coronary artery disease. 2017 , 28, 664-669	3
2147	Treatment strategies for comorbid conditions lower residual risk in patients with treated hypertension: FOURIER and other randomized outcome trials. 2017 , 26, 257-258	1
2146	Atherogenic Lipoprotein Determinants of Cardiovascular Disease and Residual Risk Among Individuals With Low Low-Density Lipoprotein Cholesterol. 2017 , 6,	70
2145	Inconsistent Guideline Recommendations for Cardiovascular Prevention and the Debate About Zeroing in on and Zeroing LDL-C Levels With PCSK9 Inhibitors. 2017 , 318, 419-420	8

2144	Navigating the Future of Cardiovascular Drug Development-Leveraging Novel Approaches to Drive Innovation and Drug Discovery: Summary of Findings from the Novel Cardiovascular Therapeutics Conference. 2017 , 31, 445-458	6
2143	Diabetes Update 2017 <i>Lipide</i> . 2017 , 13, 313-321	1
2142	2016 Guidelines for the management of dyslipidemia and the prevention of cardiovascular disease in adults by pharmacists. 2017 , 150, 243-250	5
2141	Efficacy and Safety of Alirocumab Versus Ezetimibe Over 2 Years (from ODYSSEY COMBO II). 2017 , 120, 931-939	20
2140	Diabetes-Related Dyslipidemia and Cardiovascular Events. 2017 , 354, 103-104	2
2139	Lipoprotein(a)-apheresis in the light of new drug developments. 2017 , 30, 38-43	12
2138	History of lipidology and lipoprotein apheresis. 2017 , 30, 1-8	16
2137	Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. A new drug class for the treatment of hypercholesterolemia. 2017 , 64, 341-344	1
2136	The FOURIER study: The profound study of Nature is the most fertile source of discovery. 2017 , 58, 146-147	1
2135	A case of hypocholesterolemia and steatosis in a carrier of a PCSK9 loss-of-function mutation and polymorphisms predisposing to nonalcoholic fatty liver disease. 2017 , 11, 1101-1105	6
2134	Lipidological competence centres and networks: Future perspectives to improve healthcare of patients with disorders of lipid metabolism. 2017 , 30, 63-71	2
2133	Anti-PCSK9 antibodies for hypercholesterolaemia: Overview of clinical data and implications for primary care. 2017 , 71, e12979	8
2132	Residual Risk After Treatment of Patients With Atherosclerotic Cardiovascular Disease With Proprotein Convertase Subtilisin-Kexin Type 9 Monoclonal Antibody Therapy (from the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Trial). 2017 , 120, 1220-1222	2
2131	Atherosclerosis and inflammation. Clinical aspects of a modern tale. 2017 , 58, 122-123	7
2130	Statin Intolerance and the Obsession With Aggressive Cholesterol Lowering to Prevent Coronary Heart Disease. 2017 , 70, 684	
2129	Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease. 2017 , 2, 959-966	77
2128	Rapidly progressive atherosclerosis after domino liver transplantation from a teenage donor with homozygous familial hypercholesterolemia. 2017 , 11, 1284-1288	6
2127	Revisiting Outcomes-Based Pricing Propositions for the PCSK9 Inhibitor Evolocumab. 2017 , 177, 1388-1390	6

2126	Implications of Coronary Artery Calcium Testing for Treatment Decisions Among Statin Candidates According to the ACC/AHA Cholesterol Management Guidelines: A Cost-Effectiveness Analysis. 2017 , 10, 938-952	52
2125	[Dyslipidemias : Diagnostics and management]. 2017 , 42, 607-620	
2124	Effect of the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Evolocumab on Glycemia, Body Weight, and New-Onset Diabetes Mellitus. 2017 , 120, 1521-1527	29
2123	Cognitive Function in a Randomized Trial of Evolocumab. <i>New England Journal of Medicine</i> , 2017 , 377, 633-643	59.2 263
2122	Evolocumab for the treatment of hypercholesterolemia. 2017 , 17, 1447-1461	2
2121	Application of PCSK9 Inhibitors in Practice: Challenges and Opportunities. 2017 , 121, 499-501	22
2120	Cholesterol Management in the Era of PCSK9 Inhibitors. 2017 , 19, 83	4
2119	Diversity and inclusion in genomic research: why the uneven progress?. 2017 , 8, 255-266	146
2118	Evolocumab to reduce cardiovascular events: results of the (FOURIER) multinational trial. 2017 , 7, 199-200	10
2117	Time to ditch HDL-C as a measure of HDL function?. 2017 , 28, 414-418	31
2116	Normal LDL-Cholesterol Levels Are Associated With Subclinical Atherosclerosis in the Absence of Risk Factors. 2017 , 70, 2979-2991	153
2115	Primary Prevention of Atherosclerosis: Time to Take a Selfie?. 2017 , 70, 2992-2994	14
2114	Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta-Analysis of 35 Randomized Controlled Trials. 2017 , 6,	96
2113	Target achievement with maximal statin-based lipid-lowering therapy in Korean patients with familial hypercholesterolemia: A study supported by the Korean Society of Lipid and Atherosclerosis. 2017 , 40, 1291-1296	7
2112	Guía ESC 2017 sobre el tratamiento del infarto agudo de miocardio en pacientes con elevación del segmento ST. 2017 , 70, 1082.e1-1082.e61	35
2111	Recognition, diagnosis and treatment of homozygous familial hypercholesterolemia. 2017 , 5, 933-943	
2110	PCSK9 signaling pathways and their potential importance in clinical practice. 2017 , 8, 391-402	26
2109	Familial hypercholesterolaemia. 2017 , 3, 17093	190

2108	CANTOS: A Gigantic Proof-of-Concept Trial. 2017 , 121, 1320-1322	26
2107	Alirocumab for the treatment of hyperlipidemia in high-risk patients: an updated review. 2017 , 15, 923-932	3
2106	Genome Editing: The Recent History and Perspective in Cardiovascular Diseases. 2017 , 70, 2808-2821	14
2105	Role of Payers in the Development of Cardiovascular Therapeutics: Misalignment Between Approval and Reimbursement. 2017 , 70, 2822-2830	4
2104	On P values and effect modification. 2017 , 15, 144-151	3
2103	Cognitive Function in a Randomized Trial of Evolocumab. <i>New England Journal of Medicine</i> , 2017 , 377, 1997	59.2 17
2102	PCSK-9: papel en las hipercolesterolemias y anticuerpos monoclonales específicos inhibitorios. 2017 , 24, 4-12	
2101	Propuesta personal de actualización para el tratamiento de la hipercolesterolemia en Colombia. 2017 , 24, 25-31	
2100	PCSK9 Inhibitors: Economics and Policy. 2017 , 70, 2677-2687	80
2099	ApoCIII as a Cardiovascular Risk Factor and Modulation by the Novel Lipid-Lowering Agent Volanesorsen. 2017 , 19, 62	31
2098	Eligibility for PCSK9 Inhibitors According to American College of Cardiology (ACC) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) Guidelines After Acute Coronary Syndromes. 2017 , 6,	21
2097	Estudios clínicos con inhibidores de la PCSK9. 2017 , 24, 13-18	
2096	What is sufficient drug therapy for lipoprotein elevations?. 2017 , 11, 1300-1308	
2095	Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial. 2017 , 2, 1385-1391	62
2094	Protocolo de tratamiento de la dislipidemia. 2017 , 12, 2521-2525	
2093	Tratamiento de las dislipidemias en situaciones especiales: diabetes mellitus, cardiopatía isquémica e insuficiencia renal. 2017 , 12, 2526-2533	
2092	Atherosclerosis development: lipoproteins and beyond. 2017 , 28, 520-521	
2091	Prevention of cardiovascular disease in patients with familial hypercholesterolaemia: The role of PCSK9 inhibitors. 2017 , 24, 1383-1401	32

2090	PCSK9 inhibition and clinical cardiovascular outcomes in patients with atherosclerotic cardiovascular disease. 2017 , 113, e24-e25	0
2089	Pharmacokinetics and pharmacodynamics of bococizumab, a monoclonal antibody to PCSK9, after single subcutaneous injection at three sites [NCT 02043301]. 2017 , 35, e12278	9
2088	Statin Therapy and Risk of Intracranial Hemorrhage in Patients with Ischemic Stroke. 2017 , 40, 851-853	1
2087	Improving secondary cardiovascular risk prediction: taking a few steps along the long path from probability toward certainty. 2017 , 38, 3219-3221	3
2086	Cardiovascular endocrinology: Is ANGPTL3 the next PCSK9?. 2017 , 13, 503-504	14
2085	Therapeutic targeting in nanomedicine: the future lies in recombinant antibodies. 2017 , 12, 1873-1889	34
2084	Letter by Koh Regarding Article, "Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolism". 2017 , 136, 118-119	
2083	Response by Watts et al to Letter Regarding Article, "Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolism". 2017 , 136, 120-121	
2082	Groß Endpunkt-Studien von Praxisrelevanz. 2017 , 17, 8-10	
2081	Die Säulen der lipidsenkenden Therapie. 2017 , 11, 36-42	
2080	Are the PCSK9 inhibitors the panacea of atherosclerosis treatment?. 2017 , 15, 491-494	4
2079	Therapeutische Apherese am Beispiel der Lipoproteinapherese. 2017 , 12, 211-222	
2078	Implications of Recent Clinical Trials in Cardiovascular Imaging on Primary Prevention Therapies. 2017 , 11, 1	
2077	Cardiovascular disease: PCSK9 inhibition: a new player in cholesterol-lowering therapies?. 2017 , 13, 450-451	3
2076	PCSK9 Inhibitors: Treating the Right Patients in Daily Practice. 2017 , 19, 66	1
2075	The Effect of PCSK9 Loss-of-Function Variants on the Postprandial Lipid and ApoB-Lipoprotein Response. 2017 , 102, 3452-3460	25
2074	The emerging role of proprotein convertase subtilisin/kexin type-9 inhibition in secondary prevention: from clinical trials to real-world experience. 2017 , 32, 633-641	1
2073	Diabetes und koronare Herzerkrankung. 2017 , 13, 232-238	

2072	Mendelian randomization: a novel approach for the prediction of adverse drug events and drug repurposing opportunities. 2017 , 46, 2078-2089	57
2071	Extrem niedrige LDL-Cholesterinkonzentrationen durch moderne lipidsenkende Therapien. 2017 , 17, 54-57	
2070	Managing hypertriglyceridemia: What can we learn from cardiovascular outcomes trials?. 2017 , 42 Suppl 12, 3-9	1
2069	Proprotein Convertase Subtilisin/Kexin 9 Levels in Relation to Systemic Immune Activation and Subclinical Coronary Plaque in HIV. 2017 , 4, ofx227	11
2068	Cost-effectiveness of evolocumab in treatment of heterozygous familial hypercholesterolaemia in Bulgaria: measuring health benefit by effectively treated patient-years. 2017 , 5, 1412753	5
2067	Fighting residual cardiovascular risk in stable patients with atherosclerotic vascular disease: COMPASS in context. 2017 , 113, e61-e63	3
2066	Evolocumab. 2017 , 34, 329-330a	0
2065	Very low LDL-cholesterol concentrations achieved: which target is next?. 2017 , 390, 1930-1931	3
2064	Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. 2017 , 390, 1962-1971	336
2063	Blutzucker, Blutdruck und Blutfette. 2017 , 15, 142-144	
2062	Genome-based cholesterol drug boosts heart health. 2017 ,	
2061	ACC highlights promising studies. 2017 , 23, 2	
2060	Kardiovaskuläre Risikofaktoren bei Diabetes. 2017 , 46, 324-329	
2059	Enhancing the Promise of Drug Repositioning through Genetics. 2017 , 8, 896	40
2058	Anacetrapib, a New CETP Inhibitor: The New Tool for the Management of Dyslipidemias?. 2017 , 5,	12
2057	Evolocumab and clinical outcomes in patients with cardiovascular disease. 2017 , 47, 153-155	7
2056	Clinical utility of evolocumab in the management of hyperlipidemia: patient selection and follow-up. 2017 , 11, 2121-2129	8
2055	Lipid Lowering Therapy and Circulating PCSK9 Concentration. 2017 , 24, 895-907	54

2054	Anti-inflammatory Nanomedicine for Cardiovascular Disease. 2017 , 4, 87	48
2053	Genetics of coronary artery disease: fact or fiction?. 2017 , 58, 393-395	3
2052	Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: patient selection and perspectives. 2017 , 13, 343-351	11
2051	Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol \geq 10 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy. 2017 , 13, 247-253	2
2050	Recent advances in preventing stroke recurrence. 2017 , 6, 1017	6
2049	Addressing the challenge of high-priced prescription drugs in the era of precision medicine: A systematic review of drug life cycles, therapeutic drug markets and regulatory frameworks. 2017 , 12, e0182613	54
2048	Lipidomik identifiziert Ceramide als neue kardiovaskuläre Risikomarker. 2017 , 17, 56-61	
2047	Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia. 2017 , 16, 124	77
2046	Efficacy and safety of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, a post-commercialization study. 2017 , 16, 141	4
2045	Brazilian guidelines on prevention of cardiovascular disease in patients with diabetes: a position statement from the Brazilian Diabetes Society (SBD), the Brazilian Cardiology Society (SBC) and the Brazilian Endocrinology and Metabolism Society (SBEM). 2017 , 9, 53	15
2044	PCSK9-Hemmer h� kardiovaskul�re Ereignisse in Schach. 2017 , 19, 27-27	
2043	. 2017 , 159, 16	
2042	Cardiovascular risk and dyslipidemia among persons living with HIV: a review. 2017 , 17, 551	71
2041	Hochrisikopatienten mit Hypercholesterin�mie. 2017 , 17, 27-28	
2040	Lipidwirksame Therapie bei Diabetes mellitus jenseits von Statinen. 2017 , 17, 46-49	
2039	Now is good, earlier is better. 2017 , 3, 256-257	0
2038	. 2017 , 109, 1-31	16
2037	? Evolocumab as an adjunct to statins for CVD. 2017 , 55, 76-77	

2036	Ezetimibe Use and LDL-C Goal Achievement: A Retrospective Database Analysis of Patients with Clinical Atherosclerotic Cardiovascular Disease or Probable Heterozygous Familial Hypercholesterolemia. 2017 , 23, 1270-1276	11
2035	High-dose atorvastatin versus moderate dose on early vascular protection after ST-elevation myocardial infarction. 2017 , 11, 3425-3434	8
2034	Ronda clínica y epidemiológica: club de revistas. 2017 , 30, 463-471	
2033	Report of the Annual Scientific Sessions of the American College of Cardiology (ACC), Washington DC. 2017 , 81, 777-782	3
2032	Antibody Therapy of Hypercholesterolemia. 2017 , 2, 363-364	
2031	Statin-ezetimibe versus statin lipid-lowering therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention. 2017 , 9, 1345-1352	4
2030	Effect of evacetrapib on cardiovascular outcomes in patients with high-risk cardiovascular disease. 2017 , 9, 1822-1825	0
2029	Vaccine against PCSK9: the natural strategy from passive to active immunization for the prevention of atherosclerosis. 2017 , 9, 4291-4294	5
2028	Advances in dyslipidemia management for prevention of atherosclerosis: PCSK9 monoclonal antibody therapy and beyond. 2017 , 7, S11-S20	11
2027	Key Recent Advances in Atherosclerosis Treatment with Modern Lipid-lowering Drugs: The New Frontier with PCSK9 Inhibitors. 2017 , 12, 30-32	
2026	Fasting or Non-fasting Lipids for Atherosclerotic Cardiovascular Disease Risk Assessment and Treatment?. 2018 , 20, 14	8
2025	Treating Dyslipidemia in Type 2 Diabetes. 2018 , 36, 233-239	7
2024	Effects of statins on all-cause mortality at different low-density-lipoprotein cholesterol levels in Asian patients with type 2 diabetes. 2018 , 34, 1885-1892	5
2023	Statin dose reduction with complementary diet therapy: A pilot study of personalized medicine. 2018 , 11, 137-144	9
2022	Desirable Low-Density Lipoprotein Cholesterol Levels for Preventing Stroke Recurrence: A Post Hoc Analysis of the J-STARS Study (Japan Statin Treatment Against Recurrent Stroke). 2018 , 49, 865-871	14
2021	PCSK9 inhibitor valuation: A science-based review of the two recent models. 2018 , 41, 544-550	6
2020	Evolocumab: Considerations for the Management of Hyperlipidemia. 2018 , 20, 17	4
2019	Statin Intolerance: Some Practical Hints. 2018 , 36, 225-231	26

2018	Comments on the 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases. 2018 , 71, 74-78	
2017	[Cardiovascular Medication in Elderly Patients]. 2018 , 143, 236-243	0
2016	Generation and Characterization of a Novel Small Biologic Alternative to Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Antibodies, DS-9001a, Albumin Binding Domain-Fused Anticalin Protein. 2018 , 365, 368-378	24
2015	A Clinical Guide to Combination Lipid-Lowering Therapy. 2018 , 20, 19	12
2014	The highs and lows of cardiovascular disease prevention. 2018 , 272, 222-224	
2013	Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease. 2018 , 93, 1397-1408	50
2012	Cardiovascular outcomes trial with anacetrapib in subjects with high cardiovascular risk - are major benefits REVEALed?. 2018 , 19, 611-615	2
2011	Statin utilization and lipid goal attainment in high or very-high cardiovascular risk patients: Insights from Italian general practice. 2018 , 271, 120-127	22
2010	Multimodal lipid-lowering treatment in pediatric patients with homozygous familial hypercholesterolemia-target attainment requires further increase of intensity. 2018 , 33, 1199-1208	8
2009	Small molecule modulators of PCSK9 - A literature and patent overview. 2018 , 28, 1155-1160	18
2008	Bempedoic Acid (ETC-1002): A Current Review. 2018 , 36, 257-264	35
2007	Can We Eliminate Low-Density Lipoprotein Cholesterol-Related Cardiovascular Events Through More Aggressive Primary Prevention Therapy?. 2018 , 34, 546-551	2
2006	Improved endothelial function after short-term therapy with evolocumab. 2018 , 12, 669-673	21
2005	Comentarios a la gu ESC 2017 sobre el diagntico y tratamiento de la enfermedad arterial perifrica. 2018 , 71, 74-78	1
2004	Impact of Novel Low-Density Lipoprotein-Cholesterol Assessment on the Utility of Secondary Non-High-Density Lipoprotein-C and Apolipoprotein B Targets in Selected Worldwide Dyslipidemia Guidelines. 2018 , 138, 244-254	26
2003	The Role of PCSK9 Inhibitors in the Treatment of Hypercholesterolemia. 2018 , 52, 1000-1018	15
2002	Evaluation of the cost-effectiveness of evolocumab in the FOURIER study: a Canadian analysis. 2018 , 6, E162-E167	6
2001	Attainment of Recommended Lipid Targets in Patients With Familial Hypercholesterolemia: Real-World Experience With PCSK9 Inhibitors. 2018 , 34, 1004-1009	16

2000	Diabetes and lipid metabolism. 2018 , 17, 61-67	81
1999	Analysis of predicted loss-of-function variants in UK Biobank identifies variants protective for disease. 2018 , 9, 1613	55
1998	[Optimal Medical Therapy and Secondary Prevention in Patients after an Acute Coronary Syndrome]. 2018 , 143, 672-679	0
1997	Visit-to-visit cholesterol variability correlates with coronary atheroma progression and clinical outcomes. 2018 , 39, 2551-2558	40
1996	Impact of body mass index on long-term outcomes in Japanese patients following percutaneous coronary intervention: The Juntendo PCI Registry. 2018 , 72, 208-214	6
1995	Beyond LDL: What Role for PCSK9 in Triglyceride-Rich Lipoprotein Metabolism?. 2018 , 29, 420-434	22
1994	Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering: A Systematic Review and Meta-analysis. 2018 , 319, 1566-1579	205
1993	What is new in recent STEMI guidelines?. 2018 , 8, 87-94	
1992	Effect of alirocumab on coronary atheroma volume in Japanese patients with acute coronary syndromes and hypercholesterolemia not adequately controlled with statins: ODYSSEY J-IVUS rationale and design. 2018 , 71, 583-589	8
1991	High-Density Lipoproteins: Effects on Vascular Function and Role in the Immune Response. 2018 , 36, 317-327	12
1990	Intravascular Ultrasound Studies of Plaque Progression and Regression: Impact of Lipid-Modifying Therapies. 2018 , 36, 329-334	
1989	Number of Patients Eligible for PCSK9 Inhibitors Based on Real-world Data From 2.5 Million Patients. 2018 , 71, 1010-1017	4
1988	Coste-efectividad e impacto presupuestario del tratamiento con evolocumab frente a estatinas y ezetimiba para la hipercolesterolemia en España. 2018 , 71, 1027-1035	18
1987	PCSK9 regulates expression of scavenger receptors and ox-LDL uptake in macrophages. 2018 , 114, 1145-1153	46
1986	Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab. 2018 , 12, 958-965	32
1985	Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: Analysis From FOURIER. 2018 , 138, 756-766	136
1984	Intensive Treat-to-Target Statin Therapy in High-Risk Japanese Patients With Hypercholesterolemia and Diabetic Retinopathy: Report of a Randomized Study. 2018 , 41, 1275-1284	25
1983	Cardiovascular Risk Factors and Peripheral Arterial Disease. 2018 , 189-200	

1982	Estimated individual lifetime benefit from PCSK9 inhibition in statin-treated patients with coronary artery disease. 2018 , 104, 1699-1705	11
1981	Can modulators of apolipoproteinB biogenesis serve as an alternate target for cholesterol-lowering drugs?. 2018 , 1863, 762-771	10
1980	Dyslipidemia. 2018 , 42 Suppl 1, S178-S185	26
1979	Neurocognitive Function after Cardiac Surgery: From Phenotypes to Mechanisms. 2018 , 129, 829-851	79
1978	PCSK9 Concentrations in Cerebrospinal Fluid Are Not Specifically Increased in Alzheimer's Disease. 2018 , 62, 1519-1525	14
1977	Nuovi farmaci per il trattamento dell'ipercolesterolemia. 2018 , 19, 28-30	
1976	The prevalence, low-density lipoprotein cholesterol levels, and treatment of patients at very high risk of cardiovascular events in the United Kingdom: a cross-sectional study. 2018 , 34, 1441-1447	7
1975	Major unmet needs in the cardiovascular area. 2018 , 20, C4-C7	
1974	Prevention and management of statin adverse effects: A practical approach for pharmacists. 2018 , 151, 179-188	9
1973	Cardiovascular Protection in People With Diabetes. 2018 , 42 Suppl 1, S162-S169	30
1972	The prevalence and predictors of elevated C-reactive protein after a coronary heart disease event. 2018 , 25, 923-931	20
1971	Is Lipoprotein(a) Ready for Prime-Time Use in the Clinic?. 2018 , 36, 287-298	10
1970	Temporal changes in statin prescription and intensity at discharge and impact on outcomes in patients with newly diagnosed atherosclerotic cardiovascular disease-Real-world experience within a large integrated health care system: The IMPRES study. 2018 , 12, 1008-1018.e1	4
1969	Revascularization in stable coronary disease: evidence and uncertainties. 2018 , 15, 408-419	13
1968	The Pharmacologic Role and Clinical Utility of PCSK9 Inhibitors for the Treatment of Hypercholesterolemia. 2018 , 23, 301-308	2
1967	The Interplay of Lipids, Lipoproteins, and Immunity in Atherosclerosis. 2018 , 20, 12	46
1966	Documented coronary atherothrombosis as the cause of death in post-discharge patients after coronary revascularization. 2018 , 19, 597-606	
1965	Insights from population-based analyses of plasma lipids across the allele frequency spectrum. 2018 , 50, 1-6	2

1964	Differential effects of PCSK9 variants on risk of coronary disease and ischaemic stroke. 2018 , 39, 354-359	28
1963	Inclisiran for the treatment of dyslipidemia. 2018 , 27, 287-294	27
1962	PCSK9 inhibition alters the lipidome of plasma and lipoprotein fractions. 2018 , 269, 159-165	34
1961	Role of dual lipid-lowering therapy in coronary atherosclerosis regression: Evidence from recent studies. 2018 , 269, 219-228	49
1960	The Genetic Link Between Diabetes and Atherosclerosis. 2018 , 34, 565-574	7
1959	Clinical and pathophysiological evidence supporting the safety of extremely low LDL levels-The zero-LDL hypothesis. 2018 , 12, 292-299.e3	33
1958	Long-term efficacy and safety of proprotein convertase subtilisin/kexin 9 monoclonal antibodies: A meta-analysis of 11 randomized controlled trials. 2018 , 12, 277-291.e3	12
1957	Lipoprotein apheresis affects lipoprotein particle subclasses more efficiently compared to the PCSK9 inhibitor evolocumab, a pilot study. 2018 , 57, 91-96	10
1956	Lomitapide in homozygous familial hypercholesterolemia: cardiology perspective from a single-center experience. 2018 , 19, 83-90	9
1955	Evolving targets for the treatment of atherosclerosis. 2018 , 187, 1-12	36
1954	The pharmacodynamic and clinical trial evidence for statin dose. 2018 , 84, 1128-1135	10
1953	Outcomes, Access, and Cost Issues Involving PCSK9 Inhibitors to Lower LDL-Cholesterol. 2018 , 78, 287-291	10
1952	Reply: LDL-Cholesterol and Atherosclerotic Cardiovascular Disease: Innocent Bystander or Essential Ingredient?. 2018 , 71, 706-707	
1951	Proprotein Convertase Subtilisin-Kexin type-9 (PCSK9) and triglyceride-rich lipoprotein metabolism: Facts and gaps. 2018 , 130, 1-11	17
1950	Editorial commentary: The lower the LDL the better but how and how much?. 2018 , 28, 355-356	1
1949	Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial. 2018 , 20, 1479-1489	63
1948	Nutraceuticals as therapeutic agents for atherosclerosis. 2018 , 1864, 1562-1572	47
1947	Elevated triglycerides and low high-density lipoprotein cholesterol level as marker of very high risk in type 2 diabetes. 2018 , 25, 118-129	20

1946	The final word about LDL-cholesterol lowering. 2018 , 25, 101-102	
1945	PCSK9 inhibition for primary prevention of ischaemic heart disease in heterozygous familial hypercholesterolaemia. 2018 ,	78
1944	New Therapeutic Approaches for Familial Hypercholesterolemia. 2018 , 69, 113-131	14
1943	Effect of proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies on new-onset diabetes mellitus and glucose metabolism: A systematic review and meta-analysis. 2018 , 20, 1391-1398	29
1942	The role of lipoprotein (a) in chronic kidney disease. 2018 , 59, 577-585	37
1941	No evidence of neurocognitive adverse events associated with alirocumab treatment in 3340 patients from 14 randomized Phase 2 and 3 controlled trials: a meta-analysis of individual patient data. 2018 , 39, 374-381	44
1940	Dyslipidaemias in 2017: Atherogenic lipoproteins as treatment targets. 2018 , 15, 75-76	1
1939	[Prevention of cardiovascular diseases]. 2018 , 43, 87-100	1
1938	[PCSK9 inhibitors: For which patients? For which indication? What to consider?]. 2018 , 160, 43-46	1
1937	The systematic review of randomized controlled trials of PCSK9 antibodies challenges their "efficacy breakthrough" and the "lower, the better" theory. 2018 , 34, 1725-1730	3
1936	Prior Authorization Requirements for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Across US Private and Public Payers. 2018 , 11, e003939	20
1935	Advances in lipid-lowering therapy through gene-silencing technologies. 2018 , 15, 261-272	63
1934	PCSK9 inhibitors: a non-statin cholesterol-lowering treatment option. 2018 , 130, 287-298	6
1933	Hypolipidemic Drugs and Diabetes Mellitus-Mechanisms and Data From Genetic Trials. 2018 , 23, 187-191	2
1932	Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials). 2018 , 121, 940-948	13
1931	Will Cardio-Virology Be the Next Cardio-Oncology?. 2018 , 131, 726-727	
1930	Somatic Mutations and Clonal Hematopoiesis: Unexpected Potential New Drivers of Age-Related Cardiovascular Disease. 2018 , 122, 523-532	72
1929	Lipid-lowering treatment in peripheral artery disease. 2018 , 39, 19-26	12

1928	LDL-Cholesterol and Atherosclerotic Cardiovascular Disease: Innocent Bystander or Essential Ingredient. 2018 , 71, 705-706	2
1927	Prescribing Patterns of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in Eligible Patients With Clinical Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia. 2018 , 121, 1155-1161	15
1926	The pharmacological management of metabolic syndrome. 2018 , 11, 397-410	56
1925	Selection of the Best of 2017 in Vascular Risk and Cardiac Rehabilitation. 2018 , 71, 227-228	
1924	Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor. 2018 , 57, 769-779	40
1923	A Critical Review of the Consensus Statement from the European Atherosclerosis Society Consensus Panel 2017. 2018 , 101, 184-218	15
1922	Genetics of familial hypercholesterolemia: a tool for development of novel lipid lowering pharmaceuticals?. 2018 , 29, 80-86	4
1921	Regulation of low-density lipoprotein cholesterol by intestinal inflammation and the acute phase response. 2018 , 114, 226-232	17
1920	2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. 2018 , 49, e46-e110	2946
1919	Mortality Differences Associated With Treatment Responses in CANTOS and FOURIER: Insights and Implications. 2018 , 137, 1763-1766	20
1918	Adherence to proprotein convertase subtilisin/kexin 9 inhibitors in high cardiovascular risk patients: an Italian single-center experience. 2018 , 19, 75-77	19
1917	Evolving Role of Non-Statin Therapy for the Management of Dyslipidemia and Cardiovascular Risk Reduction: Past, Present, and Future. 2018 , 38, 164-171	6
1916	Treatment patterns and low-density lipoprotein cholesterol (LDL-C) goal attainment among patients receiving high- or moderate-intensity statins. 2018 , 107, 380-388	28
1915	PCSK9 inhibitors in clinical practice: Delivering on the promise?. 2018 , 270, 205-210	36
1914	Managing Dyslipidemia in Type 2 Diabetes. 2018 , 47, 153-173	19
1913	Managing Diabetes and Cardiovascular Risk in Chronic Kidney Disease Patients. 2018 , 47, 237-257	14
1912	Cardioprotection activity and mechanism of Astragalus polysaccharide in vivo and in vitro. 2018 , 111, 947-952	27
1911	Cardiovascular risk in patients with familial hypercholesterolemia using optimal lipid-lowering therapy. 2018 , 12, 409-416	23

1910	Beyond the traditional lipid parameters in chronic kidney disease. 2018 , 38, 109-113	3
1909	Selection of the Best of 2017 in Clinical Cardiology. Therapeutic Novelties. 2018 , 71, 60	
1908	Selección de lo mejor del año 2017 en riesgo vascular y rehabilitación cardiaca. 2018 , 71, 227-228	
1907	Número de pacientes candidatos a recibir inhibidores de la PCSK9 según datos de 2,5 millones de participantes de la práctica clínica real. 2018 , 71, 1010-1017	17
1906	[Optimal cholesterol levels in patients in real-life. A systematic review]. 2018 , 44, 42-49	4
1905	Lipids. 2018 , 359-385	
1904	The Atherogenic Dyslipidemia Complex and Novel Approaches to Cardiovascular Disease Prevention in Diabetes. 2018 , 34, 595-604	37
1903	Evaluation of dyslipidaemia and the impact of hypolipidemic therapy on prognosis in high and very high risk patients through the Hyperlipidaemia Therapy in tERtiary CardiologicaL cEnTer (TERCET) Registry. 2018 , 132, 204-210	13
1902	Precision Medicine: Functional Advancements. 2018 , 69, 1-18	21
1901	New treatment options for lipid-lowering therapy in subjects with type 2 diabetes. 2018 , 55, 209-218	28
1900	Questioning the safety and benefits of evolocumab - Authors' reply. 2018 , 6, 11-12	1
1899	Discordance between lipoprotein particle number and cholesterol content: an update. 2018 , 25, 130-136	21
1898	Interleukin-1 genotypes modulate the long-term effect of lipoprotein(a) on cardiovascular events: The Ioannina Study. 2018 , 12, 338-347	11
1897	Dyslipidaemia in the elderly: to treat or not to treat?. 2018 , 11, 259-278	5
1896	Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors and Cardiovascular Risk: Does a Further Analysis of the Fourier Trial Suggest Changes in the Target of Lipid Lowering Therapy?. 2018 , 25, 5-7	
1895	Cost-effectiveness of PCSK9 inhibition in addition to standard lipid-lowering therapy in patients at high risk for vascular disease. 2018 , 253, 148-154	18
1894	Stepwise processing analyses of the single-turnover PCSK9 protease reveal its substrate sequence specificity and link clinical genotype to lipid phenotype. 2018 , 293, 1875-1886	11
1893	Management of Statin Intolerance in 2018: Still More Questions Than Answers. 2018 , 18, 157-173	86

1892	Questioning the safety and benefits of evolocumab. 2018 , 6, 11	3
1891	From the editor: A run of success in treating atherosclerotic vascular disease. 2018 , 12, 1-2	
1890	Lipid Management in Chronic Kidney Disease: Systematic Review of PCSK9 Targeting. 2018 , 78, 215-229	22
1889	LDL cholesterol: How low to go?. 2018 , 28, 348-354	8
1888	The year in cardiology 2017: coronary interventions. 2018 , 39, 914-924	1
1887	Lp(a) (Lipoprotein(a)) Levels Predict Progression of Carotid Atherosclerosis in Subjects With Atherosclerotic Cardiovascular Disease on Intensive Lipid Therapy: An Analysis of the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes) Carotid Magnetic Resonance Imaging Substudy Brief Report. 2018 , 38, 673-678	25
1886	Selección de lo mejor del año 2017 en cardiología clínica. Novedades terapéuticas. 2018 , 71, 60	2
1885	'Highest risk-highest benefit' strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies. 2018 , 39, 2546-2550	53
1884	The year in cardiology 2017: prevention. 2018 , 39, 345-353	3
1883	The challenge of peripheral arterial disease: How do we improve outcome?. 2018 , 270, 196-198	4
1882	Selection of the Best of 2017 in Ischemic Heart Disease. 2018 , 71, 124-125	
1881	New strategies for the development of lipid-lowering therapies to reduce cardiovascular risk. 2018 , 4, 119-127	11
1880	Prevention of cardiovascular disease: Much more is needed. 2018 , 25, 1083-1086	10
1879	Association between the polymorphisms and serum lipid traits, the risk of coronary artery disease and ischemic stroke in a southern Chinese Han population. 2018 , 15, 27	10
1878	Residual Inflammatory Risk on Treatment With PCSK9 Inhibition and Statin Therapy. 2018 , 138, 141-149	93
1877	In search of a physiological function of lipoprotein(a): causality of elevated Lp(a) levels and reduced incidence of type 2 diabetes. 2018 , 59, 741-744	10
1876	Pharmacogenomics of blood lipid regulation. 2018 , 19, 651-665	1
1875	Does clinician-reported lipid guideline adoption translate to guideline-adherent care? An evaluation of the Patient and Provider Assessment of Lipid Management (PALM) registry. 2018 , 200, 118-124	7

1874	RNA-guided transcriptional silencing in vivo with <i>S. aureus</i> CRISPR-Cas9 repressors. 2018 , 9, 1674	91
1873	JACC: Basic to Translational Science: The Apple That Falls Closely to the 'JACC Family Tree. 2018 , 71, 1940-1941	
1872	Posttranslational modification of proprotein convertase subtilisin/kexin type 9 is differentially regulated in response to distinct cardiometabolic treatments as revealed by targeted proteomics. 2018 , 12, 1027-1038	9
1871	Variations in time to benefit among clinical trials of cholesterol-lowering drugs. 2018 , 12, 857-862	13
1870	ESRD-induced dyslipidemia-Should management of lipid disorders differ in dialysis patients?. 2018 , 31, 398-405	13
1869	The prevalence and correlates of subclinical atherosclerosis among adults with low-density lipoprotein cholesterol. 2018 , 274, 61-66	4
1868	Structures of Angptl3 and Angptl4, modulators of triglyceride levels and coronary artery disease. 2018 , 8, 6752	29
1867	Unexplained reciprocal regulation of diabetes and lipoproteins. 2018 , 29, 186-193	11
1866	Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial. 2018 , 25, 521-538	61
1865	Best Treatment Strategies With Statins to Maximize the Cardiometabolic Benefits. 2018 , 82, 937-943	11
1864	LPA Variants Are Associated With Residual Cardiovascular Risk in Patients Receiving Statins. 2018 , 138, 1839-1849	40
1863	Statin-Related Myopathy and Rhabdomyolysis. 2018 , 760-774	2
1862	Short-Term Global Cardiovascular Disease Risk Prediction in Older Adults. 2018 , 71, 2527-2536	29
1861	Causal Effect of Lipids and Lipoproteins on Atherosclerosis: Lessons from Genomic Studies. 2018 , 36, 203-211	21
1860	Impact of statin therapy on coronary plaque burden and composition assessed by coronary computed tomographic angiography: a systematic review and meta-analysis. 2018 , 19, 850-858	33
1859	Proprotein Convertase Subtilisin Kexin 9 Inhibitors. 2018 , 36, 241-256	4
1858	Loss-of-function PCSK9 mutants evade the unfolded protein response sensor GRP78 and fail to induce endoplasmic reticulum stress when retained. 2018 , 293, 7329-7343	22
1857	TLR4 in Atherogenesis: Paying the Toll for Antimicrobial Defense. 2018 , 71, 1571-1573	3

1856	A decade of genome-wide association studies for coronary artery disease: the challenges ahead. 2018 , 114, 1241-1257	121
1855	Inflammatory and Cholesterol Risk in the FOURIER Trial. 2018 , 138, 131-140	127
1854	New pharmacological approaches for cardiovascular risk. 2018 , 151, 145-147	
1853	Molecular aspects of hypercholesterolemia treatment: current perspectives and hopes. 2018 , 50, 303-311	12
1852	An update on trials of novel lipid-lowering drugs. 2018 , 33, 416-422	3
1851	Recent major advances in cardiovascular pharmacotherapy. 2018 , 74, 853-862	3
1850	Obesity and Clinical Lipidology. 2018 , 717-722	
1849	¿Qué papel tienen los anti-PCSK9 en el tratamiento de la dislipidemia?. 2018 , 53, 51-54	0
1848	Atherosclerosis as an inflammatory disease: Doubts? No more. 2018 , 19, 1-2	12
1847	Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor use in the management of resistant hypercholesterolemia induced by mitotane treatment for adrenocortical cancer. 2018 , 12, 826-829	4
1846	The Emerging Role of Inflammation in Cardiovascular Disease. 2018 , 52, 801-809	29
1845	Assessing Cardiovascular Disease Risk and Responses to Preventive Therapies in Clinical Practice. 2018 , 20, 23	4
1844	Lipoprotein Disorders. 2018 , 27-46	1
1843	SOP Lipidmanagement. 2018 , 14, 10-14	
1842	Proprotein convertase subtilisin/kexin type 9: from genetics to clinical trials. 2018 , 33, 269-275	9
1841	A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes. 2018 , 25, 844-853	24
1840	Novel Insights in the Management of Dyslipidemia in Patients With HIV Infection. 2018 , 4, 112-119	1
1839	No benefit of arthroscopy in subacromial shoulder pain. 2018 , 391, 289-291	4

1838	Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics. 2018 , 39, 2577-2585	90
1837	Pleiotropic Anti-atherosclerotic Effects of PCSK9 Inhibitors From Molecular Biology to Clinical Translation. 2018 , 20, 20	30
1836	Clinical benefits of evolocumab appear less than hoped - Authors' reply. 2018 , 391, 934-935	2
1835	Clinical benefits of evolocumab appear less than hoped. 2018 , 391, 933-934	1
1834	Initial Clinical Experience with AZD5718, a Novel Once Daily Oral 5-Lipoxygenase Activating Protein Inhibitor. 2018 , 11, 330-338	15
1833	An amber signal lights up before the red: do not dismiss it. 2018 , 39, 303-304	2
1832	PCSK9 and infection: A potentially useful or dangerous association?. 2018 , 233, 2920-2927	21
1831	MicroRNAs: New Therapeutic Targets for Familial Hypercholesterolemia?. 2018 , 54, 224-233	21
1830	PCSK9 in context: A contemporary review of an important biological target for the prevention and treatment of atherosclerotic cardiovascular disease. 2018 , 20, 270-282	18
1829	2017 EACTS Guidelines on perioperative medication in adult cardiac surgery. 2018 , 53, 5-33	183
1828	2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Endorsed by the European Stroke Organization (ESO) The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). 2018 , 39, 763-784	1274
1827	2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). 2018 , 39, 117-177	4237
1826	2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia. 2018 , 39, 1131-1143	132
1825	Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials. 2018 , 39, 1172-1180	93
1824	Biomarkers in stable coronary artery disease. 2018 , 196, 82-96	23
1823	The effects of single- and multiple-dose administration of bococizumab (RN316/PF-04950615), a humanized IgG2 μ monoclonal antibody binding proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects treated with and without atorvastatin: Results from four phase I studies. 2018 , 36, e12309	13
1822	Implications of the FDA approval of PCSK9 inhibitors and FOURIER results for contemporary cardiovascular practice: An NCDR Research to Practice (R2P) project. 2018 , 195, 151-152	8
1821	Provider recommendations for patient-reported muscle symptoms on statin therapy: Insights from the Understanding Statin Use in America and Gaps in Patient Education survey. 2018 , 12, 78-88	17

1820	Adherence and Persistence Among Statin Users Aged 65 Years and Over: A Systematic Review and Meta-analysis. 2018 , 73, 813-819	48
1819	Human gene essentiality. 2018 , 19, 51-62	127
1818	Neurological effects of proprotein convertase subtilisin/kexin type 9 inhibitors: direct comparisons. 2018 , 4, 132-141	10
1817	PCSK9 antagonists and inflammation. 2018 , 268, 235-236	12
1816	HDL functionality in familial hypercholesterolemia: effects of treatment modalities and pharmacological interventions. 2018 , 23, 171-180	15
1815	A safety evaluation of evolocumab. 2018 , 17, 99-106	5
1814	Methylomic profiling and replication implicates deregulation of PCSK9 in alcohol use disorder. 2018 , 23, 1900-1910	43
1813	Diagnostic and prognostic benefits of computed tomography coronary angiography using the 2016 National Institute for Health and Care Excellence guidance within a randomised trial. 2018 , 104, 207-214	26
1812	Patient Characteristics and Real-World Treatment Patterns Among Early Users of PCSK9 Inhibitors. 2018 , 18, 103-108	11
1811	Lipoproteins and Cardiovascular Redox Signaling: Role in Atherosclerosis and Coronary Disease. 2018 , 29, 337-352	7
1810	CRISPR-Cas9 Genome Editing for Treatment of Atherogenic Dyslipidemia. 2018 , 38, 12-18	13
1809	Editor's Choice - 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). 2018 , 55, 305-368	449
1808	Effects of PCSK9 Inhibitors on Other than Low-Density Lipoprotein Cholesterol Lipid Variables. 2018 , 23, 3-12	20
1807	Author's Reply to: Comment: Translating Guidelines Into Practice: Interpreting the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statins Therapies for LDL Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk. 2018 , 52, 92-93	
1806	[Therapeutic options in hyperlipidemia]. 2018 , 168, 7-15	1
1805	Should an LDL-Cholesterol Target-Based Approach Be Readopted?. 2018 , 52, 175-184	4
1804	Genomic basis of atrial fibrillation. 2018 , 104, 201-206	27
1803	Payer and Pharmaceutical Manufacturer Considerations for Outcomes-Based Agreements in the United States. 2018 , 21, 33-40	9

1802	PCSK9 Inhibitors: Mechanisms of Action, Metabolic Effects, and Clinical Outcomes. 2018 , 69, 133-145	35
1801	The Influence of Big (Clinical) Data and Genomics on Precision Medicine and Drug Development. 2018 , 103, 409-418	26
1800	Anti-inflammatory agents in peripheral arterial disease. 2018 , 39, 1-8	16
1799	Canadian stroke best practice recommendations: Secondary prevention of stroke, sixth edition practice guidelines, update 2017. 2018 , 13, 420-443	119
1798	Suppression of Hepatic FLOT1 (Flotillin-1) by Type 2 Diabetes Mellitus Impairs the Disposal of Remnant Lipoproteins via Syndecan-1. 2018 , 38, 102-113	14
1797	Genetic Association of Lipids and Lipid Drug Targets With Abdominal Aortic Aneurysm: A Meta-analysis. 2018 , 3, 26-33	44
1796	Budget Impact Analysis of PCSK9 Inhibitors for the Management of Adult Patients with Heterozygous Familial Hypercholesterolemia or Clinical Atherosclerotic Cardiovascular Disease. 2018 , 36, 115-126	7
1795	Reply to: "PCSK9 antagonists and inflammation". 2018 , 268, 237-238	
1794	PCSK9 deficiency reduces atherosclerosis, apolipoprotein B secretion, and endothelial dysfunction. 2018 , 59, 207-223	45
1793	Benefits, benefits, once more benefits... with no risk? Stop overlooking the harms of medicines. 2018 , 74, 373-375	2
1792	Statin Treatment in Patients With Intracerebral Hemorrhage. 2018 , 49, 240-246	26
1791	High levels of lipoprotein (a) and premature acute coronary syndrome. 2018 , 269, 29-34	25
1790	Pharmacokinetics, pharmacodynamics and clinical efficacy of non-statin treatments for hypercholesterolemia. 2018 , 14, 9-15	10
1789	[Atherothrombosis : Novel therapeutic strategies]. 2018 , 43, 103-108	2
1788	Risk Assessment in Patients With Diabetes With the TIMI Risk Score for Atherothrombotic Disease. 2018 , 41, 577-585	16
1787	Selección de lo mejor del año 2017 en cardiopatía isquémica. 2018 , 71, 124-125	
1786	Stroke patients with familial hypercholesterolemia: need for detection and aggressive treatment. 2018 , 25, 211-212	1
1785	SGLT2 inhibitors with cardiovascular benefits: Transforming clinical care in Type 2 diabetes mellitus. 2018 , 136, 23-31	13

1784	Reaching low-density lipoprotein cholesterol treatment targets in stable coronary artery disease: Determinants and prognostic impact. 2018 , 111, 634-643	7
1783	Effects of endurance training on serum lipids. 2018 , 101, 9-20	23
1782	Drug development in the era of precision medicine. 2018 , 17, 183-196	176
1781	9. Cardiovascular Disease and Risk Management:. 2018 , 41, S86-S104	370
1780	Systematic Review of Validity Assessments of Framingham Risk Score Results in Health Economic Modelling of Lipid-Modifying Therapies in Europe. 2018 , 36, 205-213	12
1779	Statin use and risk for type 2 diabetes: what clinicians should know. 2018 , 130, 166-172	13
1778	PCSK9 Variants, Low-Density Lipoprotein Cholesterol, and Neurocognitive Impairment: Reasons for Geographic and Racial Differences in Stroke Study (REGARDS). 2018 , 137, 1260-1269	27
1777	Sex difference between target levels of cholesterol-related parameters and post-PCI long-term clinical outcomes: From the FU-Registry. 2018 , 71, 259-267	2
1776	Beyond the traditional lipid parameters in chronic kidney disease. 2018 , 38, 109-113	4
1775	Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation. 2018 , 93, 1000-1007	21
1774	Comparative effectiveness of lipid-lowering treatments to reduce cardiovascular disease. 2018 , 18, 51-69	5
1773	Membrane microdomains and the regulation of HDL biogenesis. 2018 , 29, 36-41	8
1772	Neurocognitive performance after PCSK9 inhibitor therapy: Current state of the evidence. 2018 , 96, 762-764	0
1771	Evaluation of the Pleiotropic Effects of Statins: A Reanalysis of the Randomized Trial Evidence Using Egger Regression-Brief Report. 2018 , 38, 262-265	23
1770	Apo A-I (Apolipoprotein A-I) Vascular Gene Therapy Provides Durable Protection Against Atherosclerosis in Hyperlipidemic Rabbits. 2018 , 38, 206-217	20
1769	Effect of Evolocumab on Lipoprotein Particles. 2018 , 121, 308-314	21
1768	Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. 2018 , 391, 319-328	430
1767	Treatment concentration of high-sensitivity C-reactive protein. 2018 , 391, 287-289	7

1766	Eligibility for treatment with PCSK9 inhibitors among patients with stable coronary artery disease presumed to be on maximum hypolipidaemic therapy. 2018 , 59, 293-295	4
1765	Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration. 2018 , 39, 2540-2545	75
1764	Efficacy and safety of alirocumab in people with prediabetes vs those with normoglycaemia at baseline: a pooled analysis of 10 phase III ODYSSEY clinical trials. 2018 , 35, 121-130	26
1763	How to use Mendelian randomization to anticipate the results of randomized trials. 2018 , 39, 360-362	33
1762	PCSK9 inhibition in the management of familial hypercholesterolemia. 2018 , 71, 1-7	45
1761	Ischaemic stroke. 2018 , 25, 35-40	53
1760	Trimetazidine Protects Against Atherosclerosis by Changing Energy Charge and Oxidative Stress. 2018 , 24, 8459-8468	7
1759	American Association of Clinical Endocrinologists/American College of Endocrinology Management of Dyslipidemia and Prevention of Cardiovascular Disease Clinical Practice Guidelines. 2018 , 31, 234-245	18
1758	Medikamentöse Therapie von Fettstoffwechselstörungen bei Patienten mit Typ-2-Diabetes. 2018 , 13, 403-422	
1757	Alirocumab in the management of primary hypercholesterolaemia or mixed dyslipidaemia: A budget impact analysis [Italian perspective]. 2018 , 2018, 228424031878148	
1756	Gesundheitsökonomische Aspekte der Verschreibung von PCSK9-Hemmern. 2018 , 18, 34-37	
1755	Drugs That Affect Lipid Metabolism. 2018 , 40, 559-568	
1754	Stellenwert der lipidsenkenden Therapie in der Sekundärprophylaxe bei KHK. 2018 , 47, 534-539	
1753	New and Future Parenteral Therapies for the Management of Lipid Disorders. 2018 , 49, 538-547	2
1752	Fractional flow reserve at the crossroad between revascularization and medical therapy. 2018 , 8, 556-558	1
1751	Statin Intolerance: an Overview of the Current Status and Possible Treatment Options. 2018 , 7, 77	3
1750	Therapy and clinical trials. 2018 , 29, 357-358	
1749	Reduction of Vascular Inflammation, LDL-C, or Both for the Protection from Cardiovascular Events?. 2018 , 12, 29-40	15

1748	Cardiovascular Disease as a Result of the Interactions Between Obesity, Climate Change, and Inflammation: The COCCI Syndemic. 2018 , 118, 719-729	2
1747	TNM cancer staging: can it help develop a novel staging system for type 2 diabetes?. 2018 , 11, 845-853	1
1746	Available oral lipid-lowering agents could bring most high-risk patients to target: an estimate based on the Dyslipidemia International Study II-Italy. 2018 , 19, 485-490	3
1745	Eligibility, Clinical Outcomes, and Budget Impact of PCSK9 Inhibitor Adoption: The CANHEART PCSK9 Study. 2018 , 7, e010007	10
1744	Just Price for PCSK9 Inhibitors: No less, No More. 2018 , 7, e010884	1
1743	Treatment patterns and patient characteristics among early initiators of PCSK9 inhibitors. 2018 , 14, 409-418	13
1742	Pleiotropic effects of proprotein convertase subtilisin/kexin type 9 inhibitors?. 2018 , 29, 333-339	15
1741	Cardiovascular Disease and Risk Management: Review of the American Diabetes Association Standards of Medical Care in Diabetes 2018. 2018 , 168, 640-650	48
1740	Genetic testing for a patient with suspected familial hypercholesterolaemia. 2018 , 2018,	2
1739	Lipid Management for Prevention of Atherosclerotic Cardiovascular Diseases. 2018 , 45, 755-769	
1738	ApoE4 May be a Promising Target for Treatment of Coronary Heart Disease and Alzheimer's Disease. 2018 , 19, 1038-1044	10
1737	Lipid-Lowering Therapies: Risks in Women and Evidence-Based Options. 2018 , 45, 238-239	0
1736	Association between Vitamin D Receptor (VDR) Gene Polymorphisms and Type-2 Diabetes Mellitus in Population of Pakistan. 2018 , 06,	2
1735	In combination with statins, evolocumab could reduce CV events. 2018 , 24, 31	
1734	Prävention kardiovaskulärer Erkrankungen durch medikamentöse LDL-Cholesterin-Senkung. 2018 , 14, 331-342	
1733	OBSOLETE: Management and Care of Older Cardiac Patients. 2018 ,	
1732	OBSOLETE: STEMI: Management. 2018 ,	
1731	Einschätzung des kardiovaskulären Hochrisikopatienten. 2018 , 18, 43-48	

1730 Bedeutung individueller Therapieprognosen. **2018**, 18, 38-42

1729	. 2018 ,	1
1728	Prevalence of hypobetalipoproteinemia and related psychiatric characteristics in a psychiatric population: results from the retrospective HYPOPSY Study. 2018 , 17, 249	7
1727	Targeting Non-coding RNA in Vascular Biology and Disease. 2018 , 9, 1655	38
1726	Genetic variant at coronary artery disease and ischemic stroke locus 1p32.2 regulates endothelial responses to hemodynamics. 2018 , 115, E11349-E11358	31
1725	Association Between Obesity and Cardiovascular Outcomes: A Systematic Review and Meta-analysis of Mendelian Randomization Studies. 2018 , 1, e183788	90
1724	Medical Expenditures Among Medicare Beneficiaries with Statin-Associated Adverse Effects Following Myocardial Infarction. 2018 , 32, 601-610	4
1723	Coronary Microvascular Disease Pathogenic Mechanisms and Therapeutic Options: JACC State-of-the-Art Review. 2018 , 72, 2625-2641	187
1722	Is lower low-density lipoprotein cholesterol associated with lower androgen and erectile dysfunction in men?. 2018 , 28, 1304-1310	7
1721	PCSK9 - A Journey to Cardiovascular Outcomes. <i>New England Journal of Medicine</i> , 2018 , 379, 2161-2162 59.2	12
1720	Patient adherence, compliance, and perspectives on evolocumab for the management of resistant hypercholesterolemia. 2018 , 12, 2263-2266	14
1719	Serum Triglycerides and Atherosclerotic Cardiovascular Disease: Insights from Clinical and Genetic Studies. 2018 , 10,	20
1718	Inclisiran for the treatment of cardiovascular disease: the ORION clinical development program. 2018 , 14, 433-442	40
1717	Mendelian Randomization Studies Promise to Shorten the Journey to FDA Approval. 2018 , 3, 690-703	9
1716	Healthy Behavior, Risk Factor Control, and Survival in the COURAGE Trial. 2018 , 72, 2297-2305	24
1715	Design of the randomized, placebo-controlled evolocumab for early reduction of LDL-cholesterol levels in patients with acute coronary syndromes (EVOPACS) trial. 2018 , 41, 1513-1520	14
1714	What the diabetes data in the FOURIER trial fail to show. 2019 , 21, 741-742	1
1713	Lipid-Lowering Drug Effects Beyond the Cardiovascular System: Relevance for Neuropsychiatric Disorders. 2018 , 21, 1076-1078	5

1712	Serum PCSK9 is modified by interleukin-6 receptor antagonism in patients with hypercholesterolaemia following non-ST-elevation myocardial infarction. 2018 , 5, e000765	7
1711	Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , 2018 , 379, 2097-2107	59.2 1277
1710	T2 magnetic resonance mapping: The key to find the 'Brahmastra' against atherosclerosis?. 2018 , 279, 95-96	
1709	Cardiologist and Diabetologist crosstalk in the era of cardiovascular outcome trials of novel glucose-lowering drugs. 2018 , 21, 80-86	2
1708	Clinician's Guide to Reducing Inflammation to Reduce Atherothrombotic Risk: JACC Review Topic of the Week. 2018 , 72, 3320-3331	81
1707	Coronary Artery Plaque Regression by a PCSK9 Antibody and Rosuvastatin in Double-heterozygous Familial Hypercholesterolemia with an LDL Receptor Mutation and a PCSK9 V4I Mutation. 2018 , 57, 3551-3557 ⁶	6
1706	Estimated Life Expectancy Without Recurrent Cardiovascular Events in Patients With Vascular Disease: The SMART-REACH Model. 2018 , 7, e009217	34
1705	Canadian Cardiovascular Society Position Statement on Familial Hypercholesterolemia: Update 2018. 2018 , 34, 1553-1563	58
1704	The Complex Interplay between Lipids, Immune System and Interleukins in Cardio-Metabolic Diseases. 2018 , 19,	18
1703	ORBITA - much ado about nothing?. 2018 , 48, 40-43	
1702	Atherothrombotic risk stratification after acute myocardial infarction: The Thrombolysis in Myocardial Infarction Risk Score for Secondary Prevention in the light of the French Registry of Acute ST Elevation or non-ST Elevation Myocardial Infarction registries. 2019 , 42, 227-234	8
1701	Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY OUTCOMES Trial. 2018 , 34, 1600-1605	18
1700	Metabolomic Consequences of Genetic Inhibition of PCSK9 Compared With Statin Treatment. 2018 , 138, 2499-2512	36
1699	Engineering of a GLP-1 analogue peptide/anti-PCSK9 antibody fusion for type 2 diabetes treatment. 2018 , 8, 17545	11
1698	Anti-Inflammatory Effects of a Vegan Diet Versus the American Heart Association-Recommended Diet in Coronary Artery Disease Trial. 2018 , 7, e011367	54
1697	Current concepts in atherosclerosis. 2018 , 34, 198-205	1
1696	Full Issue PDF. 2018 , 3, I-CXLVII	
1695	[Lipidology - important changes of the last 10 years]. 2018 , 160, 42-44	

1694	Interaction between platelets and endothelium: from pathophysiology to new therapeutic options. 2018 , 8, 568-580	42
1693	Medical Therapy for Long-Term Prevention of Atherothrombosis Following an Acute Coronary Syndrome: JACC State-of-the-Art Review. 2018 , 72, 2886-2903	33
1692	Impact of lipid-lowering therapy on glycemic control and the risk for new-onset diabetes mellitus. 2018 , 7, 212562	5
1691	Key aspects of PCSK9 inhibition beyond LDL lowering. 2018 , 29, 453-458	6
1690	The prediction of therapy-benefit for individual cardiovascular disease prevention: rationale, implications, and implementation. 2018 , 29, 436-444	15
1689	[Screening for familial hypercholesterolemia from low-density lipoprotein cholesterol levels at admission in the coronary care unit]. 2018 , 67, 300-309	
1688	Alirocumab dosing patterns during 40 months of open-label treatment in patients with heterozygous familial hypercholesterolemia. 2018 , 12, 1463-1470	2
1687	Current and Emerging Reconstituted HDL-apoA-I and HDL-apoE Approaches to Treat Atherosclerosis. 2018 , 8,	13
1686	Time to Make a Change: Assessing LDL-C Accurately in the Era of Modern Pharmacotherapeutics and Precision Medicine. 2018 , 12, 1	2
1685	Statin-Associated Muscle Disease: Advances in Diagnosis and Management. 2018 , 15, 1006-1017	35
1684	Epidemiology of familial hypercholesterolaemia: Community and clinical. 2018 , 277, 289-297	19
1683	CETP inhibition, statins and diabetes. 2018 , 278, 143-146	9
1682	Familial hypercholesterolemia in Canada: Initial results from the FH Canada national registry. 2018 , 277, 419-424	10
1681	Relationship of lipoprotein-associated apolipoprotein C-III with lipid variables and coronary artery disease risk: The EPIC-Norfolk prospective population study. 2018 , 12, 1493-1501.e11	6
1680	Medication-based versus target-based lipid management. 2018 , 10, 789-792	0
1679	T2 mapping MRI technique quantifies carotid plaque lipid, and its depletion after statin initiation, following acute myocardial infarction. 2018 , 279, 100-106	13
1678	Sterol Metabolism and Transport in Atherosclerosis and Cancer. 2018 , 9, 509	16
1677	Are Injection Site Reactions in Monoclonal Antibody Therapies Caused by Polysorbate Excipient Degradants?. 2018 , 107, 2735-2741	30

1676	Genetics of blood lipids among ~300,000 multi-ethnic participants of the Million Veteran Program. 2018 , 50, 1514-1523	260
1675	Trade-Off Between Lipid-Lowering Therapy and Costs in Patients With Cardiovascular Disease. 2018 , 82, 2481-2482	
1674	Therapie der diabetischen Dyslipidämie. 2018 , 14, 404-410	1
1673	Age-Biomarkers-Clinical Risk Factors for Prediction of Cardiovascular Events in Patients With Coronary Artery Disease. 2018 , 38, 2519-2527	16
1672	Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials. 2018 , 392, 1311-1320	208
1671	Familial hypercholesterolemia prevalence in an admixed racial society: Sex and race matter. The ELSA-Brasil. 2018 , 277, 273-277	12
1670	Lipoprotein(a) Is Risky, but What Do We Do About It?. 2018 , 12, 1	1
1669	Landmark Trials in Cardiology in 2017-Celebrating 40 Years of Angioplasty. 2018 , 27, 167-173	3
1668	Long-term safety and efficacy of alirocumab in patients with heterozygous familial hypercholesterolemia: An open-label extension of the ODYSSEY program. 2018 , 278, 307-314	30
1667	Dyslipidemias in clinical practice. 2018 , 487, 117-125	15
1666	LDL-cholesterol target achievement in patients with heterozygous familial hypercholesterolemia at Groote Schuur Hospital: Minority at target despite large reductions in LDL-C. 2018 , 277, 327-333	7
1665	Nonstatin Therapy for Dyslipidemia. 2018 , 123, 1036-1038	1
1664	Lower extremity arterial disease in patients with diabetes: a contemporary narrative review. 2018 , 17, 138	58
1663	Realizing Value With Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: Are We Closer to Finding the Sweet Spot?. 2018 , 138, 767-769	1
1662	PCSK9 (Proprotein Convertase Subtilisin/Kexin 9) Status and Protection Against Ischemic Stroke: PheWAS, TreWAS, and More. 2018 , 11, e002247	
1661	Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial. 2018 , 6, 934-943	58
1660	Large-Scale Phenome-Wide Association Study of Variants Demonstrates Protection Against Ischemic Stroke. 2018 , 11, e002162	27
1659	How to Interpret Recent CV Outcome Trials and Future: PCSK9 Inhibitors. 2018 , 7, 1	0

1658	Lipid management in patients with chronic kidney disease. 2018 , 14, 727-749	82
1657	Impact of Apolipoprotein(a) Isoform Size on Lipoprotein(a) Lowering in the HPS2-THRIVE Study. 2018 , 11, e001696	38
1656	Evidence-Based Management of Diabetes in Older Adults. 2018 , 35, 1065-1078	11
1655	Lipoprotein(a) and secondary prevention of atherothrombotic events: A critical appraisal. 2018 , 12, 1358-1366	20
1654	Eradicating the Burden of Atherosclerotic Cardiovascular Disease by Lowering Apolipoprotein B Lipoproteins Earlier in Life. 2018 , 7, e009778	43
1653	Beyond Statins: Who and When to Prescribe?. 2018 , 18, 126	3
1652	Vulnerable Plaques, Vulnerable Patients, and Intravascular Imaging. 2018 , 72, 2022-2026	5
1651	Familial Hypercholesterolaemia Diagnosis and Management. 2018 , 13, 14-20	18
1650	New joint consensus initiative on quantifying atherogenic lipoproteins. 2018 , 279, 97-99	1
1649	The best in coronary artery disease management is yet to come. 2018 , 111, 621-624	0
1648	Management of Severe Dyslipidaemia: Role of PCSK9 Inhibitors. 2018 , 13, 9-13	1
1647	Safety and efficacy of statin therapy. 2018 , 15, 757-769	131
1646	Lower On-Treatment Low-Density Lipoprotein Cholesterol and Major Adverse Cardiovascular Events in Women and Men: Pooled Analysis of 10 ODYSSEY Phase 3 Alirocumab Trials. 2018 , 7, e009221	4
1645	Measurement of Low-Density Lipoprotein Cholesterol Levels in Primary and Secondary Prevention Patients: Insights From the PALM Registry. 2018 , 7, e009251	5
1644	[Newer evidences and recommendations in lipidology]. 2018 , 159, 1303-1309	1
1643	Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017. 2018 , 25, 846-984	295
1642	A comment to: Predictors of low-density lipoprotein cholesterol target value attainment in the DYSIS II Europe Study. 2018 , 25, 1964-1965	
1641	The Effect of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Nonfasting Remnant Cholesterol in a Real World Population. 2018 , 2018, 9194736	6

1640	Associations of device-measured physical activity across adolescence with metabolic traits: Prospective cohort study. 2018 , 15, e1002649	24
1639	Prevalence and pharmacologic management of familial hypercholesterolemia in an unselected contemporary cohort of patients with stable coronary artery disease. 2018 , 41, 1075-1083	5
1638	Percutaneous Coronary Intervention in Familial Hypercholesterolemia Is Understudied. 2018 , 5, 116	4
1637	Examining the Role of and Treatment Directed at IL-1 α in Atherosclerosis. 2018 , 20, 53	17
1636	Value of a Hypothetical Pharmacogenomic Test for the Diagnosis of Statin-Induced Myopathy in Patients at High Cardiovascular Risk. 2018 , 22, 641-652	1
1635	Effect of Money-Back Guarantees on the Cost-Effectiveness of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors. 2018 , 168, 896-898	4
1634	Primary and Secondary Prevention of Cardiovascular Disease. 2018 , 63-76	
1633	Lipids: a personal view of the past decade. 2018 , 17, 461-478	5
1632	Diagnostic expansion in clinical trials: myocardial infarction, stroke, cancer recurrence, and metastases may not be the hard endpoints you thought they were. 2018 , 362, k3783	6
1631	Cardiovascular and microvascular outcomes of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled cardiovascular outcome trials with trial sequential analysis. 2018 , 19, 58	10
1630	LDL-C does not cause cardiovascular disease: a comprehensive review of the current literature. 2018 , 11, 959-970	52
1629	Biologic bases of residual risk of cardiovascular events: A flawed concept. 2018 , 25, 1831-1835	2
1628	Circulating PCSK9 levels are not associated with the severity of hepatic steatosis and NASH in a high-risk population. 2018 , 278, 82-90	17
1627	Optimising treatment of hyperlipidaemia: Quantitative evaluation of UK, USA and European guidelines taking account of both LDL cholesterol levels and cardiovascular disease risk. 2018 , 278, 135-142	12
1626	[Acute coronary syndrome]. 2018 , 160, 52-61	1
1625	Associations between very low concentrations of low density lipoprotein cholesterol, high sensitivity C-reactive protein, and health outcomes in the Reasons for Geographical and Racial Differences in Stroke (REGARDS) study. 2018 , 39, 3641-3653	41
1624	Relationship between very low low-density lipoprotein cholesterol concentrations not due to statin therapy and risk of type 2 diabetes: A US-based cross-sectional observational study using electronic health records. 2018 , 15, e1002642	15
1623	A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9. 2018 ,	

1622	Pharmacogenetics in Cardiovascular Medicine. 2018 , 83, 333-360	4
1621	Prevention of Heart Failure With SGLT-2 Inhibition: Insights From CVD-REAL. 2018 , 71, 2507-2510	7
1620	A Deeper Dive Into the CANTOS "Responders" Substudy. 2018 , 93, 830-833	5
1619	From lipid locus to drug target through human genomics. 2018 , 114, 1258-1270	10
1618	PCSK9 expression in the ischaemic heart and its relationship to infarct size, cardiac function, and development of autophagy. 2018 , 114, 1738-1751	39
1617	Cholesterol and inflammation: The lesser the better in atherothrombosis. 2018 , 25, 944-947	7
1616	Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM. 2018 , 64, 1006-1033	124
1615	Further options for treating lipids in people with diabetes: targeting LDL-cholesterol and beyond. 2018 , 35, 1173	2
1614	Achievement of low-density lipoprotein cholesterol goals in 18 countries outside Western Europe: The International ChoLesterol management Practice Study (ICLPS). 2018 , 25, 1087-1094	53
1613	Comparison of LDL-C Reduction Using Different Evolocumab Doses and Intervals: Biological Insights and Treatment Implications. 2018 , 23, 423-432	7
1612	Elevated plasma lipoprotein(a) levels were associated with increased risk of cardiovascular events in Chinese patients with stable coronary artery disease. 2018 , 8, 7726	21
1611	PCSK9 inhibition: ready for prime time in CKD?. 2018 , 93, 1267-1269	7
1610	Atherosclerotic Cardiovascular Disease in South Asians in the United States: Epidemiology, Risk Factors, and Treatments: A Scientific Statement From the American Heart Association. 2018 , 138, e1-e34	169
1609	Are PCSK9 Inhibitors Cost Effective?. 2018 , 36, 1031-1041	14
1608	Interplay between hypercholesterolaemia and inflammation in atherosclerosis: Translating experimental targets into clinical practice. 2018 , 25, 948-955	27
1607	Economic Evaluation of the PCSK9 Inhibitors in Prevention of the Cardiovascular Diseases. 2018 , 20, 51	2
1606	Towards a More Personalized Treatment of Dyslipidemias to Prevent Cardiovascular Disease. 2018 , 20, 56	2
1605	PCSK9 inhibitors in familial hypercholesterolemia: What is the evidence?. 2018 , 12, 1106-1108	3

1604	Risk factor profile and anatomic features of previously asymptomatic patients presenting with carotid-related stroke. 2018 , 68, 1390-1395	19
1603	Combination Lipid-Lowering Therapies for the Prevention of Recurrent Cardiovascular Events. 2018 , 20, 55	4
1602	Mendelian randomization: Its impact on cardiovascular disease. 2018 , 72, 307-313	18
1601	PCSK9 monoclonal antibody on a knife-edge: An article of faith in FH?. 2018 , 12, 844-848	0
1600	The Genetic Background of Neonatal Disease. 2018 , 113, 400-405	4
1599	: The Apple That Falls Closely to the Family Tree. 2018 , 3, 332-333	
1598	The cost-effectiveness of PCSK9 inhibitors - The Australian healthcare perspective. 2018 , 267, 183-187	19
1597	Projected Real-World Effectiveness of Using Aggressive Low-Density Lipoprotein Cholesterol Targets Among Elderly Statin Users Following Acute Coronary Syndromes in Canada. 2018 , 7,	9
1596	Role of PCSK9 in lipid metabolism and atherosclerosis. 2018 , 104, 36-44	26
1595	PCSK-9: Entering a new era of cardiovascular risk prediction. 2018 , 263, 152-153	1
1594	Alirocumab as add-on therapy to statins: current evidence and clinical potential. 2018 , 12, 191-202	3
1593	Diabetes mellitus and cardiovascular risk: Update of the recommendations of the Diabetes and Cardiovascular Disease working group of the Spanish Diabetes Society (SED, 2018). 2018 , 30, 137-153	8
1592	Association of Plasma Lipoprotein(a) With Long-Term Adverse Events in Patients With Chronic Kidney Disease Who Underwent Percutaneous Coronary Intervention. 2018 , 122, 2043-2048	7
1591	Update on statin drugs for lipid disorders. 2018 , 39, 350-351	1
1590	Have we reached the bottom of the bottomless pit- lessons from the recent lipid-lowering trials?. 2018 , 70, 331-334	
1589	[Peripheral Arterial Disease: When is a PCSK9 Inhibitor Useful?]. 2018 , 143, 1391-1396	1
1588	Effects of a Novel Selective Peroxisome Proliferator-Activated Receptor β -Modulator K-877 (Pemafibrate) on Postprandial hyperlipidemia. 2018 , 25, 126-127	1
1587	PCSK9 and neurocognitive function: Should it be still an issue after FOURIER and EBBINGHAUS results?. 2018 , 12, 1123-1132	27

1586	Causal Inference in Cancer Epidemiology: What Is the Role of Mendelian Randomization?. 2018 , 27, 995-1010	43
1585	Advances in Clinical Cardiology 2017: A Summary of Key Clinical Trials. 2018 , 35, 899-927	1
1584	Inhibition of low-density lipoprotein receptor degradation with a cyclic peptide that disrupts the homodimerization of IDOL E3 ubiquitin ligase. 2018 , 9, 5957-5966	13
1583	Lipoprotein(a) and cardiovascular disease: current state and future directions for an enigmatic lipoprotein. 2018 , 23, 1099-1112	16
1582	The annual rate of coronary artery calcification with combination therapy with a PCSK9 inhibitor and a statin is lower than that with statin monotherapy. 2018 , 4, 7	21
1581	Unmet Need for Adjunctive Dyslipidemia Therapy in Hypertriglyceridemia Management. 2018 , 72, 330-343	107
1580	Personalized regimen for PCSK9 inhibitors: A therapeutic option that maintains efficacy and reduces costs. 2018 , 12, 1324-1325	16
1579	Nichtmedikamentöse Therapie von Fettstoffwechselstörungen: Möglichkeiten und Grenzen. 2018 , 13, 1-11	
1578	Lipid management in ACS: Should we go lower faster?. 2018 , 275, 368-375	23
1577	Cardiovascular Outcomes of PCSK9 Inhibitors: With Special Emphasis on Its Effect beyond LDL-Cholesterol Lowering. 2018 , 2018, 3179201	14
1576	PCSK9 Inhibitors in Lipid Management of Patients With Diabetes Mellitus and High Cardiovascular Risk: A Review. 2018 , 7,	32
1575	Rationale and design of a randomized study to assess the efficacy and safety of evolocumab in patients with diabetes and dyslipidemia: The BERSON clinical trial. 2018 , 41, 1117-1122	9
1574	Case reports of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition nonresponse. 2018 , 12, 1141-1145	6
1573	Cost-effectiveness and Budget Impact of Treatment with Evolocumab Versus Statins and Ezetimibe for Hypercholesterolemia in Spain. 2018 , 71, 1027-1035	5
1572	Novel Therapeutic Targets for Managing Dyslipidemia. 2018 , 39, 733-747	22
1571	STEMI: Management. 2018 , 474-488	
1570	Cardiovascular disease risk associated with elevated lipoprotein(a) attenuates at low low-density lipoprotein cholesterol levels in a primary prevention setting. 2018 , 39, 2589-2596	56
1569	Efficacy and safety of alirocumab in individuals with type 2 diabetes mellitus with or without mixed dyslipidaemia: Analysis of the ODYSSEY LONG TERM trial. 2018 , 276, 124-130	18

1568	Roles of Spicy Foods and Their Bioactive Compounds in Management of Hypercholesterolemia. 2018 , 66, 8662-8671	13
1567	From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: Impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients. 2018 , 25, 1843-1851	11
1566	Non-Native Conformational Isomers of the Catalytic Domain of PCSK9 Induce an Immune Response, Reduce Lipids and Increase LDL Receptor Levels. 2018 , 19,	1
1565	Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels: A Meta-analysis. 2018 , 3, 823-828	102
1564	Low-Density Lipoprotein Cholesterol and Cardiovascular Risk Reduction: How Low Is Low Enough Without Causing Harm?. 2018 , 3, 802-803	1
1563	Precision Medicine and Personalized Management of Lipoprotein and Lipid Disorders in Chronic and End-Stage Kidney Disease. 2018 , 38, 369-382	2
1562	Letter by Alkhalil Regarding Article, "Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)". 2018 , 138, 220-221	
1561	Medical Therapies. 2018 , 357-372	
1560	Lipid and Non-lipid Factors Affecting Macrophage Dysfunction and Inflammation in Atherosclerosis. 2018 , 9, 654	41
1559	Recent Advances in Primary and Secondary Prevention of Atherosclerotic Stroke. 2018 , 20, 145-166	22
1558	Diabetes and Dislipidemia. 2018 , 1-20	
1557	Hypercholesterolaemia - practical information for non-specialists. 2018 , 14, 1-21	30
1556	Patent foramen ovale increases stroke risk in older people. 2018 , 14, 573-574	4
1555	The interplay between cholesterol and breast cancer: is there a potential role for statin therapy?. 2018 , 14, 1885-1888	3
1554	Familial Hypercholesterolemia: New Horizons for Diagnosis and Effective Management. 2018 , 9, 707	22
1553	Beware of early drug intolerance in secondary prevention of cardiovascular disease. 2018 , 4, 202-204	
1552	PCSK9 inhibition for patients with and without prior coronary revascularization: Potential additional benefit of a novel therapeutic agent. 2018 , 277, 177-178	2
1551	Cost-Effectiveness of PCSK9 Inhibitor Plus Statin in Patients With Triple-Vessel Coronary Artery Disease in Japan. 2018 , 82, 2602-2608	7

1550	Pharmacovigilance and expedited drug approvals. 2018 , 41, 50-53	4
1549	Sitosterolemia, Hypercholesterolemia, and Coronary Artery Disease. 2018 , 25, 783-789	55
1548	Effect of Infusion of High-Density Lipoprotein Mimetic Containing Recombinant Apolipoprotein A-I Milano on Coronary Disease in Patients With an Acute Coronary Syndrome in the MILANO-PILOT Trial: A Randomized Clinical Trial. 2018 , 3, 806-814	84
1547	Sex Differences in the Coronary System. 2018 , 1065, 257-278	28
1546	PCSK9 inhibitors for prevention of atherosclerotic cardiovascular disease. 2018 , 12, 835-843	5
1545	Safety and Efficacy of Extremely Low LDL-Cholesterol Levels and Its Prospects in Hyperlipidemia Management. 2018 , 2018, 8598054	21
1544	Highlights from the 2018 American College of Cardiology scientific session in Orlando, Florida. 2018 , 46, 431-433	
1543	Scientific Contributions of Population-Based Studies to Cardiovascular Epidemiology in the GWAS Era. 2018 , 5, 57	2
1542	Antiinflammatory Therapy in Clinical Care: The CANTOS Trial and Beyond. 2018 , 5, 62	45
1541	Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. 2018 , 362, k601	576
1540	Clonal Hematopoiesis: Somatic Mutations in Blood Cells and Atherosclerosis. 2018 , 11, e001926	20
1539	Management of Dyslipidemia in Type 2 Diabetes: Recent Advances in Nonstatin Treatment. 2018 , 6,	1
1538	CVD Risk Stratification in the PCSK9 Era: Is There a Role for LDL Subfractions?. 2018 , 6,	7
1537	Editorial commentary: Confessions of a drug dealer. 2018 , 28, 532-533	
1536	Lipid lowering drugs and inflammatory changes: an impact on cardiovascular outcomes?. 2018 , 50, 461-484	18
1535	PCSK9 inhibitors and LDL reduction: pharmacology, clinical implications, and future perspectives. 2018 , 16, 567-578	9
1534	Coding variants in and increase risk of atrial fibrillation. 2018 , 1, 68	21
1533	Low-Grade Inflammation Modifies Cardiovascular Risk Even at Very Low LDL-C Levels: Are We Aiming for a Dual Target Concept?. 2018 , 138, 150-153	15

1532	Recent Advances in Treatment of Coronary Artery Disease: Role of Science and Technology. 2018 , 19,	54
1531	The Role of High-Density Lipoproteins in Diabetes and Its Vascular Complications. 2018 , 19,	19
1530	Deleting Death and Dialysis: Conservative Care of Cardio-Vascular Risk and Kidney Function Loss in Chronic Kidney Disease (CKD). 2018 , 10,	19
1529	CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2018 EXECUTIVE SUMMARY. 2018 , 24, 91-120	321
1528	Profile of evolocumab and its cost-effectiveness in patients with high cardiovascular risk: literature review. 2018 , 18, 461-474	2
1527	Hyperlipidemia: Management with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors. 2018 , 31, 628-634	7
1526	Cardiovascular Risk Assessment in Patients with Hypertriglyceridemia. 2018 , 20, 71	
1525	Efficacy and safety of alirocumab in patients with or without prior coronary revascularization: Pooled analysis of eight ODYSSEY phase 3 trials. 2018 , 277, 211-218	9
1524	Clinical Lipidology and the Prevention of Vascular Disease: Time for Personalized Therapy. 2018 , 104, 269-281	1
1523	Cost-effectiveness of Evolocumab. 2018 , 71, 1089	
1522	Susceptibility of low-density lipoprotein particles to aggregate depends on particle lipidome, is modifiable, and associates with future cardiovascular deaths. 2018 , 39, 2562-2573	72
1521	Lipoprotein(a): the perpetual supporting actor. 2018 , 39, 2597-2599	6
1520	¶The lower the better¶revisited: low-density lipoprotein and lipoprotein(a). 2018 , 39, 2509-2512	1
1519	Inclisiran: A New Promising Agent in the Management of Hypercholesterolemia. 2018 , 6,	37
1518	Plasma high density lipoproteins: Therapeutic targeting and links to atherogenic inflammation. 2018 , 276, 39-43	37
1517	Extending the "Lower is Better" Principle to Japanese and Possibly Other Asian Populations. 2018 , 137, 2010-2012	1
1516	High- Versus Low-Dose Statin: Effects on Cardiovascular Events and All-Cause Death. 2018 , 137, 2013-2015	4
1515	Therapeutic Agents Targeting Cardiometabolic Risk for Preventing and Treating Atherosclerotic Cardiovascular Diseases. 2018 , 104, 257-268	8

1514	Report from the 3rd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group. 2018 , 17, 30	15
1513	Incidence, timing, and type of first and recurrent ischemic events in patients with and without peripheral artery disease after an acute coronary syndrome. 2018 , 201, 25-32	6
1512	Biologics and Cardiovascular Disease. 2018 , 72, 77-85	9
1511	Genetic Regulation of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Plasma Levels and Its Impact on Atherosclerotic Vascular Disease Phenotypes. 2018 , 11, e001992	22
1510	PCSK9: From Basic Science Discoveries to Clinical Trials. 2018 , 122, 1420-1438	115
1509	Clinical trials. 2018 , 29, 277-278	
1508	Baseline serum sitosterol level as predictor of adverse clinical events in acute coronary syndrome patients with dyslipidaemia: A sub-analysis of HIJ-PROPER. 2018 , 274, 139-145	17
1507	Anticalin Proteins as Therapeutic Agents in Human Diseases. 2018 , 32, 233-243	52
1506	SOAT1 deficiency attenuates atherosclerosis by regulating inflammation and cholesterol transportation via HO-1 pathway. 2018 , 501, 343-350	11
1505	Critical Appraisal of the 2018 ACC Scientific Sessions Late-Breaking Trials From a Statistician's Perspective. 2018 , 71, 2957-2969	16
1504	Role of proprotein convertase subtilisin/kexin type 9 inhibitors in patients with coronary artery disease undergoing percutaneous coronary intervention. 2018 , 16, 419-429	4
1503	Which Lipids Should Be Analyzed for Diagnostic Workup and Follow-up of Patients with Hyperlipidemias?. 2018 , 20, 88	10
1502	Lipoprotein-apheresis in familial hypercholesterolemia: Long-term patient compliance in a French cohort. 2018 , 277, 66-71	8
1501	Money-Back Guarantees for Expensive Drugs: Wolf's Clothing but a Sheep Underneath. 2018 , 168, 888-889	5
1500	Is there a role for fractional flow reserve in coronary artery bypass graft (CABG) planning?. 2018 , 7, 546-551	4
1499	Prescription of statins at discharge and 1-year risk of major clinical outcomes among acute coronary syndromes patients with extremely low LDL-cholesterol in clinical pathways for acute coronary syndromes studies. 2018 , 41, 1192-1200	3
1498	RNA Therapeutics in Cardiovascular Precision Medicine. 2018 , 9, 953	42
1497	Novel pharmacological targets for calcific aortic valve disease: Prevention and treatments. 2018 , 136, 74-82	20

1496	Imaging Coronary Anatomy and Reducing Myocardial Infarction. <i>New England Journal of Medicine</i> , 2018 , 379, 977-978	59.2	6
1495	Coronary CT Angiography and 5-Year Risk of Myocardial Infarction. <i>New England Journal of Medicine</i> , 2018 , 379, 924-933	59.2	471
1494	Low-Density Lipoprotein Cholesterol: Is 160 the New 190?. 2018 , 138, 2326-2329		8
1493	Non-invasive detection of coronary inflammation using computed tomography and prediction of residual cardiovascular risk (the CRISP CT study): a post-hoc analysis of prospective outcome data. 2018 , 392, 929-939		255
1492	New pharmacological approaches for cardiovascular risk. 2018 , 151, 145-147		
1491	Growth Differentiation Factor 15 Maturation Requires Proteolytic Cleavage by PCSK3, -5, and -6. 2018 , 38,		21
1490	Lipid Target in Very High-Risk Cardiovascular Patients: Lesson from PCSK9 Monoclonal Antibodies. 2018 , 6,		8
1489	Current Role of Lipoprotein Apheresis in the Treatment of High-Risk Patients. 2018 , 5,		20
1488	Pulse pressure for selecting the optimal cardiac strategy in patients with type 2 diabetes and coronary artery disease. 2018 , 273, 1-7		2
1487	Drugs for lipid disorders, antiplatelet drugs and fibrinolytics. 2018 , 46, 573-577		
1486	Gazing into smoldering volcanoes: precision cardiac imaging. 2018 , 4, FSO294		
1485	Strategies to achieve low-density lipoprotein cholesterol targets in high-risk patients. 2018 , 34, 1713-1715		
1484	National Trends in Nonstatin Use and Expenditures Among the US Adult Population From 2002 to 2013: Insights From Medical Expenditure Panel Survey. 2018 , 7,		16
1483	Prices For Common Cardiovascular Drugs In The US Are Not Consistently Aligned With Value. 2018 , 37, 1298-1305		4
1482	Lipid-lowering Therapy and Goal Achievement in High-risk Patients From French General Practice. 2018 , 40, 1484-1495.e22		5
1481	Diagnosing Resistance to a Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor. 2018 , 168, 376-379		26
1480	The ODYSSEY Outcomes trial: Clinical implications and exploration of the limits of what can be achieved through lipid lowering. 2018 , 12, 1102-1105		4
1479	What is the role of PCSK9 inhibitors in treating hypercholesterolemia?. 2018 , 31, 14-15		3

1478	Lipid-lowering therapy with PCSK9-inhibitors in the real-world setting: Two-year experience of a regional lipid clinic. 2018 , 36, e12439	18
1477	Recomendaciones preventivas cardiovasculares. Actualizaci3n PAPPs 2018. 2018 , 50 Suppl 1, 4-28	10
1476	A clinical and proteomics approach to predict the presence of obstructive peripheral arterial disease: From the Catheter Sampled Blood Archive in Cardiovascular Diseases (CASABLANCA) Study. 2018 , 41, 903-909	9
1475	Full Issue PDF. 2018 , 3, I-CLXXIV	
1474	Response by Bohula et al to Letters Regarding Article, "Prevention of Stroke With the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)". 2018 , 137, 2662-2663	
1473	Immune Mechanisms in Atherosclerosis and Potential for Immunomodulatory Therapies. 2018 , 211-224	
1472	HDL-cholesterol, genetics, and coronary artery disease: the myth of the 'good cholesterol'?. 2018 , 39, 2179-2182	8
1471	Squaring up the health economics of PCSK9 monoclonal antibodies 'down under'. 2018 , 267, 193-194	3
1470	Statement for Appropriate Clinical Use of PCSK9 Inhibitors. 2018 , 25, 747-750	4
1469	Determinants of Achieved LDL Cholesterol and "Non-HDL" Cholesterol in the Management of Dyslipidemias. 2018 , 20, 60	4
1468	Proprotein Convertase Subtilisin/kexin type 9 Inhibition in Cardiovascular Prevention. 2018 , 24, 442-450	0
1467	Towards more specific treatment for diabetic dyslipidemia. 2018 , 29, 307-312	10
1466	Comparative Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition and Statins on Postprandial Triglyceride-Rich Lipoprotein Metabolism. 2018 , 38, 1644-1655	19
1465	NLRP3 Inflammasome and the IL-1 Pathway in Atherosclerosis. 2018 , 122, 1722-1740	293
1464	Role of genetics in the prediction of statin-associated muscle symptoms and optimization of statin use and adherence. 2018 , 114, 1073-1081	29
1463	Long-Term Prognosis of Patients With Transient Ischemic Attack or Stroke and Symptomatic Vascular Disease in Multiple Arterial Beds. 2018 , 49, 1639-1646	10
1462	Lowering LDL-Cholesterol and CV Benefits: Is There a Limit to How Low LDL-C Needs to be for Optimal Health Benefits?. 2018 , 104, 290-296	1
1461	Diabetes mellitus and cardiovascular risk: Update of the recommendations of the Diabetes and Cardiovascular Disease working group of the Spanish Diabetes Society (SED, 2018). 2018 , 30, 137-153	1

1460	Comparison of Low-Density Lipoprotein Cholesterol Assessment by Martin/Hopkins Estimation, Friedewald Estimation, and Preparative Ultracentrifugation: Insights From the FOURIER Trial. 2018 , 3, 749-753	66
1459	Measuring Low-Density Lipoprotein Cholesterol: When Is More Accurate Better?. 2018 , 3, 754-755	
1458	PCSK9 in cholesterol metabolism: from bench to bedside. 2018 , 132, 1135-1153	22
1457	Efficacy, safety, and tolerability of evolocumab in pediatric patients with heterozygous familial hypercholesterolemia: Rationale and design of the HAUSER-RCT study. 2018 , 12, 1199-1207	15
1456	Proprotein convertase subtilisin/kexin type 9 inhibitors for reduction of cardiovascular events. 2018 , 75, 747-754	2
1455	ESC 2017 STEMI Guidelines: a step forward for a better cure. 2018 , 4, 133-135	2
1454	Pharmacological treatment for dyslipidemia. 2018 , 24, 32-37	
1453	Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies: A Mendelian Randomization Analysis. 2018 , 3, 619-627	235
1452	Pharmacological Management of Dyslipidemia in Atherosclerosis: Limitations, Challenges, and New Therapeutic Opportunities. 2019 , 70, 197-209	10
1451	Cholesterol Lowering Guidelines: From Whence We Came and Where We Are Now. 2019 , 35, 590-597	2
1450	Efficacy and Safety of Alirocumab in Japanese Patients with Diabetes Mellitus: Post-hoc Subanalysis of ODYSSEY Japan. 2019 , 26, 282-293	5
1449	Risk Reduction to Disease Management: Clinical Pharmacists as Cardiovascular Care Providers. 2019 , 44, 276-293	2
1448	Adverse Events Associated With PCSK9 Inhibitors: A Real-World Experience. 2019 , 105, 496-504	28
1447	Dyslipidemia. 2019 , 150-155	
1446	Using Genetic Variants in the Targets of Lipid Lowering Therapies to Inform Drug Discovery and Development: Current and Future Treatment Options. 2019 , 105, 568-581	3
1445	ABCA1 Overexpression in Endothelial Cells In Vitro Enhances ApoA1-Mediated Cholesterol Efflux and Decreases Inflammation. 2019 , 30, 236-248	25
1444	A New Perspective for Chinese Medicine Intervention for Coronary Artery Disease: Targeting Inflammation. 2019 , 25, 3-8	8
1443	Dyslipidemia in Diabetes. 2019 , 186-198	2

1442	Whole-body magnetic resonance angiography. 2019 , 74, 3-12	3
1441	Lipids and Women's Health: Recent Updates and Implications for Practice. 2019 , 28, 752-760	3
1440	The Effect of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition on Sterol Absorption Markers in a Cohort of Real-World Patients. 2019 , 24, 54-61	3
1439	Decoding inflammation, its causes, genomic responses, and emerging countermeasures. 2019 , 90, e12812	24
1438	PCSK9 Inhibitors in a Statin-Intolerant Transgender Man With Heterozygous Familial Hypercholesterolemia: A Case Report. 2019 , 3, 1461-1464	1
1437	Epidemiology of Vascular Diseases. 2019 , 299-306	
1436	[Gene editing in drug discovery and therapeutic innovation]. 2019 , 35, 309-315	
1435	Strategies to Overcome Residual Risk During Statins Era. 2019 , 83, 1973-1979	14
1434	In Stufen zu möglichst niedrigem LDL-Cholesterin bei Diabetes. 2019 , 13, 35-41	
1433	Biomarkers and Clinical Cardiovascular Outcomes With Ezetimibe in the IMPROVE-IT Trial. 2019 , 74, 1057-1068	21
1432	Association Between Baseline, Achieved, and Reduction of CRP and Cardiovascular Outcomes After LDL Cholesterol Lowering with Statins or Ezetimibe: A Systematic Review and Meta-Analysis. 2019 , 8, e012428	5
1431	Konservative Therapie der peripheren arteriellen Verschlusskrankheit. 2019 , 24, 431-440	0
1430	Atherosclerosis. 2019 , 5, 56	657
1429	More- Versus Less-Intensive Lipid-Lowering Therapy. 2019 , 12, e005460	2
1428	Prinzip der mendelschen Randomisierung und Anwendung in der kardiovaskulären Medizin. 2019 , 13, 146-152	1
1427	Pharmacological lipid-modification therapies for prevention of ischaemic heart disease: current and future options. 2019 , 394, 697-708	43
1426	The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019). 2019 , 42, 1235-1481	468
1425	Lipid-lowering agents for concurrent cardiovascular and chronic kidney disease. 2019 , 20, 2007-2017	14

1424	The patient journey with proprotein convertase subtilisin/kexin type 9 inhibitors in community practice. 2019 , 13, 725-734	8
1423	PCSK9 inhibition in patients with heart transplantation: A case series. 2019 , 13, 721-724	7
1422	Anti-PCSK9 antibodies inhibit pro-atherogenic mechanisms in APOE*3Leiden.CETP mice. 2019 , 9, 11079	13
1421	Myocardial Infarction-From Atherosclerosis to Thrombosis. 2019 , 39, e176-e185	39
1420	Optimizing Dyslipidemia Management for the Prevention of Cardiovascular Disease: a Focus on Risk Assessment and Therapeutic Options. 2019 , 21, 110	11
1419	Treatment effect of alirocumab according to age group, smoking status, and hypertension: Pooled analysis from 10 randomized ODYSSEY studies. 2019 , 13, 735-743	1
1418	Simulation of impact on cardiovascular events due to lipid-lowering therapy intensification in a population with atherosclerotic cardiovascular disease. 2019 , 216, 30-41	4
1417	Effects of ezetimibe/simvastatin 10/10 mg versus Rosuvastatin 10 mg on carotid atherosclerotic plaque inflammation. 2019 , 19, 201	4
1416	Natriuretic Peptides in the Cardiovascular System: Multifaceted Roles in Physiology, Pathology and Therapeutics. 2019 , 20,	19
1415	PCSK9 inhibition and inflammation: A narrative review. 2019 , 288, 146-155	52
1414	Targeting Early Atherosclerosis: A Focus on Oxidative Stress and Inflammation. 2019 , 2019, 8563845	191
1413	Lipids in South Asians: Epidemiology and Management. 2019 , 13, 1	3
1412	Genetically-predicted life-long lowering of low-density lipoprotein cholesterol is associated with decreased frailty: A Mendelian randomization study in UK biobank. 2019 , 45, 487-494	6
1411	Definitions, adjudication, and reporting of pulmonary embolism-related death in clinical studies: A systematic review. 2019 , 17, 1590-1607	19
1410	Diabetes and Atherogenic Dyslipidemia. 2019 , 587-596	1
1409	Effect of initiating statin therapy on long-term outcomes of patients with dyslipidemia after intracerebral hemorrhage. 2019 , 288, 137-145	8
1408	Impact of Lipid-Lowering Therapy on Mortality According to the Baseline Non-HDL Cholesterol Level: A Meta-Analysis. 2019 , 26, 263-272	3
1407	BMS consensus statement for primary prevention of coronary heart disease in women. 2019 , 25, 64-69	1

1406	Economic evaluation of lipid lowering with PCSK9 inhibitors in patients with familial hypercholesterolemia: Methodological aspects. 2019 , 287, 140-146	5
1405	PEARL: A Non-interventional Study of Real-World Alirocumab Use in German Clinical Practice. 2019 , 6, 115-123	6
1404	Lipoprotein(a): An independent, genetic, and causal factor for cardiovascular disease and acute myocardial infarction. 2019 , 71, 99-112	16
1403	Mortality reduction with PCSK9 inhibition: A case of cautious optimism. 2019 , 13, 712-713	
1402	Extreme Atherosclerotic Cardiovascular Disease (ASCVD) Risk Recognition. 2019 , 19, 61	20
1401	Practical guide for the use of PCSK9 inhibitors in Portugal. 2019 , 38, 391-405	
1400	PCSK9 inhibitors: what we know, what we should have understood, and what is to come. 2019 ,	2
1399	Effect of Access to Prescribed PCSK9 Inhibitors on Cardiovascular Outcomes. 2019 , 12, e005404	29
1398	The Future of Lipid-lowering Therapy. 2019 , 8,	8
1397	Incidence of Cardiovascular Disease in Patients with Familial Hypercholesterolemia Phenotype: Analysis of 5 Years Follow-Up of Real-World Data from More than 1.5 Million Patients. 2019 , 8,	21
1396	Integrative analysis of loss-of-function variants in clinical and genomic data reveals novel genes associated with cardiovascular traits. 2019 , 12, 108	5
1395	PCSK9 Inhibition: New Treatment Options and Perspectives to Lower Atherogenic Lipoprotein Particles and Cardiovascular Risk. 2019 , 21, 40	2
1394	Lipid-lowering agents for the treatment of hyperlipidemia in patients with chronic kidney disease and end-stage renal disease on dialysis: a review. 2019 , 35, 431-441	2
1393	Rounding the corner on residual risk: Implications of REDUCE-IT for omega-3 polyunsaturated fatty acids treatment in secondary prevention of atherosclerotic cardiovascular disease. 2019 , 42, 829	9
1392	Low-Density Lipoprotein Cholesterol After an Acute Coronary Syndrome: How Low to Go?. 2019 , 21, 77	3
1391	Optimal Non-invasive Strategies to Reduce Recurrent Atherosclerotic Cardiovascular Disease Risk. 2019 , 21, 38	
1390	Association of baseline LDL-C with total and cardiovascular mortality in patients using proprotein convertase subtilisin-kexin type 9 inhibitors: A systematic review and meta-analysis. 2019 , 13, 538-549	9
1389	Observational study of the medical management of patients with peripheral artery disease. 2019 , 106, 1168-1177	25

1388	Indications of PCSK9 inhibitors in clinical practice. Recommendations of the Spanish Society of Arteriosclerosis (SEA), 2019. 2019 , 31, 128-139		
1387	From Drug-Eluting Balloon to Drug-Coated Balloon To Eradication of Intracoronary Metal, a New Ending Story. 2019 , 1-7		
1386	Low Density Lipoprotein (LDL) Cholesterol as a Causal Role for Atherosclerotic Disease: Potential Role of PCSK9 Inhibitors. 2019 , 26, 199-207		9
1385	Lipid levels achieved after a first myocardial infarction and the prediction of recurrent atherosclerotic cardiovascular disease. 2019 , 296, 1-7		7
1384	Low LDL Cholesterol by PCSK9 Variation Reduces Cardiovascular Mortality. 2019 , 73, 3102-3114		13
1383	PCSK9 Function and Cardiovascular Death: The Knot Tightens. 2019 , 73, 3115-3117		1
1382	Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials. 2019 ,		44
1381	Efficacy and safety of PCSK9 monoclonal antibodies. 2019 , 18, 1191-1201		6
1380	Lipid Management for the Prevention of Atherosclerotic Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2019 , 381, 1557-1567	59.2	102
1379	HEART UK consensus statement on Lipoprotein(a): A call to action. 2019 , 291, 62-70		56
1378	Evolocumab Treatment of Hypercholesterolemia in OSLER-1: Enduring Efficacy, Tolerability, and Safety Over 5 Years. 2019 , 74, 2147-2149		2
1377	Long-Term Efficacy and Safety of Evolocumab in Patients With Hypercholesterolemia. 2019 , 74, 2132-2146		58
1376	Can one overcome "unhealthy genes"?. 2019 , 4, 24		1
1375	Efficacy and Safety of Alirocumab 300 mg Every 4 Weeks in Individuals With Type 2 Diabetes on Maximally Tolerated Statin. 2019 , 104, 5253-5262		1
1374	Progressive LDL Reduction to Very Low Levels Improves Dimeric Nitric Oxide Synthase, Nitric Oxide Bioavailability and Reduces Peroxynitrite in Endothelial Cells during Hyperglycemia. 2019 , 14, 7-16		2
1373	Vascular calcification in response to pharmacological interventions. 2019 , 181-189		
1372	Effect of evolocumab on lipoprotein apheresis requirement and lipid levels: Results of the randomized, controlled, open-label DE LAVAL study. 2019 , 13, 901-909.e3		10
1371	Practical guide for the use of PCSK9 inhibitors in Portugal. 2019 , 38, 391-405		0

1370 Full Issue PDF. **2019**, 4, I-XCIV

- 1369 Chronic kidney disease and coronary atherosclerosis: evidences from intravascular imaging. **2019**, 17, 707-716 1
- 1368 Mortality Benefit of Alirocumab: A Bayesian Perspective. **2019**, 8, e013170 4
- 1367 A Look Beyond Statins and Ezetimibe: a Review of Other Lipid-Lowering Treatments for Cardiovascular Disease Prevention in High-Risk Patients. **2019**, 13, 1
- 1366 Preventive Cardiology as a Subspecialty of Cardiovascular Medicine: JACC Council Perspectives. **2019**, 74, 1926-1942 19
- 1365 AHA/ACC/Multisociety Cholesterol Guidelines: highlights. **2019**, 13, 1753944719881579 4
- 1364 Exploration d'une anomalie lipidique : quoi de neuf en 2019 ?. **2019**, 30, 25-27
- 1363 High dose statins on the high street: where are the data?. **2019**, 367, l5911
- 1362 Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management. **2019**, 62, 414-422 14
- 1361 Suggested clinical approach for the diagnosis and management of 'statin intolerance' with an emphasis on muscle-related side-effects. **2019**, 49, 1081-1091 7
- 1360 Identifying Patients at High Risk of Coronary Events After Stroke: A Prerequisite for Better Prevention. **2019**, 50, 3335-3336 1
- 1359 Gene Editing: Friend or Foe? Evidence Indicates Endogenous Exosomes Can Deliver Functional gRNA and Cas9 Protein (Small 38/2019). **2019**, 15, 1970205 6
- 1358 Does low-density lipoprotein cholesterol induce inflammation? If so, does it matter? Current insights and future perspectives for novel therapies. **2019**, 17, 197 18
- 1357 Qing-Xin-Jie-Yu Granule for patients with stable coronary artery disease (QUEST Trial): A multicenter, double-blinded, randomized trial. **2019**, 47, 102209 5
- 1356 Angiotensin-Like 3: From Discovery to Therapeutic Gene Editing. **2019**, 4, 755-762 17
- 1355 News from ESC congress 2019: New ESC/EAS guidelines for dyslipidaemia management published. **2019**, 291, 124-126 1
- 1354 Implications of cost-effectiveness analyses of lipid-lowering therapies: From the policy-maker's desk to the patient's bedside. **2019**, 62, 406-413 6
- 1353 Differences in phenotype, genotype and cardiovascular events between patients with probable and definite heterozygous familial hypercholesterolemia. **2019**, 16, 467-478

1352	Implications for REDUCE IT in clinical practice. 2019 , 62, 395-400	6
1351	Gender Disparities in Health Resource Utilization in Patients with Atherosclerotic Cardiovascular Disease: A Retrospective Cross-Sectional Study. 2019 , 36, 3424-3434	6
1350	Hand Trajectory Extraction of Human Assembly Based on Multi-Leap Motions. 2019 ,	4
1349	A tip of the CAP1 to cholesterol metabolism. 2020 , 41, 253-254	3
1348	Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES. 2019 , 140, 2054-2062	41
1347	Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies. 2019 , 18, 149	13
1346	Clinical Evaluation Of Evolocumab For The Treatment Of Homozygous Familial Hypercholesterolemia In Chinese Patients. 2019 , 15, 1209-1216	1
1345	Omega-3 Polyunsaturated Fatty Acids and Stroke Burden. 2019 , 20,	8
1344	Bempedoic Acid for Lowering LDL Cholesterol. 2019 , 322, 1769-1771	11
1343	Achievement of Very Low Low-Density Lipoprotein Cholesterol Levels: Is It Time to Unlearn Concern for Hemorrhagic Stroke?. 2019 , 140, 2063-2066	4
1342	Attributable Burden and Expenditure of Cardiovascular Diseases and Associated Risk Factors in Mexico and other Selected Mega-Countries. 2019 , 16,	6
1341	Ischemic Event Rates in Very-High-Risk Adults. 2019 , 74, 2496-2507	17
1340	Cardiovascular event rates and trajectories of LDL-cholesterol levels and lipid-lowering therapy in patients with atherosclerotic cardiovascular disease: A population-based cohort study. 2019 , 183, 124-130	8
1339	Investigating the lowest threshold of vascular benefits from LDL cholesterol lowering with a PCSK9 mAb inhibitor (alirocumab) in healthy volunteers - a mechanistic physiological study (INTENSITY-LOW): protocol and study rationale. 2019 , 8, 167-174	1
1338	Fatal Recurrent Infection in a Patient With an Aortic Endostent Under Alirocumab. 2019 , 12, 1178633719885387	
1337	Recent Progress in Polyhydroxyalkanoates-Based Copolymers for Biomedical Applications. 2019 , 14, e1900283	36
1336	Update of therapeutic planning tables oriented towards obtaining therapeutic objectives. 2019 , 31, 271-277	1
1335	Essen Risk Score in Prediction of Myocardial Infarction After Transient Ischemic Attack or Ischemic Stroke Without Prior Coronary Artery Disease. 2019 , 50, 3393-3399	11

1334	Efficacité et sécurité des inhibiteurs de PCSK9 dans le diabète. 2019 , 13, 147-155	0
1333	Meta-analysis of Randomized Controlled Trials Assessing the Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies on Mortality and Cardiovascular Outcomes. 2019 , 124, 1869-1875	9
1332	Sea Change for Marine Omega-3s: Randomized Trials Show Fish Oil Reduces Cardiovascular Events. 2019 , 94, 2524-2533	13
1331	The Modern Randomized Clinical Trial: Is it Time to Sharpen a Blunt Instrument?. 2019 , 11,	1
1330	[European dyslipidemia guidelines 2019 : What is new?]. 2019 , 44, 688-695	3
1329	Novel strategies to target proprotein convertase subtilisin kexin 9: beyond monoclonal antibodies. 2019 , 115, 510-518	41
1328	Cholesterol levels and development of cardiovascular disease in Koreans with type 2 diabetes mellitus and without pre-existing cardiovascular disease. 2019 , 18, 139	13
1327	2018 Guidelines for the Management of Dyslipidemia in Korea. 2019 , 8, 78-131	40
1326	Differential effects of red yeast rice, Berberis aristata and Morus alba extracts on PCSK9 and LDL uptake. 2019 , 29, 1245-1253	6
1325	Impact of improved low-density lipoprotein cholesterol assessment on guideline classification in the modern treatment era-Results from a racially diverse Brazilian cross-sectional study. 2019 , 13, 804-811.e2	7
1324	An update on pharmacotherapies in diabetic dyslipidemia. 2019 , 62, 334-341	11
1323	The role of red yeast rice (RYR) supplementation in plasma cholesterol control: A review and expert opinion. 2019 , 39, e1-e8	18
1322	LDL: hoe lager, hoe duurder. 2019 , 62, 34-35	
1321	Nuovi farmaci ipolipemizzanti: anticorpi monoclonali inibitori di PCSK9. 2019 , 20, 148-152	
1320	Longitudinal low density lipoprotein cholesterol goal achievement and cardiovascular outcomes among adult patients with familial hypercholesterolemia: The CASCADE FH registry. 2019 , 289, 85-93	35
1319	2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. 2019 , 290, 140-205	259
1318	Association of Metabolic Surgery With Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes and Obesity. 2019 , 322, 1271-1282	176
1317	Lipid trafficking in cardiovascular disease. 2019 , 92, 105-140	5

1316	Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery. 2019 , 74, 1177-1186	33
1315	CODAP: A multidisciplinary consensus among Portuguese experts on the definition, detection and management of atherogenic dyslipidemia. 2019 , 38, 531-542	2
1314	Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes. 2019 , 140, 1578-1589	24
1313	Paclitaxel-Based Devices for the Treatment of PAD: Balancing Clinical Efficacy with Possible Risk. 2019 , 21, 57	4
1312	12-Week Effectiveness and Safety of Low-Density Lipoprotein Cholesterol-Lowering Therapy by Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition in Patients With Familial Hypercholesterolemia and Hypercholesterolemia - Data From a Real-World Observational Study of Evolocumab in Japan. 2019 , 1, 219-227	2
1311	Serious Adverse Effects of Extended-release Niacin/Laropiprant: Results From the Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) Trial. 2019 , 41, 1767-1777	11
1310	PCSK9 inhibition, atherosclerotic cardiovascular disease, and health economics: Challenges at the crossroads. 2019 , 13, 714-720	5
1309	Evolocumab for Early Reduction of LDL Cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS). 2019 , 74, 2452-2462	56
1308	Platelet Acetyl-CoA Carboxylase Phosphorylation: A Risk Stratification Marker That Reveals Platelet-Lipid Interplay in Coronary Artery Disease Patients. 2019 , 4, 596-610	4
1307	How the Cow Ate the CABG: Aim Low, Live Longer?. 2019 , 74, 1187-1189	
1306	Drug-drug interactions when treating HIV-related metabolic disorders. 2019 , 15, 787-802	4
1305	Prediction of Familial Hypercholesterolemia in Patients at High Atherosclerotic Cardiovascular Disease Risk Using a Recently Validated Algorithm. 2019 , 1, 190-197	2
1304	Lipid management for coronary heart disease patients: an appraisal of updated international guidelines applying Appraisal of Guidelines for Research and Evaluation II-clinical practice guideline appraisal for lipid management in coronary heart disease. 2019 , 11, 3534-3546	6
1303	Use of fenofibrate on cardiovascular outcomes in statin users with metabolic syndrome: propensity matched cohort study. 2019 , 366, l5125	27
1302	Interdose lipid profile evaluation of PCSK9i in real life. 2019 , 219, 466-468	
1301	Looking back and thinking forwards - 15 years of cardiology and cardiovascular research. 2019 , 16, 651-660	7
1300	Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels: One-Year Follow-up of the ORION-1 Randomized Clinical Trial. 2019 , 4, 1067-1075	58
1299	Diabetes, heart failure, and renal dysfunction: The vicious circles. 2019 , 62, 298-302	61

1298	Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors. 2019 , 191, E894	1
1297	Overcoming Obstacles in Lipid-lowering Therapy in Patients with HIV - A Systematic Review of Current Evidence. 2018 , 20, 205-219	3
1296	Lipoprotein apheresis efficacy, challenges and outcomes: A descriptive analysis from the UK Lipoprotein Apheresis Registry, 1989-2017. 2019 , 290, 44-51	15
1295	Lipoprotein Apheresis and PCSK9-Inhibitors. Impact on Atherogenic Lipoproteins and Anti-Inflammatory Mediators in Familial Hypercholesterolaemia. 2018 , 24, 3634-3637	5
1294	Smashing Low-Density Lipoprotein Levels and Preventing Coronary Allograft Vasculopathy: One Heart Transplant Patient at a Time. 2019 , 35, 17-18	1
1293	The cost-effectiveness of canakinumab for secondary prevention of cardiovascular disease: The Australian healthcare perspective. 2019 , 285, 1-5	9
1292	Identification of a Helical Segment within the Intrinsically Disordered Region of the PCSK9 Prodomain. 2019 , 431, 885-903	4
1291	Cholesteryl Ester Transfer Protein Inhibition for Preventing Cardiovascular Events: JACC Review Topic of the Week. 2019 , 73, 477-487	68
1290	The Cat Has 9 Lives, Until it Dies. 2019 , 73, 397-399	1
1289	Preventing recurrent stroke and other serious vascular events. 2019 , 745-865	
1288	A Review of the 2018 Cholesterol Guidelines: Focus on Nonstatin Lipid-lowering Drugs. 2019 , 15, 205-206.e1	
1287	Anticytokine Agents: Targeting Interleukin Signaling Pathways for the Treatment of Atherothrombosis. 2019 , 124, 437-450	104
1286	Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease. 2019 , 124, 416-425	22
1285	Lipid-Lowering Agents. 2019 , 124, 386-404	87
1284	Cholesterol-Lowering Agents. 2019 , 124, 364-385	25
1283	Cardiovascular Disease in Type 2 Diabetes: A Review of Sex-Related Differences in Predisposition and Prevention. 2019 , 94, 287-308	24
1282	PCSK9 inhibition 2018: riding a new wave of coronary prevention. 2019 , 133, 205-224	7
1281	Moving Targets: Recent Advances in Lipid-Lowering Therapies. 2019 , 39, 349-359	27

1280	Rivaroxaban With or Without Aspirin for the Secondary Prevention of Cardiovascular Disease: Clinical Implications of the COMPASS Trial. 2019 , 19, 343-348	7
1279	Improvement in arterial stiffness after short-term treatment with PCSK9 inhibitors. 2019 , 29, 527-529	14
1278	A New Personalized, Patient-Centric, and Cost-Conscious Guideline for Contemporary Cholesterol Management. 2019 , 321, 749-750	1
1277	Clinician's Guide to the Updated ABCs of Cardiovascular Disease Prevention: A Review Part 2. 2019 , 132, e599-e609	7
1276	Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial. 2019 , 40, 2801-2809	27
1275	Indications of PCSK9 inhibitors in clinical practice. Recommendations of the Spanish Society of Arteriosclerosis (SEA), 2019. 2019 , 31, 128-139	13
1274	The Goal of Achieving Atherosclerotic Plaque Regression with Lipid-Lowering Therapy: Insights from IVUS Trials. 2019 , 26, 592-600	18
1273	Safety and tolerability of injectable lipid-lowering drugs: an update of clinical data. 2019 , 18, 611-621	25
1272	Awareness of Familial Hypercholesterolemia Among Healthcare Providers Involved in the Management of Acute Coronary Syndrome in Victoria, Australia. 2019 , 1, 168-172	1
1271	Effects of Non-statin Lipid-Modifying Agents on Cardiovascular Morbidity and Mortality Among Statin-Treated Patients: A Systematic Review and Network Meta-Analysis. 2019 , 10, 547	9
1270	LDL-C Targets in Secondary Prevention: How Low Should We Go?. 2019 , 13, 1	4
1269	Advances in rehabilitation for chronic diseases: improving health outcomes and function. 2019 , 365, l2191	19
1268	Cost effectiveness of lifelong therapy with PCSK9 inhibitors for lowering cardiovascular events in patients with stable coronary artery disease: Insights from the Ludwigshafen Risk and Cardiovascular Health cohort. 2019 , 120, 106566	9
1267	Correctly understanding the diabetes data in FOURIER. 2019 , 21, 2342-2343	
1266	Comparison of Conventional Lipoprotein Tests and Apolipoproteins in the Prediction of Cardiovascular Disease. 2019 , 140, 542-552	51
1265	Genetics, Dyslipidemia, and Cardiovascular Disease: New Insights. 2019 , 21, 68	23
1264	TIMI risk score for secondary prevention of recurrent cardiovascular events in a real-world cohort of post-non-ST-elevation myocardial infarction patients. 2019 , 95, 372-377	0
1263	New Insights in the Control of Low-Density Lipoprotein Cholesterol to Prevent Cardiovascular Disease. 2019 , 21, 69	8

1262	Emerging Role of Coronary Computed Tomography Angiography in Lipid-Lowering Therapy: a Bridge to Image-Guided Personalized Medicine. 2019 , 21, 72	4
1261	Primary and Secondary Prevention of Cardiovascular Disease in Patients with Chronic Kidney Disease. 2019 , 21, 32	9
1260	Current pharmacotherapy for the treatment of dyslipidemia associated with HIV infection. 2019 , 20, 1719-1729	4
1259	Lipoprotein (a) interactions with cholesterol-containing lipids on angiographic coronary collateralization in type 2 diabetic patients with chronic total occlusion. 2019 , 18, 82	9
1258	Familial Hypercholesterolemia and Lipoprotein Apheresis. 2019 , 26, 679-687	19
1257	Proprotein Convertase Subtilisin/Kexin Type 9, Brain Cholesterol Homeostasis and Potential Implication for Alzheimer's Disease. 2019 , 11, 120	30
1256	Cost-Effectiveness Analysis of Non-Statin Lipid-Modifying Agents for Secondary Cardiovascular Disease Prevention Among Statin-Treated Patients in Thailand. 2019 , 37, 1277-1286	6
1255	The selective peroxisome proliferator-activated receptor alpha modulator (SPPARM) paradigm: conceptual framework and therapeutic potential : A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation. 2019 , 18, 71	64
1254	Hellenic Postprandial Lipemia Study (HPLS): Rationale and design of a prospective, open-label trial to determinate the prevalence of abnormal postprandial lipemia as well as its interaction with statins in patients at high- and very high-risk for cardiovascular disease. 2019 , 82, 101-105	2
1253	Complementary low-density lipoprotein-cholesterol lowering and pharmacokinetics of adding bempedoic acid (ETC-1002) to high-dose atorvastatin background therapy in hypercholesterolemic patients: A randomized placebo-controlled trial. 2019 , 13, 568-579	26
1252	ST-segment elevation myocardial infarction. 2019 , 5, 39	78
1251	Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial. 2019 , 73, 2961-2970	59
1250	Supervised Exercise Therapy and Revascularization for Intermittent Claudication: Network Meta-Analysis of Randomized Controlled Trials. 2019 , 12, 1125-1136	13
1249	Atherogenic markers in predicting cardiovascular risk and targeting residual cardiovascular risk. 2019 , 1, 100001	3
1248	Practice-level variation in statin use and low-density lipoprotein cholesterol control in the United States: Results from the Patient and Provider Assessment of Lipid Management (PALM) registry. 2019 , 214, 113-124	9
1247	Need for multiple risk reduction strategies in clinical trials enrolling high risk patients - FOURIER investigating PCSK-9 inhibitor to lower cholesterol revisited. 2019 , 28, 144-145	
1246	Prise en charge de la maladie coronaire chronique : vers de nouvelles recommandations ?. 2019 , 11, S28-S39	
1245	Un risque thrombotique persistant malgré les traitements de référence. 2019 , 11, S4-S10	

1244	Residual vascular risk in diabetes - Will the SPPARM alpha concept hold the key?. 2019 , 13, 2723-2725	2
1243	Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT. 2019 , 73, 2791-2802	152
1242	Characteristics, Prevention, and Management of Cardiovascular Disease in People Living With HIV: A Scientific Statement From the American Heart Association. 2019 , 140, e98-e124	176
1241	Updated Cost-effectiveness Analysis of Evolocumab in Patients With Very High-risk Atherosclerotic Cardiovascular Disease. 2019 , 4, 691-695	40
1240	Reduced plasma PCSK9 response in patients with bacteraemia is associated with mortality. 2019 , 286, 553-561	21
1239	Management of diabetic dyslipidemia: An update. 2019 , 10, 280-290	26
1238	Proprotein convertase subtilisin/kexin type 9 in kidney disease. 2019 , 34, 1266-1271	10
1237	Extent of coronary artery disease is associated with myocardial infarction and mortality in patients with diabetes mellitus. 2019 , 11, 419-428	9
1236	Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease: A Prespecified Analysis From the FOURIER Trial. 2019 , 4, 613-619	41
1235	Plasma proprotein convertase subtilisin/kexin type 9 inhibitors and cataract risk: A systematic review and meta-analysis. 2019 , 94, 75-80	
1234	Alirocumab after Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , 2019 , 380, 2074-2075	59.2 1
1233	Effects of immunization against PCSK9 in an experimental model of breast cancer. 2019 , 15, 570-579	27
1232	Assessment and Management of Patients with Hyperlipidemia Referred for Initiation of PCSK9 Inhibitor Therapy: A Lipid Clinic Experience. 2019 , 19, 553-559	3
1231	Initial Real-World Experience With PCSK-9 Inhibitors in Current Indications for Reimbursement in Spain. 2019 , 72, 968-970	3
1230	Effect of Alirocumab on Mortality After Acute Coronary Syndromes. 2019 , 140, 103-112	72
1229	Advances in Clinical Cardiology 2018: A Summary of Key Clinical Trials. 2019 , 36, 1549-1573	3
1228	Clinical characteristics and lipid lowering treatment of patients initiated on proprotein convertase subtilisin-kexin type 9 inhibitors: a nationwide cohort study. 2019 , 9, e022702	3
1227	Diabetic outcomes: Cardiovascular outcomes with lipid modification H2D. 2019 , 11, 617-618	1

1226	Mendelian randomization studies on atherosclerotic cardiovascular disease: evidence and limitations. 2019 , 62, 758-770	5
1225	Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association. 2019 , 13, 374-392	156
1224	Pharmaceutical strategies for reducing LDL-C and risk of cardiovascular disease. 2019 , 1, 100002	2
1223	The STatin Adverse Treatment Experience Survey: Experience of patients reporting side effects of statin therapy. 2019 , 13, 415-424	16
1222	Current pharmacotherapeutic options for primary dyslipidemia in adults. 2019 , 20, 1277-1288	14
1221	Comparative efficacy and safety of lipid-lowering agents in patients with hypercholesterolemia: A frequentist network meta-analysis. 2019 , 98, e14400	18
1220	Residual cardiovascular risk of lipid origin. Components and pathophysiological aspects. 2019 , 31, 75-88	2
1219	Potential utility of the SAFEHEART risk equation for rationalising the use of PCSK9 monoclonal antibodies in adults with heterozygous familial hypercholesterolemia. 2019 , 286, 40-45	6
1218	Lipoprotein(a): An underrecognized genetic risk factor for malignant coronary artery disease in young Indians. 2019 , 71, 184-198	18
1217	Residual Inflammatory Risk in Patients With Low LDL Cholesterol Levels Undergoing Percutaneous Coronary Intervention. 2019 , 73, 2401-2409	25
1216	Familial Hypercholesterolemia Among Young Adults With Myocardial Infarction. 2019 , 73, 2439-2450	45
1215	Evaluation and Management of the Vulnerable Plaque. 2019 , 13, 1	1
1214	Enhancing the value of PCSK9 monoclonal antibodies by identifying patients most likely to benefit. A consensus statement from the National Lipid Association. 2019 , 13, 525-537	33
1213	Low-density lipoprotein cholesterol lowering for the prevention of cardiovascular outcomes in patients with ischemic stroke. 2019 , 14, 476-482	4
1212	Remnant Lipoproteins Are Residual Risk Factor for Future Cardiovascular Events in Patients With Stable Coronary Artery Disease and On-Statin Low-Density Lipoprotein Cholesterol Levels. 2019 , 83, 1302-1308	17
1211	An updated review of lipid-modifying therapy. 2019 , 211, 87-92	6
1210	Dyslipidemia Profiles in Patients with Peripheral Artery Disease. 2019 , 21, 42	11
1209	Emerging Lipid-Lowering Therapies in Secondary Prevention. 2019 , 13, 1	

1208	Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries. 2019 , 285, 135-146	106
1207	Lifestyle, Glycosylated Hemoglobin A1c, and Survival Among Patients With Stable Ischemic Heart Disease and Diabetes. 2019 , 73, 2049-2058	12
1206	Relative Effect of Current Intensive Lipid-Lowering Drugs on Cardiovascular Outcomes in Secondary Prevention - A Meta-Analysis of 12 Randomized Trials. 2019 , 83, 1356-1367	4
1205	Achievement of low density lipoprotein (LDL) cholesterol targets in primary and secondary prevention: Analysis of a large real practice database in Italy. 2019 , 285, 40-48	23
1204	Subsequent Event Risk in Individuals With Established Coronary Heart Disease. 2019 , 12, e002470	13
1203	2018 American Heart Association/American College of Cardiology/Multisociety Guideline on the Management of Blood Cholesterol-Secondary Prevention. 2019 , 4, 589-591	21
1202	Diet-induced hepatic steatosis abrogates cell-surface LDLR by inducing PCSK9 expression in mice. 2019 , 294, 9037-9047	23
1201	What's new on therapies for elevated lipoprotein(a). 2019 , 12, 495-499	
1200	Efficacy and safety of proprotein convertase subtilisin/kexin 9 inhibitors in people with diabetes and dyslipidaemia. 2019 , 21 Suppl 1, 39-51	4
1199	Clinical guidance on the contemporary use of proprotein convertase subtilisin/kexin type 9 monoclonal antibodies. 2019 , 21 Suppl 1, 52-62	10
1198	Contribution of aorta glycosaminoglycans and PCSK9 to hyperlipidemia in experimental rabbits: the role of 10-dehydrogingerdione as effective modulator. 2019 , 46, 3921-3928	4
1197	Clinical trials of eicosapentaenoic acid (EPA) prescription products for the treatment of hypertriglyceridemia. 2019 , 20, 1221-1225	6
1196	Quantifying Unmet Need in Statin-Treated Hyperlipidemia Patients and the Potential Benefit of Further LDL-C Reduction Through an EHR-Based Retrospective Cohort Study. 2019 , 25, 544-554	6
1195	Is There a Need to Revise Goals in the Management of Dyslipidemias?. 2019 , 21, 51	2
1194	An Evidence-Based Practice Approach to Evaluating Biotechnologically Derived Medications. 2019 , 275-280	
1193	Management of patients with type 2 diabetes mellitus and acute coronary syndrome: Better be safe than sorry!. 2019 , 33, 465-467	6
1192	The 2018 ACC/AHA Lipid Guidelines: A Little More or Less Canadian?. 2019 , 35, 558-563	
1191	PCSK9 Inhibitor Use in the Real World: Data From the National Patient-Centered Research Network. 2019 , 8, e011246	22

1190	Long-Term Treatment With Evolocumab Among Japanese Patients - Final Report of the OSLER Open-Label Extension Studies. 2019 , 83, 971-977	1
1189	Cholesterol metabolism, pancreatic β cell function and diabetes. 2019 , 1865, 2149-2156	30
1188	Statine in der Primärprävention abhängig von Lebensalter und Komorbiditäten?. 2019 , 144, 232-234	
1187	What is new in lipid-lowering therapies in diabetes?. 2019 , 49, 1472-1480	4
1186	Interpreting the Findings From the Recent PCSK9 Monoclonal Antibody Cardiovascular Outcomes Trials. 2019 , 6, 14	20
1185	Association of Lowering Low-Density Lipoprotein Cholesterol With Contemporary Lipid-Lowering Therapies and Risk of Diabetes Mellitus: A Systematic Review and Meta-Analysis. 2019 , 8, e011581	25
1184	Ökonomische Überlegungen zur medikamentösen Lipidsenkung. 2019 , 15, 258-259	
1183	How much further do we need to decrease LDL cholesterol levels in heterozygous familial hypercholesterolemia?. 2019 , 284, 218-220	
1182	Prehospital statin use and low-density lipoprotein cholesterol levels at admission in acute coronary syndrome patients with history of myocardial infarction or revascularization: Findings from the Improving Care for Cardiovascular Disease in China (CCC) project. 2019 , 212, 120-128	8
1181	Using Human Genetics to Drive Drug Discovery: A Perspective. 2019 , 74, 111-119	5
1180	Serum Low-Density Lipoprotein Cholesterol Level After Endovascular Therapy in Patients With Claudication. 2019 , 26, 402-410	1
1179	Hemmung der Proproteinkonvertase Subtilisin/Kexin Typ 9. 2019 , 15, 30-38	
1178	The New Face of Hyperlipidemia and the Role of PCSK9 Inhibitors. 2019 , 21, 18	4
1177	Clinical, behavioral and biomarker predictors of PCSK9 levels in HIV-infected patients naïve of statin therapy: A cross-sectional analysis from the Swiss HIV cohort. 2019 , 284, 253-259	7
1176	Thrombolysis in Myocardial Infarction Risk Score for Secondary Prevention of Recurrent Cardiovascular Events in a Real-World Cohort of Post-Acute Myocardial Infarction Patients. 2019 , 83, 809-817	5
1175	Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and meta-analysis. 2019 , 105, 1149-1159	15
1174	Lipoprotein apheresis is an optimal therapeutic option to reduce increased Lp(a) levels. 2019 , 14, 33-38	10
1173	Lipoprotein(a) and mortality-a high risk relationship. 2019 , 14, 13-19	5

1172	Can Lp(a) Lowering Against Background Statin Therapy Really Reduce Cardiovascular Risk?. 2019 , 21, 14	11
1171	Relation of Cardiovascular Events and Deaths to Low-Density Lipoprotein Cholesterol Level Among Statin-Treated Patients With Atherosclerotic Cardiovascular Disease. 2019 , 123, 1739-1744	6
1170	[PCSK9 inhibitors: What place in the management of dyslipidemia?]. 2019 , 48, 227-237	3
1169	Randomised study of evolocumab in patients with type 2 diabetes and dyslipidaemia on background statin: Primary results of the BERSON clinical trial. 2019 , 21, 1455-1463	17
1168	Cholesterol and Inflammation in Stroke Recurrence. 2019 , 26, 406-407	1
1167	Effects on hepatic lipid metabolism in human hepatoma cells following overexpression of TGF β induced factor homeobox 1 or 2. 2019 , 1864, 756-762	3
1166	Coronary Vessel Wall Imaging: State of the Art and Future Directions. 2019 , 12, 1	4
1165	Triglycerides and cardiovascular risk: Apolipoprotein B holds the key. 2019 , 284, 221-222	13
1164	Genetics of Common, Complex Coronary Artery Disease. 2019 , 177, 132-145	84
1163	Management of dyslipidaemias in the elderly population-A narrative review. 2019 , 124, 93-99	3
1162	Evaluating the efficacy and safety of atorvastatin + ezetimibe in a fixed-dose combination for the treatment of hypercholesterolemia. 2019 , 20, 917-928	6
1161	Trials in "True" Dyslipidemic Patients Are Urged to Reconsider Comprehensive Lipid Management as a Means to Reduce Residual Cardiovascular Risk. 2019 , 106, 960-967	0
1160	PCSK9 monoclonal antibodies and lipoprotein apheresis for lowering lipoprotein(a): making choices in an era of RNA-based therapies. 2019 , 26, 998-1000	7
1159	[Immunity and inflammation in atherosclerosis]. 2019 , 44, 107-120	8
1158	Therapeutic Genome Editing in Cardiovascular Diseases. 2019 , 4, 122-131	19
1157	Effects of Evolocumab on the ApoA1 Remnant Ratio: A Pooled Analysis of Phase 3 Studies. 2019 , 8, 91-102	1
1156	Causal associations of blood lipids with risk of ischemic stroke and intracerebral hemorrhage in Chinese adults. 2019 , 25, 569-574	100
1155	Randomized study of evolocumab in patients with type 2 diabetes and dyslipidaemia on background statin: Pre-specified analysis of the Chinese population from the BERSON clinical trial. 2019 , 21, 1464-1473	11

1154	Report from the 4th Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group. 2019 , 18, 30	24
1153	Most Promising Therapies in Interventional Cardiology. 2019 , 21, 26	3
1152	Lipid Lowering Therapy, Low-Density Lipoprotein Level and Risk of Intracerebral Hemorrhage - A Meta-Analysis. 2019 , 28, 1703-1709	18
1151	The benefit of secondary prevention with oat fiber in reducing future cardiovascular event among CAD patients after coronary intervention. 2019 , 9, 3091	8
1150	Elevated Serum Non-HDL (High-Density Lipoprotein) Cholesterol and Triglyceride Levels as Residual Risks for Myocardial Infarction Recurrence Under Statin Treatment. 2019 , 39, 934-944	11
1149	Recent Updates on the Use of PCSK9 Inhibitors in Patients with Atherosclerotic Cardiovascular Disease. 2019 , 21, 16	9
1148	Targeting Residual Inflammatory Risk: A Shifting Paradigm for Atherosclerotic Disease. 2019 , 6, 16	60
1147	Drugs for Treatment of Dyslipidemia Available in the USA. 2019 , 171-195	
1146	[Orphan drugs]. 2019 , 60, 396-398	
1145	Latest Updates on Lipid Management. 2019 , 26, 85-100	3
1144	Statins in Ischemic Stroke Prevention: What Have We Learned in the Post-SPARCL (The Stroke Prevention by Aggressive Reduction in Cholesterol Levels) Decade?. 2019 , 21, 22	10
1143	Stroke genetics: discovery, biology, and clinical applications. 2019 , 18, 587-599	60
1142	Guidelines impact cholesterol management. 2019 , 13, 432-442	4
1141	Regulatory Considerations for Early Clinical Development of Drugs for Diabetes, Obesity, Nonalcoholic Steatohepatitis (NASH) and Other Cardiometabolic Disorders. 2019 , 487-515	
1140	Diabetes and Dyslipidemia. 2019 , 1-20	
1139	Tracing new atherogenic properties of PCSK9: Another insight into the pathogenesis of atherosclerosis 'the Minotaur's labyrinth'. 2019 , 60, 129-130	1
1138	Four Cases of Cholesterol Management Informed by the 2018 American Heart Association/American College of Cardiology Multisociety Guideline on the Management of Blood Cholesterol. 2019 , 4, 473-477	1
1137	ACC/AHA lipids & ASCVD guidelines: 2018 update. 2019 , 99, 116-118	1

1136	The Role of PCSK9 Inhibitors in the Improvement of Outcomes in Patients after Acute Coronary Syndrome: Results of ODYSSEY OUTCOMES Trial. 2019 , 14, 922-934	2
1135	[Lipids-Diagnosis and therapy in diabetes mellitus (Update 2019)]. 2019 , 131, 136-138	
1134	Baseline LDL-C levels and risk of cardiovascular events: is there any room for questions?. 2019 , 286, 166-167	
1133	Estimated Percentage of Patients With Stable Coronary Heart Disease Candidates for PCSK9 Inhibitors. 2019 , 72, 518-519	1
1132	'Precision medicine' and ischaemic heart disease: the stage is set for the new antibody based therapies (lipid lowering and anti-inflammatory). 2019 , 21, B73-B75	0
1131	Impact of Lipoprotein (a) Levels on Long-Term Outcomes in Patients With Coronary Artery Disease and Left Ventricular Systolic Dysfunction. 2019 , 83, 1047-1053	6
1130	Cardiovascular events with PCSK9 inhibitors: an updated meta-analysis of randomised controlled trials. 2019 , 143, 143-150	18
1129	Vaccination against atherosclerosis. 2019 , 59, 15-24	21
1128	Estimated Percentage of Patients With Stable Coronary Heart Disease Candidates for PCSK9 Inhibitors. Response. 2019 , 72, 519-520	
1127	CLEAR Serenity Trial: More Clarity for the Future of Bempedoic Acid in Patients Unable to Take Statins?. 2019 , 8, e012352	7
1126	Treat stroke to target trial design: First trial comparing two LDL targets in patients with atherothrombotic strokes. 2019 , 4, 271-280	11
1125	The 2018 Cholesterol Management Guidelines: Topics in Secondary ASCVD Prevention Clinicians Need to Know. 2019 , 21, 20	9
1124	Temporal Trends in Statin Prescriptions and Residual Cholesterol Risk in Patients With Stable Coronary Artery Disease Undergoing Percutaneous Coronary Intervention. 2019 , 123, 1788-1795	6
1123	Targeting the Immune System in Atherosclerosis: JACC State-of-the-Art Review. 2019 , 73, 1691-1706	74
1122	Treatment with PCSK9 inhibitors reduces atherogenic VLDL remnants in a real-world study. 2019 , 116, 8-15	9
1121	The complex interplay between fitness, genetics, lifestyle, and inflammation in the pathogenesis of coronary atherosclerosis: lessons from the Amazon rainforest. 2019 , 21, B76-B79	1
1120	Recent advances in developing PCSK9 inhibitors for lipid-lowering therapy. 2019 , 11, 423-441	10
1119	Albuminuria as a Predictor of Cardiovascular Outcomes in Patients With Acute Myocardial Infarction. 2019 , 8, e010546	10

1118	Efficacy and safety of evolocumab in individuals with type 2 diabetes mellitus: primary results of the randomised controlled BANTING study. 2019 , 62, 948-958	25
1117	Changes in circulating pro-protein convertase subtilisin/kexin type 9 levels - experimental and clinical approaches with lipid-lowering agents. 2019 , 26, 930-949	44
1116	Characteristics and Cardiovascular Disease Event Rates among African Americans and Whites Who Meet the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) Trial Inclusion Criteria. 2019 , 33, 189-199	6
1115	Evidence-Based Cardiovascular Risk Management in Diabetes. 2019 , 19, 439-448	5
1114	A Simplified Approach to Reducing Cardiovascular Risk. 2019 , 104, 6033-6039	5
1113	Relative effects of LDL-C on ischemic stroke and coronary disease: A Mendelian randomization study. 2019 , 92, e1176-e1187	16
1112	Full Issue PDF. 2019 , 4, I-CXLII	
1111	Stabilization of vulnerable carotid plaques with proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab. 2019 , 161, 597-600	8
1110	Current pharmacotherapies for atherosclerotic cardiovascular diseases. 2019 , 42, 206-223	6
1109	Undiagnosed coronary artery disease in long-term type 1 diabetes. The Dialong study. 2019 , 33, 383-389	10
1108	Estimaci3n del porcentaje de pacientes con enfermedad coronaria estable candidatos a recibir inhibidores de PCSK9. Respuesta. 2019 , 72, 519-520	2
1107	Relationship Between Low-Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab. 2019 , 8, e010932	31
1106	Prevalence, treatment, and control of dyslipidemia in diabetic participants of two brazilian cohorts: a place far from heaven. 2019 , 65, 3-8	1
1105	Management of dyslipidemia in adult solid organ transplant recipients. 2019 , 13, 231-245	19
1104	Systemic Delivery of Monoclonal Antibodies to the Central Nervous System for Brain Tumor Therapy. 2019 , 31, e1805697	54
1103	Impact of Age on the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia. 2019 , 33, 69-76	9
1102	How Low to Go With Lipid-Lowering Therapies in a Cost-effective and Prudent Manner. 2019 , 94, 660-669	5
1101	Integrated specialty pharmacy yields high PCSK9 inhibitor access and initiation rates. 2019 , 13, 254-264	18

1100	Side chain determinants of biopolymer function during selection and replication. 2019 , 15, 419-426	15
1099	New agents to reduce cholesterol levels: implications for nephrologists. 2020 , 35, 213-218	2
1098	Identifying asymptomatic patients at high-risk for stroke. 2019 , 60, 332-344	0
1097	ETC-1002 (Bempedoic acid) for the management of hyperlipidemia: from preclinical studies to phase 3 trials. 2019 , 20, 791-803	27
1096	Inadequate control of atherosclerotic cardiovascular disease risk factors in Europe: EUROASPIRE repeats itself. 2019 , 26, 820-823	3
1095	Real-world study: Escalating targeted lipid-lowering treatment with PCSK9-inhibitors and lipoprotein apheresis. 2019 , 34, 423-433	8
1094	A phenome-wide association study to discover pleiotropic effects of , , and. 2019 , 4, 3	14
1093	Genetic Polymorphisms in Sepsis and Cardiovascular Disease: Do Similar Risk Genes Suggest Similar Drug Targets?. 2019 , 155, 1260-1271	15
1092	Completing the genetic spectrum influencing coronary artery disease: from germline to somatic variation. 2019 , 115, 830-843	7
1091	CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2019 EXECUTIVE SUMMARY. 2019 , 25, 69-100	191
1090	Clinical Management of High and Very High Risk Patients with Hyperlipidaemia in Central and Eastern Europe: An Observational Study. 2019 , 36, 608-620	7
1089	Dyslipidemia: Contemporary Therapy Options in Terms of Worldwide Guidelines. 2019 , 5, 87-97	
1088	A systematic approach for successful PCSK9 inhibitor prescribing in clinical practice. 2019 , 13, 265-271	7
1087	Effects of PCSK9 inhibitors on LDL cholesterol, cardiovascular morbidity and all-cause mortality: a systematic review and meta-analysis of randomized controlled trials. 2019 , 42, 1029-1039	22
1086	Proprotein Convertase Subtilisin/Kexin Type 9 Antibody and Statin-Associated Autoimmune Myopathy. 2019 , 171, 68-69	2
1085	2018 Cholesterol Clinical Practice Guidelines: Synopsis of the 2018 American Heart Association/American College of Cardiology/Multisociety Cholesterol Guideline. 2019 , 170, 779-783	27
1084	10. Cardiovascular Disease and Risk Management:. 2019 , 42, S103-S123	335
1083	Management of established coronary artery disease in aircrew without myocardial infarction or revascularisation. 2019 , 105, s25-s30	9

1082	2018 Guidelines for the management of dyslipidemia. 2019 , 34, 723-771	79
1081	Management of established coronary artery disease in aircrew with previous myocardial infarction or revascularisation. 2019 , 105, s31-s37	4
1080	Correction of Hypercholesterolemia in Primary and Secondary Prevention of Cardiovascular Diseases: Features and Controversial Issues. 2019 , 14, 917-921	3
1079	Dyslipidemia in Special Populations, the Elderly, Women, HIV, Chronic Kidney Disease and ESRD, and Minority Groups. 2019 ,	3
1078	Convalescent troponin and cardiovascular death following acute coronary syndrome. 2019 , 105, 1717-1724	7
1077	Effect of coexisting vascular disease on long-term risk of recurrent events after TIA or stroke. 2019 , 93, e695-e707	8
1076	Medikamentöse Therapie von Fettstoffwechselstörungen bei Patienten mit Typ-2-Diabetes. 2019 , 06, 63-82	
1075	Evidence, Guidelines and Treatment Algorithms for Patients with Arterial Hypertension and Dyslipidemia: the Need for Compromise and Optimization of Tactics in Practical Healthcare. 2019 , 15, 578-585	
1074	Effect of Alirocumab and Rosuvastatin or Rosuvastatin Alone on Lipid Core Plaque in Coronary Artery Disease Seen on Near-Infrared Spectroscopy Intravascular Ultrasound (ANTARES). 2019 , 1, 107-111	
1073	Medical therapeutics: mortality effects, uncertainty, and informed consent. 2019 , 4, e35	1
1072	The changing face of hepatology. 2019 , 1, 415-417	
1071	Demographic And Clinical Characteristics Of Patients Prescribed Proprotein Convertase Subtilisin/kexin Type 9 Inhibitor Therapy And Patients Whose Current Lipid-Lowering Therapy Was Modified. 2019 , 15, 1325-1332	2
1070	ASPC Abstracts Supplement. 2019 , 42 Suppl 2, S36-S49	
1069	Highlights from Selected Cardiovascular Disease Prevention Studies Presented at the 2019 European Society of Cardiology Congress. 2019 , 21, 46	12
1068	A Retrospective Observational Study to Determine Baseline Characteristics and Early Prescribing Patterns for Patients Receiving Alirocumab in UK Clinical Practice. 2019 , 6, 205-213	2
1067	References. 2019 , 415-510	
1066	Applying contemporary antithrombotic therapy in the secondary prevention of chronic atherosclerotic cardiovascular disease. 2019 , 218, 100-109	4
1065	The 2018 AHA/ACC/Multi-Society Cholesterol guidelines: Looking at past, present and future. 2019 , 62, 375-383	15

1064	Lipoprotein signatures of cholesteryl ester transfer protein and HMG-CoA reductase inhibition. 2019 , 17, e3000572	15
1063	Insights on the efficacy and safety of PCSK-9 inhibitor in Taiwanese patients. 2019 , 82, 809-810	
1062	knockout exacerbates diet-induced non-alcoholic steatohepatitis, fibrosis and liver injury in mice. 2019 , 1, 418-429	22
1061	. 2019 ,	7
1060	Primary and Novel Lipid-Lowering Therapies to Reduce Risk in Patients With Peripheral Arterial Disease. 2019 , 21, 94	1
1059	Icosapent ethyl for hypertriglyceridemia: insights from the REDUCE-IT Trial. 2019 , 15, 391-394	7
1058	New evidence on the role of inflammation in CVD risk. 2019 , 34, 418-423	16
1057	Modulation of cholesterol efflux capacity in patients with myocardial infarction. 2019 , 34, 714-720	1
1056	Risk factor reduction in type 2 diabetes demands a multifactorial approach. 2019 , 26, 81-91	6
1055	Heterozygous Ldlr-Deficient Hamster as a Model to Evaluate the Efficacy of PCSK9 Antibody in Hyperlipidemia and Atherosclerosis. 2019 , 20,	8
1054	PCSK9 inhibition as a novel therapeutic target for alcoholic liver disease. 2019 , 9, 17167	26
1053	Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk. 2019 , 19, 146	4
1052	Full Issue PDF. 2019 , 12, I-CCXLIII	1
1051	Lower extremity artery disease in patients with type 2 diabetes. 2019 , 26, 114-124	5
1050	Full Issue PDF. 2019 , 4, I-CVII	
1049	High thrombotic risk increases adverse clinical events up to 5 years after acute myocardial infarction. A nationwide retrospective cohort study. 2019 , 89,	4
1048	Management of Lipid Abnormalities in Patients with Diabetes. 2019 , 21, 147	7
1047	Application of non-HDL cholesterol for population-based cardiovascular risk stratification: results from the Multinational Cardiovascular Risk Consortium. 2019 , 394, 2173-2183	75

1046	Angiopietin-Like 3 Protein Inhibition: A New Frontier in Lipid-Lowering Treatment. 2019 , 27, 211-217	15
1045	Comparative effects of high-dose atorvastatin versus rosuvastatin on lipid parameters, oxidized low-density lipoprotein, and proprotein convertase subtilisin kexin 9 in acute coronary syndrome. 2019 , 30, 285-290	5
1044	Proprotein convertase subtilisin/kexin type 9 inhibitors and lipoprotein(a)-mediated risk of atherosclerotic cardiovascular disease: more than meets the eye?. 2019 , 30, 428-437	4
1043	Budget impact analysis of PCSK9 inhibitors costs from a community payers' perspective in Apulia, Italy. 2019 , 6, e001018	2
1042	Polyvascular Disease: Reappraisal of the Current Clinical Landscape. 2019 , 12, e007385	18
1041	Coronary Atherosclerosis in Masters Athletes: Mechanisms and Implications for Cardiovascular Disease Risk. 2019 , 21, 87	4
1040	CODAP: A multidisciplinary consensus among Portuguese experts on the definition, detection and management of atherogenic dyslipidemia. 2019 , 38, 531-542	1
1039	Managing dyslipidemia for CVD prevention: A review of recent clinical practice guidelines. 2019 , 44, 8-16	6
1038	Future role of proprotein convertase subtilisin/kexin type 9 inhibitors in preventive cardiology. 2019 , 34, 519-525	2
1037	Can atherosclerosis be cured?. 2019 , 30, 477-484	5
1036	Diabetes and Cardiovascular Disease: an Update. 2019 , 19, 161	20
1035	Diagnosis and Treatment of Heterozygous Familial Hypercholesterolemia. 2019 , 8, e013225	44
1034	Management of Hyperlipidemia After Stroke. 2019 , 21, 93	5
1033	Hyperlipidemia and cardiovascular disease: new insights on lipoprotein(a). 2019 , 30, 260-261	8
1032	New Directions in the Management of Peripheral Artery Disease. 2019 , 26, e284-e293	5
1031	Strategies to alter the trajectory of atherosclerotic cardiovascular disease. 2019 , 30, 438-445	2
1030	Balanced Dysfunction in the Healthcare Ecosystem Harms Patients. 2019 , 140, 1860-1864	1
1029	Experience with proprotein convertase subtilisin/kexine type 9 inhibitors (PCSK9i) in patients undergoing lipoprotein apheresis. 2019 , 40, 38-43	4

1028	Therapeutic effect of nanoliposomal PCSK9 vaccine in a mouse model of atherosclerosis. 2019 , 17, 223	31
1027	Proprotein convertase subtilisin/kexin type 9 and lipid metabolism. 2019 , 30, 186-191	7
1026	Bempedoic acid: effects on lipoprotein metabolism and atherosclerosis. 2019 , 30, 1-9	29
1025	Long-Term Administration of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Reduces Arterial FDG Uptake. 2019 , 12, 2573-2574	6
1024	Behandlungsoptionen bei schweren Hypercholesterinämien. 2019 , 19, 31-34	1
1023	Combining cholesterol-lowering strategies with imaging data: a visible benefit?. 2019 , 26, 365-379	
1022	Novel and Emerging Therapeutics for Primary Prevention of Cardiovascular Disease. 2019 , 132, 16-24	4
1021	Indole alkaloid from <i>Nauclea latifolia</i> promotes LDL uptake in HepG2 cells by inhibiting PCSK9. 2019 , 55, 264-268	7
1020	Moderate Renal Impairment Does Not Impact the Ability of CSL112 (Apolipoprotein A-I [Human]) to Enhance Cholesterol Efflux Capacity. 2019 , 59, 427-436	6
1019	Efficacy of alirocumab for reducing plaque vulnerability: Study protocol for ALTAIR, a randomized controlled trial in Japanese patients with coronary artery disease receiving rosuvastatin. 2019 , 73, 228-232	7
1018	Genome Editing for Cardiovascular Diseases-A Brief Review for Cardiologists. 2019 , 123, 1002-1006	
1017	The effects of proprotein convertase subtilisin/kexin type 9 inhibitors on lipid metabolism and cardiovascular function. 2019 , 109, 1171-1180	4
1016	Pharmacology of PCSK9 Inhibitors: Current Status and Future Perspectives. 2018 , 24, 3622-3633	6
1015	Reverse Cholesterol Transport and Atherosclerosis. 2019 , 39, 2-4	12
1014	Predictive value of targeted proteomics for coronary plaque morphology in patients with suspected coronary artery disease. 2019 , 39, 109-117	29
1013	Remnant lipoproteins and atherosclerotic cardiovascular disease. 2019 , 490, 1-5	9
1012	Metabolomics, Proteomics, and Genomics. 2019 , 159-170	3
1011	Pharmacological Options in Atherosclerosis: A Review of the Existing Evidence. 2019 , 8, 5-20	9

1010	Identifying the anti-inflammatory response to lipid lowering therapy: a position paper from the working group on atherosclerosis and vascular biology of the European Society of Cardiology. 2019 , 115, 10-19	32
1009	Liver and Gastrointestinal Pharmacology. 2019 , 645-656	
1008	Residual cardiovascular risk of lipid origin. Components and pathophysiological aspects. 2019 , 31, 75-88	4
1007	Conceptual design of hybrid PCSK9 lead inhibitors against coronary artery disease. 2019 , 17, 427-440	6
1006	Safety and Efficacy of PCSK9 Inhibitors After Heart Transplantation. 2019 , 35, 104.e1-104.e3	15
1005	Implications of de novo mutations in guiding drug discovery: A study of four neuropsychiatric disorders. 2019 , 110, 83-92	3
1004	Cholesterol Mass Efflux Capacity, Incident Cardiovascular Disease, and Progression of Carotid Plaque. 2019 , 39, 89-96	64
1003	Cholesterol Lowering and Prevention of Stroke. 2019 , 50, 537-541	13
1002	Is very low LDL-C harmful?. 2018 , 24, 3658-3664	10
1001	Alirocumab for low-density lipoprotein cholesterol lowering. 2019 , 15, 17-29	5
1000	A Pound of Prevention? Assessing the Value of New Cholesterol-Lowering Drugs. 2019 , 170, 264-265	2
999	Should we Consider Lipoprotein (a) in Cardiovascular Disease Risk Assessment in Patients with Familial Hypercholesterolaemia?. 2018 , 24, 3665-3671	5
998	New Horizons in the Pathogenesis, Pathophysiology and Treatment of Familial Hypercholesterolaemia. 2018 , 24, 3599-3604	2
997	Tackling Residual Atherosclerotic Risk in Statin-Treated Adults: Focus on Emerging Drugs. 2019 , 19, 113-131	2
996	Generalizability of the FOURIER trial to routine clinical care: Do trial participants represent patients in everyday practice?. 2019 , 209, 54-62	5
995	Drugs that Mimic the Effect of Gene Mutations for the Prevention or the Treatment of Atherosclerotic Disease: From PCSK9 Inhibition to ANGPTL3 Inactivation. 2018 , 24, 3638-3646	7
994	DNA Sequence Variation in Encoding the Activin Receptor-Like Kinase 7 Influences Body Fat Distribution and Protects Against Type 2 Diabetes. 2019 , 68, 226-234	12
993	Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 2019 , 129, e1144-e1141	55

992	Hepatic Glucagon Signaling Regulates PCSK9 and Low-Density Lipoprotein Cholesterol. 2019 , 124, 38-51	16
991	Cardiovascular risk in renal transplant recipients. 2019 , 32, 389-399	46
990	2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 2019 , 73, e285-e350	895
989	2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 2019 , 139, e1046-e1081	187
988	2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 2019 , 139, e1082-e1143	836
987	Bariatric Endocrinology. 2019 ,	
986	Small molecules as inhibitors of PCSK9: Current status and future challenges. 2019 , 162, 212-233	33
985	2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 2019 , 73, 3168-3209	654
984	PCSK9 inhibitors: clinical evidence and implementation. 2019 , 16, 155-165	84
983	Safety and efficacy of mipomersen in patients with heterozygous familial hypercholesterolemia. 2019 , 280, 109-117	28
982	ApoB in clinical care: Pro and Con. 2019 , 282, 169-175	18
981	Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 2019 , 73, 3310-3327	58
980	Coronary Artery Calcium and Cardiovascular Events in Patients With Familial Hypercholesterolemia Receiving Standard Lipid-Lowering Therapy. 2019 , 12, 1797-1804	56
979	HDL Cholesterol: A "Pathogen Lipid Sink" for Sepsis?. 2019 , 199, 812-814	7
978	Protecting the gains: What changes are needed to prevent a reversal of the downward cardiovascular disease mortality trend?. 2019 , 42, 47-55	5
977	Cell-associated heparin-like molecules modulate the ability of LDL to regulate PCSK9 uptake. 2019 , 60, 71-84	10
976	Cholesterol and inflammatory risk: Insights from secondary and primary prevention. 2019 , 280, 192-193	2
975	Association between proprotein convertase subtilisin/kexin 9 (PCSK9) and lipoprotein subclasses in children with type 1 diabetes mellitus: Effects of glycemic control. 2019 , 280, 14-20	13

974	Estimaci3n del porcentaje de pacientes con enfermedad coronaria estable candidatos a recibir inhibidores de la PCSK9. 2019 , 72, 518-519	2
973	Future perspectives of the pharmacological management of diabetic dyslipidemia. 2019 , 12, 129-143	12
972	Cardiovascular event rates in a high atherosclerotic cardiovascular disease risk population: estimates from Swedish population-based register data. 2019 , 5, 225-232	12
971	Pretreatment With PCSK9 Inhibitor Protects the Brain Against Cardiac Ischemia/Reperfusion Injury Through a Reduction of Neuronal Inflammation and Amyloid Beta Aggregation. 2019 , 8, e010838	26
970	Adjunctive Pharmacologic Therapies in Acute Myocardial Infarction. 2019 , 117-138.e7	1
969	What have we learned about lipids and cardiovascular risk from PCSK9 inhibitor outcome trials: ODYSSEY and FOURIER?. 2019 , 115, e26-e31	30
968	Hypercholesterolaemia and coronary artery disease: A silent killer with several faces. 2019 , 112, 75-78	1
967	PCSK9 in Haemostasis and Thrombosis: Possible Pleiotropic Effects of PCSK9 Inhibitors in Cardiovascular Prevention. 2019 , 119, 359-367	41
966	Application of PCSK9 Inhibitors in Practice. 2019 , 124, 32-37	37
965	Non-antibody Approaches to Proprotein Convertase Subtilisin Kexin 9 Inhibition: siRNA, Antisense Oligonucleotides, Adnectins, Vaccination, and New Attempts at Small-Molecule Inhibitors Based on New Discoveries. 2018 , 5, 199	20
964	Drug Therapy of Dyslipidemia in the Elderly. 2019 , 36, 321-340	13
963	Association Between Low-Density Lipoprotein Cholesterol Levels and Risk for Sepsis Among Patients Admitted to the Hospital With Infection. 2019 , 2, e187223	20
962	Is the impact of conventional risk factors the same in men and women? Plea for a more gender-specific approach. 2019 , 286, 214-219	16
961	Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. 2019 , 95, 268-280	145
960	Serum apolipoprotein B is associated with increased risk of metabolic syndrome among middle-aged and elderly Chinese: A cross-sectional and prospective cohort study. 2019 , 11, 752-760	6
959	Immunity and Inflammation in Atherosclerosis. 2019 , 124, 315-327	427
958	Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation. 2019 , 14, e0210373	15
957	Omega-3 Fatty Acid and Cardiovascular Outcomes: Insights From Recent Clinical Trials. 2019 , 21, 1	23

956	Association of Clinician Knowledge and Statin Beliefs With Statin Therapy Use and Lipid Levels (A Survey of US Practice in the PALM Registry). 2019 , 123, 1011-1018	9
955	Disconcordance between ESC prevention guidelines and observed lipid profiles in patients with known coronary artery disease. 2019 , 22, 73-77	8
954	Plasma proprotein convertase subtilisin/kexin type 9 inhibitors and cataract risk: A systematic review and meta-analysis. 2019 , 94, 75-80	1
953	Apheresis for severe hypercholesterolaemia and elevated lipoprotein(a). 2019 , 51, 227-232	15
952	Genetic Assessment of Potential Long-Term On-Target Side Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors. 2019 , 12, e002196	9
951	Novel Data on the Prevalence, Identification, Scouting, and Treatment of Familial Hypercholesterolaemia. 2018 , 24, 3597-3598	
950	Are toll-like receptors potential drug targets for atherosclerosis? Evidence from genetic studies to date. 2019 , 71, 1-11	3
949	Pre-existing treatment with aspirin or statins influences clinical presentation, infarct size and inflammation in patients with de novo acute coronary syndromes. 2019 , 275, 171-178	7
948	Review of the 2017 European Society of Cardiology's Guidelines for the Management of Acute Myocardial Infarction in Patients Presenting with ST-Segment Elevation and Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease Developed in Collaboration with the European Association for Cardio-Thoracic Surgery. 2019 , 33, 2334-2343	5
947	Inhibiting PCSK9 - biology beyond LDL control. 2018 , 15, 52-62	49
946	Capitalizing on Insights from Human Genetics to Identify Novel Therapeutic Targets for Coronary Artery Disease. 2019 , 70, 19-32	4
945	Imaging as a surrogate marker of drug efficacy in cardiovascular disease. 2019 , 105, 567-578	5
944	Evaluation and Treatment of Atherogenic Dyslipidemia. 2019 , 211-234	
943	Bempedoic Acid (ETC-1002): ATP Citrate Lyase Inhibitor: Review of a First-in-Class Medication with Potential Benefit in Statin-Refractory Cases. 2019 , 27, 49-56	18
942	Prognostic impact of familial hypercholesterolemia on long-term outcomes in patients undergoing percutaneous coronary intervention. 2019 , 13, 115-122	9
941	Cumulative Effects of LDL Cholesterol and CRP Levels on Recurrent Stroke and TIA. 2019 , 26, 432-441	13
940	The interrelations between PCSK9 metabolism and cholesterol synthesis and absorption. 2019 , 60, 161-167	11
939	Cardiovascular calcification: artificial intelligence and big data accelerate mechanistic discovery. 2019 , 16, 261-274	74

938	PCSK9 inhibitors and diabetes: Translational biology to clinical practice. 2019 , 21, 451-453	
937	ANGPTL3 Inhibitors - Their Role in Cardiovascular Disease Through Regulation of Lipid Metabolism. 2019 , 83, 267-273	17
936	Role of PCSK9 Inhibitors in High Risk Patients with Dyslipidemia: Focus on Familial Hypercholesterolemia. 2018 , 24, 3647-3653	7
935	Interindividual Variation in Low-Density Lipoprotein Cholesterol Level Reduction With Evolocumab: An Analysis of FOURIER Trial Data. 2019 , 4, 59-63	24
934	The Role of PCSK9 in the Pathogenesis of Non-alcoholic Fatty Liver Disease and the Effect of PCSK9 Inhibitors. 2018 , 24, 3654-3657	27
933	Management of Dyslipidemia. 2019 , 39-69	
932	Management of Diabetes Mellitus. 2019 , 113-177	
931	PCSK9: from biology to clinical applications. 2019 , 51, 177-183	21
930	Characteristics of lipid profile and effectiveness of management of dyslipidaemia in patients with acute coronary syndromes - Data from the TERCET registry with 19,287 patients. 2019 , 139, 460-466	10
929	Can cardiac rehabilitation improve LDL-cholesterol target attainment after acute coronary syndromes?. 2019 , 26, 246-248	1
928	Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status: The ORION-1 Randomized Clinical Trial. 2019 , 42, 173-176	43
927	New Directions in Managing Dyslipidemia. 2019 , 15, 73-79.e2	2
926	Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk. 2019 , 139, 1483-1492	288
925	Apolipoproteins A1, B, and apoB/apoA1 ratio are associated with first ST-segment elevation myocardial infarction but not with recurrent events during long-term follow-up. 2019 , 108, 520-538	18
924	Plaque Stabilization by Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor in a Patient With Familial Hypercholesterolemia Undergoing Percutaneous Coronary Intervention. 2019 , 83, 1084	
923	Low Baseline High-Sensitive C-Reactive Protein is Associated with Coronary Atherosclerosis Regression: Insights from the MILLION Study. 2019 , 26, 442-451	4
922	Polyunsaturated Fatty Acids and Atherosclerosis: Insights from Pre-Clinical Studies. 2019 , 121, 1800029	12
921	PCSK9: A novel inflammation modulator in atherosclerosis?. 2019 , 234, 2345-2355	34

920	Baseline low-density lipoprotein cholesterol to predict the extent of cardiovascular benefit from lipid-lowering therapies: a review. 2019 , 5, 47-54	9
919	Real-world use of PCSK9 inhibitors: A single-center experience. 2019 , 47, 265-270	4
918	World Heart Federation Cholesterol Roadmap. 2017 , 12, 179-197.e5	15
917	IL-1 family cytokines in cardiovascular disease. 2019 , 122, 154215	26
916	Critical review of 2016 ACC guidelines on therapies for cholesterol lowering with reference to laboratory testing. 2019 , 489, 189-195	3
915	Effects of monoclonal antibodies against PCSK9 on clinical cardiovascular events : A meta-analysis of randomized controlled trials. 2019 , 44, 336-346	2
914	Mortality impact of post-discharge myocardial infarction size after percutaneous coronary intervention: a patient-level pooled analysis from the 4 large-scale Japanese studies. 2019 , 34, 47-58	1
913	A Small Change Can Make a Big Difference: A Lesson from Evolocumab. 2019 , 28, e21-e22	0
912	Should we continue to consider serum cholesterol as an exogenous poisoning?. 2019 , 53, 1045	
911	A review of interventions 16 months by pharmacists on adherence to medicines in cardiovascular disease: Characteristics of what works and what doesn't. 2019 , 15, 119-129	5
910	Circulating non-coding RNAs in biomarker-guided cardiovascular therapy: a novel tool for personalized medicine?. 2019 , 40, 1643-1650	43
909	Comparative Pharmacokinetics and Pharmacodynamics of Bococizumab Following a Single Subcutaneous Injection Using Drug Substance Manufactured at Two Sites or Administration via Two Different Devices. 2019 , 8, 40-48	3
908	Tolerance of Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) Inhibitors in Patients With Self-Reported Statin Intolerance. 2020 , 33, 276-282	5
907	Outcome postponement as a potential patient centred measure of therapeutic benefit: examples in cardiovascular medicine. 2020 , 75, 10-19	1
906	Real-World Effectiveness of High- Versus Moderate-Intensity Statin Therapy in Thai Patients With Acute Coronary Syndrome and Who Had Undergone Primary Percutaneous Coronary Intervention. 2020 , 33, 640-646	2
905	Icosapent ethyl: Where will it fit into guideline-based medical therapy for high risk atherosclerotic cardiovascular disease?. 2020 , 30, 151-157	2
904	Long-Term All-Cause and Cause-Specific Mortality in Asymptomatic Patients With CAC \geq 1,000: Results From the CAC Consortium. 2020 , 13, 83-93	34
903	Vascular Positron Emission Tomography and Restenosis in Symptomatic Peripheral Arterial Disease: A Prospective Clinical Study. 2020 , 13, 1008-1017	21

902	Treatment practices and lipid profile of patients with acute coronary syndrome: results from a tertiary care hospital. 2020 , 75, 527-534	4
901	Protein convertase subtilisin/kexin type 9 biology in nephrotic syndrome: implications for use as therapy. 2020 , 35, 1663-1674	9
900	The PCSK9 revolution: Current status, controversies, and future directions. 2020 , 30, 179-185	32
899	Are current dietary guidelines relevant to subjects on cholesterol-lowering drugs?. 2020 , 79, 88-94	1
898	Cardiomyopathy in obesity, insulin resistance and diabetes. 2020 , 598, 2977-2993	52
897	Sodium Tanshinone II A Sulfonate for Coronary Heart Disease: A Systematic Review of Randomized Controlled Trials. 2020 , 26, 219-226	12
896	Association between circulating proprotein convertase subtilisin/kexin type 9 levels and prognosis in patients with severe chronic kidney disease. 2020 , 35, 632-639	6
895	Effect of evolocumab therapy on coronary fibrous cap thickness assessed by optical coherence tomography in patients with acute coronary syndrome. 2020 , 75, 289-295	17
894	Dyslipidemia Management in Adults With Diabetes. 2020 , 44, 53-60	19
893	High-intensity lipid-lowering regimens in patients with stable coronary artery disease: the intriguing question of all-cause mortality. 2020 , 6, 328-330	3
892	Cholesterol Lowering and Stroke: No Longer Room for Pleiotropic Effects of Statins - Confirmation from PCSK9 Inhibitor Studies. 2020 , 133, 95-99.e6	9
891	Statin Intolerance Clinical Guide 2018. 2020 , 27, 375-396	7
890	Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trial. 2020 , 27, 296-307	17
889	Residual inflammatory risk after contemporary lipid lowering therapy. 2020 , 6, 105-111	1
888	Nonalcoholic Fatty Liver Disease in Adults: Current Concepts in Etiology, Outcomes, and Management. 2020 , 41,	56
887	PCSK9-D374Y mediated LDL-R degradation can be functionally inhibited by EGF-A and truncated EGF-A peptides: An in vitro study. 2020 , 292, 209-214	4
886	The lipid-lowering effect of once-daily soya drink fortified with phytosterols in normocholesterolaemic Chinese: a double-blind randomized controlled trial. 2020 , 59, 2739-2746	2
885	Vessel Based Imaging Techniques. 2020 ,	0

884	PCSK9 inhibitors and cardiovascular outcomes. 2020 , 20, 35-47	6
883	Lipid management in rheumatoid arthritis: a position paper of the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology. 2020 , 6, 104-114	14
882	Key Articles and Guidelines in the Management of Dyslipidemia: 2019 Update. 2020 , 33, 882-894	2
881	HeFH in real life, how to: More evolocumab than authorized. 2020 , 27, 2079-2080	1
880	PCSK9: from molecular biology to clinical applications. 2020 , 57, 7-25	5
879	Three-year events and mortality in cardiovascular disease patients without lipid-lowering treatment. 2020 , 27, 2102-2104	1
878	Residual inflammatory risk in coronary heart disease: incidence of elevated high-sensitive CRP in a real-world cohort. 2020 , 109, 315-323	19
877	The age of randomized clinical trials: three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid and diabetes trials. 2020 , 6, 97-103	4
876	Heterogeneity of Plaque Structural Stress Is Increased in Plaques Leading to MACE: Insights From the PROSPECT Study. 2020 , 13, 1206-1218	14
875	Editorial commentary: Using PCSK9 inhibitors to win at "cholesterol limbo". 2020 , 30, 186-187	
874	Statins increase Lp(a) plasma level: is this clinically relevant?. 2020 , 41, 2285-2287	7
873	Efficacy of lipid-lowering therapy beyond statins to prevent cardiovascular events: a meta-analysis. 2020 , 27, 1675-1678	3
872	Statin-based therapy for primary and secondary prevention of ischemic stroke: A meta-analysis and critical overview. 2020 , 15, 377-384	15
871	2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. 2020 , 41, 407-477	1835
870	2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. 2020 , 41, 111-188	2236
869	2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. 2020 , 41, 255-323	1360
868	Risk of Cardiovascular Events in Patients With Type 2 Diabetes and Metabolic Dyslipidemia Without Prevalent Atherosclerotic Cardiovascular Disease. 2020 , 133, 200-206	1
867	Long-term outcomes of chronic coronary syndrome worldwide: insights from the international CLARIFY registry. 2020 , 41, 347-356	20

866	Association of lowering apolipoprotein B with cardiovascular outcomes across various lipid-lowering therapies: Systematic review and meta-analysis of trials. 2020 , 27, 1255-1268	13
865	High-Dose Omega-3 Fatty Acids in Cardiovascular Prevention: Finally Living Up to Their Potential?. 2020 , 20, 11-18	
864	The Potential of Probiotics in the Prevention and Treatment of Atherosclerosis. 2020 , 64, e1900797	16
863	Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score: Results From the FOURIER Trial. 2020 , 141, 616-623	61
862	Therapeutic strategy for atherosclerosis based on bone-vascular axis hypothesis. 2020 , 206, 107436	10
861	Microcirculation. 2020 ,	1
860	Efficacy of Evolocumab vs low-density lipoprotein cholesterol apheresis in patients with familial hypercholesterolemia and high cardiovascular risk (EVOLAFER01). 2020 , 35, 9-17	4
859	Patients With High Genome-Wide Polygenic Risk Scores for Coronary Artery Disease May Receive Greater Clinical Benefit From Alirocumab Treatment in the ODYSSEY OUTCOMES Trial. 2020 , 141, 624-636	66
858	Predicting risk of cardiovascular events 1 to 3 years post-myocardial infarction using a global registry. 2020 , 43, 24-32	6
857	Genetics and Genomics of Atherosclerotic Cardiovascular Disease. 2020 , 209-230	
856	Getting to an ImprOved Understanding of Low-Density Lipoprotein-Cholesterol and Dyslipidemia Management (GOULD): Methods and baseline data of a registry of high cardiovascular risk patients in the United States. 2020 , 219, 70-77	9
855	The changing landscape of lipid-lowering therapy after the new ESC/EAS guidelines for the management of dyslipidaemias: Launching the era of triple hypolipidaemic therapy in very high risk patients. 2020 , 292, 231-233	8
854	Overall Mortality and LDL Cholesterol Reduction in Secondary Prevention Trials of Cardiovascular Disease. 2020 , 20, 325-332	
853	Platelet function and activation markers in primary hypercholesterolemia treated with anti-PCSK9 monoclonal antibody: A 12-month follow-up. 2020 , 30, 282-291	20
852	Effect of Preoperative Administration of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor on Carotid Artery Stenting. 2020 , 135, e36-e42	1
851	PCSK9 inhibitors: Ratification of the role of LDL cholesterol in cardiovascular prevention. Towards a convergence of European and North American prevention guidelines?. 2020 , 220, 374-382	
850	Lipoprotein(a) plasma levels are not associated with survival after acute coronary syndromes: An observational cohort study. 2020 , 15, e0227054	8
849	Cardioprotective effect of the polysaccharide from <i>Ophiopogon japonicus</i> on isoproterenol-induced myocardial ischemia in rats. 2020 , 147, 233-240	21

848	Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome. 2020 , 75, 133-144	147
847	Renal Impairment, Cardiovascular Disease, and the Short-Term Efficacy and Safety of PCSK9 Targeted by Inclisiran. 2020 , 95, 12-14	1
846	PCSK9 inhibitors for treating hypercholesterolemia. 2020 , 21, 353-363	16
845	Non-High-Density Lipoprotein Cholesterol and Guidelines for Cholesterol Lowering in Recent History. 2020 , 51, 14-23	3
844	Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9. 2020 , 41, 239-252	28
843	Beneficial effect of ezetimibe-atorvastatin combination therapy in patients with a mutation in ABCG5 or ABCG8 gene. 2020 , 19, 3	13
842	Eligibility and Preventive Potential for New Evidence-Based Cardiovascular Drugs in Secondary Prevention. 2020 , 5, 209-215	13
841	Exosome-Mediated Transfer of Anti-miR-33a-5p from Transduced Endothelial Cells Enhances Macrophage and Vascular Smooth Muscle Cell Cholesterol Efflux. 2020 , 31, 219-232	11
840	An expert opinion paper on statin adherence and implementation of new lipid-lowering medications by the ESC Working Group on Cardiovascular Pharmacotherapy: Barriers to be overcome. 2020 , 6, 115-121	20
839	Profound reductions in first and total cardiovascular events with icosapent ethyl in the REDUCE-IT trial: why these results usher in a new era in dyslipidaemia therapeutics. 2020 , 41, 2304-2312	33
838	ODYSSEY EAST: Alirocumab efficacy and safety vs ezetimibe in high cardiovascular risk patients with hypercholesterolemia and on maximally tolerated statin in China, India, and Thailand. 2020 , 14, 98-108.e8	14
837	Apolipoprotein B48 metabolism in chylomicrons and very low-density lipoproteins and its role in triglyceride transport in normo- and hypertriglyceridemic human subjects. 2020 , 288, 422-438	12
836	Inflammation and atherosclerosis: what is on the horizon?. 2020 , 106, 80-85	25
835	Macrophages in Atherosclerosis Regression. 2020 , 40, 20-33	127
834	Inclisiran-New hope in the management of lipid disorders?. 2020 , 14, 16-27	45
833	Effects of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 Studies. 2020 , 95, 77-89	37
832	Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis. 2020 , 41, 2248-2258	29
831	Control of cardiovascular risk factors and health behaviors in patients post acute coronary syndromes eligible for protein convertase subtilisin/kexin-9 inhibitors. 2020 , 299, 289-295	0

830	Recent developments in pharmacotherapy for hypertriglyceridemia: what's the current state of the art?. 2020 , 21, 107-120	6
829	Role of PCSK9 in the course of ejection fraction change after ST-segment elevation myocardial infarction: a pilot study. 2020 , 7, 117-122	10
828	Familial Hypercholesterolaemia in 2020: A Leading Tier 1 Genomic Application. 2020 , 29, 619-633	11
827	Familial Hypercholesterolaemia in a Bulgarian Population of Patients with Dyslipidaemia and Diabetes: An Observational Study. 2020 , 11, 453-465	0
826	Trends and Factors Associated With Insurer Approval of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Prescriptions. 2020 , 23, 209-216	3
825	Widening the spectrum of genetic testing in familial hypercholesterolaemia: Will it translate into better patient and population outcomes?. 2020 , 97, 543-555	6
824	Update on cardiovascular prevention in clinical practice: A position paper of the European Association of Preventive Cardiology of the European Society of Cardiology. 2020 , 27, 181-205	76
823	Intensive LDL cholesterol-lowering treatment beyond current recommendations for the prevention of major vascular events: a systematic review and meta-analysis of randomised trials including 327 037 participants. 2020 , 8, 36-49	58
822	Impact of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab on the postprandial responses of triglyceride-rich lipoproteins in type II diabetic subjects. 2020 , 14, 77-87	15
821	Brothers in Arms: ABCA1- and ABCG1-Mediated Cholesterol Efflux as Promising Targets in Cardiovascular Disease Treatment. 2020 , 72, 152-190	49
820	Statins, LDL Cholesterol Control, Cardiovascular Disease Prevention, and Atherosclerosis Progression: A Clinical Perspective. 2020 , 20, 405-412	2
819	Evolocumab treatment in patients with HIV and hypercholesterolemia/mixed dyslipidemia: BEIJERINCK study design and baseline characteristics. 2020 , 220, 203-212	4
818	Evolving concepts on the management of dyslipidaemia. 2020 , 75, 80-90	1
817	Finally, the big picture of morbidity and mortality in peripheral arterial disease?. 2020 , 293, 92-93	2
816	Intensified lipid lowering using ezetimibe after publication of the IMPROVE-IT trial: A contemporary analysis from the SPUM-ACS cohort. 2020 , 303, 8-13	4
815	Circulating PCSK9 levels are not associated with the conversion to type 2 diabetes. 2020 , 293, 49-56	9
814	Have the Government's prescription algorithm and the 2013 American College of Cardiology/American Heart Association guidelines for managing dyslipidemia influenced the management of dyslipidemia? The MEJORALO-CV Project. 2020 , 220, 282-289	
813	ISCHEMIA Trial: A Hope or a Hype for Patients with Stable Coronary Artery Disease?. 2020 , 133, e218-e219	1

812	Cost-effectiveness analysis of PCSK9 inhibitors in cardiovascular diseases: a systematic review. 2020 , 25, 1077-1088	12
811	Recommendations to improve lipid control. Consensus document of the Spanish Society of Cardiology. 2020 , 73, 161-167	1
810	PCSK9 and inflammation: role of shear stress, pro-inflammatory cytokines, and LOX-1. 2020 , 116, 908-915	35
809	Evolocumab vs. Ezetimibe in Statin-Intolerant Hyperlipidemic Japanese Patients: Phase 3 GAUSS-4 Trial. 2020 , 27, 471-484	9
808	PCSK9 inhibitors in clinical practice: Novel directions and new experiences. 2020 , 61, 241-245	7
807	EGF-A peptides: A promising strategy for PCSK9 inhibition. 2020 , 292, 204-206	8
806	Impact of new lipid management guidelines on the treatment of extreme and very high-risk patients: AACE/ACE and AHA/ACC guidelines. 2020 , 12, 105-109	1
805	Small Interfering RNA Therapeutic Inclisiran: A New Approach to Targeting PCSK9. 2020 , 34, 1-9	28
804	Passive Monoclonal and Polyclonal Antibody Therapies. 2020 , 251-348	5
803	A practical algorithm for the management of patients with statin-associated muscle symptoms. 2020 , 61, 137-140	4
802	What Proportion of Patients Admitted with Stroke or Transient Ischemic Attack May Be Suitable for Newer Cholesterol-Lowering Treatment?. 2020 , 29, 104457	2
801	Statin-Related Myotoxicity: A Comprehensive Review of Pharmacokinetic, Pharmacogenomic and Muscle Components. 2019 , 9,	75
800	From hemorrhagic stroke to lipid paradox: a double-hit hypothesis underlying low low-density lipoprotein cholesterol related cardiovascular risk narrative review. 2020 , 3, 97-103	0
799	Current Concepts in Management of Lipid Abnormalities in Patients With Coronary Artery Disease. 2020 , 1, 164-173	
798	Monocyte Chemoattractant Protein-1 Is an Independent Predictor of Coronary Artery Ectasia in Patients with Acute Coronary Syndrome. 2020 , 9,	4
797	Clinical profile of patients treated with evolocumab in lipid/internal medicine units of Spain. Observational study (RETOSS-IMU). 2020 , 32, 183-192	
796	Lipid-lowering treatment in secondary prevention of ischaemic cerebrovascular disease. 2020 , 32, 175-182	1
795	Influence of Anatomical and Clinical Characteristics on Long-Term Prognosis of FFR-Guided Deferred Coronary Lesions. 2020 , 13, 1907-1916	1

794	The Cardio-Rheumatology Approach to Atherosclerotic Cardiovascular Disease. 2020 , 16, 311-312	
793	Secondary prevention after CABG: do new agents change the paradigm?. 2020 , 35, 664-672	1
792	Adverse events beyond 1 year after percutaneous coronary intervention. 2020 , 35, 687-696	2
791	PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. 2020 , 10, CD011748	12
790	Nanoparticle-based "Two-pronged" approach to regress atherosclerosis by simultaneous modulation of cholesterol influx and efflux. 2020 , 260, 120333	12
789	Primary prevention of cardiovascular disease: Updated review of contemporary guidance and literature. 2020 , 9, 2048004020949326	6
788	The genetics of asthma and the promise of genomics-guided drug target discovery. 2020 , 8, 1045-1056	33
787	P2X7 Receptors: An Untapped Target for the Management of Cardiovascular Disease. 2021 , 41, 186-199	13
786	Atherosclerosis and inflammation. New therapeutic approaches. 2020 , 155, 256-262	2
785	Atherosclerosis and inflammation. New therapeutic approaches. 2020 , 155, 256-262	7
784	Cost-effectiveness of PCSK9 inhibition with evolocumab in patients with a history of myocardial infarction in Sweden. 2020 ,	5
783	Low-density Lipoprotein-Cholesterol Lowering Strategies for Prevention of Atherosclerotic Cardiovascular Disease: Focus on siRNA Treatment Targeting PCSK9 (Inclisiran). 2020 , 22, 176	11
782	Successful pharmacological management of a child with compound heterozygous familial hypercholesterolemia and review of the recent literature. 2020 , 14, 639-645	0
781	PCSK9 and LRP5 in macrophage lipid internalization and inflammation. 2021 , 117, 2054-2068	19
780	LDL-C: lower is better for longer-even at low risk. 2020 , 18, 320	34
779	Statins in primary prevention: is the enthusiasm justified?. 2020 , 72, 221-224	
778	Bempedoic acid for high-risk patients with CVD as adjunct lipid-lowering therapy: A cost-effectiveness analysis. 2020 , 14, 772-783	9
777	The role of Lipoprotein(a) in cardiovascular disease: Current concepts and future perspectives. 2020 , 61, 398-403	2

776	Managing hyperlipidaemia in patients with COVID-19 and during its pandemic: An expert panel position statement from HEART UK. 2020 , 313, 126-136	30
775	DA VINCI study: Change in approach to cholesterol management will be needed to reduce the implementation gap between guidelines and clinical practice in Europe. 2020 , 314, 74-76	5
774	Early impact of the 2018 AHA/ACC/multisociety cholesterol guideline on lipid monitoring after statin initiation. 2020 , 14, 784-790	0
773	A Newly Approved Cholesterol Drug Joins the Lipid-Lowering Arsenal: Bempedoic Acid. 2020 , 16, 722-725	0
772	Treatment with PCSK9 inhibitors induces a more anti-atherogenic HDL lipid profile in patients at high cardiovascular risk. 2020 , 135, 106804	3
771	Coronary atherosclerotic plaque progression: contributing factors in statin-treated patients. 2020 , 18, 873-880	1
770	Comparing a novel machine learning method to the Friedewald formula and Martin-Hopkins equation for low-density lipoprotein estimation. 2020 , 15, e0239934	7
769	Review of the Protective Effects of Statins on Cognition. 2021 , 29, 328-335	0
768	The therapeutic management of South African dyslipidaemic patients at very high cardiovascular risk (CARDIO TRACK): a cross-sectional study. 2020 , 31, 245-251	
767	[Current approaches to cardiovascular risk management in patients with ischemic stroke. (Press-Release) Proceedings of the Symposium on October 28, 2021 at the Interregional Scientific-Practical Conference with International Participation "Stroke: an Interdisciplinary Problem] - 2021 , 121, 77-80	
766	THE EFFECT OF EVOLOCUMAB ALONE AND IN COMBINATION WITH ATORVASTATIN ON LIPID PROFILE. 2021 , 74, 3184-3187	
765	Dyslipidemia and prevention of atherosclerotic cardiovascular disease in the elderly. 2021 ,	1
764	????????:?????????????????????. 2021 ,	
763	Real-world utilization of bempedoic acid in an academic preventive cardiology practice.. 2021 ,	2
762	Is there a role of lipid-lowering therapies in the management of fatty liver disease?. 2022 , 14, 119-139	4
761	Immunotherapeutic Strategies in Cancer and Atherosclerosis-Two Sides of the Same Coin.. 2021 , 8, 812702	
760	Asymptomatic carotid stenosis: Several guidelines with unclear answers. 2022 ,	0
759	Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention in Germany.. 2022 , 1	2

758	PCSK9 as a Target for Development of a New Generation of Hypolipidemic Drugs.. 2022 , 27,	4
757	Addressing dyslipidemic risk beyond LDL-cholesterol.. 2022 , 132,	6
756	Beyond Lipid-Lowering: Effects of Statins on Cardiovascular and Cerebrovascular Diseases and Cancer.. 2022 , 15,	0
755	JCS 2018 Guideline on Revascularization of Stable Coronary Artery Disease.. 2022 , 86,	3
754	Emerging Cholesterol Modulators for Atherosclerotic Cardiovascular Disease.. 2022 ,	0
753	Short-Term Treatment with Alirocumab, Flow-Dependent Dilatation of the Brachial Artery and Use of Magnetic Resonance Diffusion Tensor Imaging to Evaluate Vascular Structure: An Exploratory Pilot Study.. 2022 , 10,	0
752	The Impact of the COVID-19 Outbreak on Patients' Adherence to PCSK9 Inhibitors Therapy.. 2022 , 11,	1
751	Drug delivery systems for RNA therapeutics.. 2022 ,	30
750	Modifying pH-sensitive PCSK9/LDLR interactions as a strategy to enhance hepatic cell uptake of low-density lipoprotein cholesterol (LDL-C).. 2022 , 35,	1
749	Targeted proteomics improves cardiovascular risk prediction in secondary prevention.. 2022 ,	3
748	Global assessment improves risk stratification for major adverse cardiac events across a wide range of triglyceride levels: Insights from the KP REACH study.. 2022 , 9, 100319	0
747	The Association between Low Levels of Low Density Lipoprotein Cholesterol and Intracerebral Hemorrhage: Cause for Concern?. 2022 , 11,	1
746	Dyslipidaemia management in the cardiac rehabilitation clinic of a tertiary referral centre: analysis of the impact of new ESC guidance on LDL-C target achievement.. 2022 , 1	0
745	Long-term effects of evolocumab in participants with HIV and dyslipidemia: results from the open-label extension period.. 2022 , 36,	1
744	[Le LDL-cholestérol : une brique supplémentaire dans le mur de l'athérosclérose].. 2022 ,	
743	Traitement médical de l'artéropathie athéromateuse des membres inférieurs. 2022 , 2022, 9-13	
742	Effects of Alirocumab on Triglyceride Metabolism: A Fat-Tolerance Test and Nuclear Magnetic Resonance Spectroscopy Study.. 2022 , 10,	1
741	An evaluation of the pharmacokinetics of inclisiran in the treatment of atherosclerotic cardiovascular disease.. 2022 , 1-9	1

740	PCSK9 Inhibitors in Clinical Practice: Experience of a Specialized Lipid Center. 2022 , 17, 808-815	1
739	Exploring the Role of Nutraceuticals (Red Yeast Rice) in Secondary Prevention: A New Pathway Can Be Opened. 2022 , 12, 24-29	
738	Assessing the Validity of the Criteria for the Extreme Risk Category of Atherosclerotic Cardiovascular Disease: A Nationwide Population-Based Study.. 2022 , 11, 73-83	1
737	A New Look at Novel Cardiovascular Risk Biomarkers: The Role of Atherogenic Lipoproteins and Innovative Antidiabetic Therapies.. 2022 , 12,	3
736	Estimation of recurrent atherosclerotic cardiovascular event risk in patients with established cardiovascular disease: the updated SMART2 algorithm.. 2022 ,	1
735	Exciting new therapies for familial hypercholesterolemia, but we can also make better use of some old ones.. 2022 ,	
734	Dyslipidemia. 2022 , 529-537	
733	Updated Recommendations on Cardiovascular Prevention in 2022: An Executive Document of the Italian Society of Cardiovascular Prevention.. 2022 , 29, 91	1
732	Comprehensive Management of Cardiovascular Risk Factors for Adults With Type 2 Diabetes: A Scientific Statement From the American Heart Association.. 2022 , CIR0000000000001040	15
731	Gene Therapy Targeting .. 2022 , 12,	4
730	PCSK9 inhibitor recaticimab for hypercholesterolemia on stable statin dose: a randomized, double-blind, placebo-controlled phase 1b/2 study.. 2022 , 20, 13	
729	Dyslipidemias and stroke prevention: Recommendations of the Study Group of Cerebrovascular Diseases of the Spanish Society of Neurology.. 2022 , 37, 61-72	
728	Rare coding variants in 35 genes associate with circulating lipid levels-A multi-ancestry analysis of 170,000 exomes.. 2021 ,	0
727	Vulnerable Plaque in Patients with Acute Coronary Syndrome: Identification, Importance, and Management. 16,	0
726	Highlights of Cardiovascular Disease Studies Presented at the 2021 American Heart Association Scientific Sessions.. 2022 , 24, 61	3
725	Application of the very high risk criterion and evaluation of cholesterol guideline adherence in acute myocardial infarction patients at an urban academic medical center. 2022 , 13, 100082	
724	Impact of Lipoprotein(a) as a Residual Risk Factor in Long-Term Cardiovascular Outcomes in Patients With Acute Coronary Syndrome Treated With Statins.. 2022 ,	1
723	New targets for treating hypertriglyceridemia.. 2022 , 29,	0

722	Prevalence of familial hypercholesterolaemia in patients presenting with premature acute coronary syndrome.. 2022 ,	1
721	Consensus clinical recommendations for the management of plasma lipid disorders in the Middle East: 2021 update.. 2021 , 343, 28-50	4
720	Development of small-molecule PCSK9 inhibitors for the treatment of hypercholesterolemia.. 2022 ,	3
719	2022 Summary of recommendations for long-term secondary prevention after myocardial infarction. 2022 , 64, 7-28	
718	What Is Hidden Behind Yellow Pixels: from Pathology to Intravascular Imaging of Atherosclerotic Plaque.. 2022 , 24, 97	
717	DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases.. 2021 , 36, 108101	2
716	Lowering Cholesterol and Intracerebral Hemorrhage: There Won't Be Blood!. 2021 , STROKEAHA121037523	0
715	What is the Optimal Low-Density Lipoprotein Cholesterol?. 2022 , 106, 285-298	
714	Mechanisms of cinnamic aldehyde against myocardial ischemia/hypoxia injury in vivo and in vitro: Involvement of regulating PI3K/AKT signaling pathway.. 2022 , 147, 112674	1
713	Effectiveness and safety of PCSK9 inhibitor therapy in patients with familial hypercholesterolemia within a therapeutic program in Poland: Preliminary multicenter data.. 2022 ,	
712	The dream for therapeutic vaccines for cardiovascular diseases. 2022 ,	
711	Lower levels of low-density lipoprotein cholesterol are associated with a lower prevalence of thin-cap fibroatheroma in statin-treated patients with coronary artery disease.. 2021 ,	0
710	Caffeine blocks SREBP2-induced hepatic PCSK9 expression to enhance LDLR-mediated cholesterol clearance.. 2022 , 13, 770	5
709	Barriers to prescribing proprotein convertase subtilisin-kexin type 9 inhibitors after coronary revascularisation.. 2022 ,	0
708	Building your Peripheral Artery Disease Tool Kit: Medical Management of PAD in 2022.. 2022 ,	1
707	Clonal hematopoiesis in cardiovascular disease and therapeutic implications.	2
706	Contemporary Management of Stable Coronary Artery Disease.. 2022 , 1	0
705	Discordance Between Standard Equations for Determination of LDL Cholesterol in Patients With Atherosclerosis.. 2022 , 79, 530-541	1

704	Diabetes mellitus and cardiovascular risk: an update of the recommendations of the Diabetes and Cardiovascular Disease Working Group of the Spanish Society of Diabetes (SED, 2021). 2022,	
703	Long-term clinical impact of low-density lipoprotein cholesterol target attainment according to lesion complexity after percutaneous coronary intervention.. 2022,	
702	Situation in 2020 of the requirements for the use of PCSK9 inhibitors in Spain: Results of a national survey. 2022, 34, 10-10	
701	Coronary artery calcium scores indicating secondary prevention level risk: Findings from the CAC consortium and FOURIER trial.. 2022,	0
700	Immune Checkpoint Therapies and Atherosclerosis: Mechanisms and Clinical Implications: JACC State-of-the-Art Review.. 2022, 79, 577-593	0
699	Nanobiotechnology approaches for cardiovascular diseases: site-specific targeting of drugs and nanoparticles for atherothrombosis.. 2022, 20, 75	0
698	A practical guideline of genomics-driven drug discovery in the era of global biobank meta-analysis.	2
697	Anti-inflammatory Strategies in Atherosclerosis.. 2021, 41, 433-442	4
696	Phospholipid nanoparticles: Therapeutic potentials against atherosclerosis via reducing cholesterol crystals and inhibiting inflammation. 2021, 74, 103725	2
695	10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2022.. 2022, 45, S144-S174	46
694	1. Frontiers of Laboratory Examination and Treatment of Dyslipidemia. 2021, 110, 546-555	
693	Safety issues associated with the clinical application of PCSK9 inhibitors: Current findings.. 2022,	
692	New cardiology aspects of triple antithrombotic therapy, diabetes without insulin therapy as a risk factor in atrial fibrillation, treatment of gout, cholesterol lowering treatment, prostate cancer treatment, out-of-hospital cardiac arrest, Fabry disease, beta-blocker use after myocardial infarction in patients with normal ejection fraction, cardio-renal benefits of SGLT2 Inhibitors and interpretation of clinical trials.. 2022,	
691	Stroke Genomics: Current Knowledge, Clinical Applications and Future Possibilities.. 2022, 12,	
690	Low density lipoprotein cholesterol levels exceed the recommended European threshold for PCSK9i initiation: lessons from the HEYMANS study.. 2022,	1
689	Elevated lipoprotein(a) levels as an independent predictor of long-term recurrent events in patients with acute coronary syndrome: an observational, retrospective cohort study.. 2022,	0
688	Therapeutic RNA-silencing oligonucleotides in metabolic diseases.. 2022,	4
687	Efficacy and Safety of PCSK9 Monoclonal Antibodies in Patients With Diabetes.. 2022,	1

686 Lipid management. **2022**, 400-418

685 Rationale and design of two trials assessing the efficacy, safety, and tolerability of inclisiran in adolescents with homozygous and heterozygous familial hypercholesterolaemia.. **2022**, 0

684 Evinacumab for the treatment of homozygous familial hypercholesterolemia.. **2022**, 1-7

683 Differential Biological Effects of Dietary Lipids and Irradiation on the Aorta, Aortic Valve, and the Mitral Valve.. **2022**, 9, 839720 1

682 Circulating Cytokines in Myocardial Infarction Are Associated With Coronary Blood Flow.. **2022**, 13, 837642 0

681 Association Between Intensity of Low-Density Lipoprotein Cholesterol Reduction With Statin-Based Therapies and Secondary Stroke Prevention: A Meta-analysis of Randomized Clinical Trials.. **2022**, 2

680 Association of Prior Statin Therapy With Cardiovascular Outcomes in Patients With Initial Diagnosis of OCAD and LDL-C Below 1.8 mmol/L.. **2022**, 33197221075861

679 Clinical efficacy and safety outcomes of bempedoic acid for LDL-C lowering therapy in patients at high cardiovascular risk: a systematic review and meta-analysis.. **2022**, 12, e048893 1

678 Fettstoffwechsel: Diagnostik und Therapie. **2022**, 17, 38-51

677 Individuelle kardiovaskuläre Risiken der Patientin in der Lebensmitte. **2022**, 25, 19-30

676 Relative contributions of statin intensity, achieved low-density lipoprotein cholesterol level, and statin therapy duration to cardiovascular risk reduction in patients with type 2 diabetes: population based cohort study.. **2022**, 21, 28 1

675 Low-Density Lipoprotein Cholesterol Level After a Stroke-Reducing It by Any Means.. **2022**,

674 Contemporary Management of Dyslipidemia.. **2022**, 1 1

673 Effect of Parathyroidectomy on Metabolic Homeostasis in Primary Hyperparathyroidism.. **2022**, 11, 0

672 Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE-IT PCI.. **2022**, e022937 3

671 Management of atherosclerotic extracranial carotid artery stenosis.. **2022**, 21, 273-283 0

670 Effect of Evolocumab in Patients With Prior Percutaneous Coronary Intervention.. **2022**, CIRCINTERVENTIONS121011382

669 Coronary plaque vulnerability in statin-treated patients with elevated LDL-C and hs-CRP: optical coherence tomography study. 1

668	Statin intolerance: how common is it and how do we work with patients to overcome it?. 2022,	1
667	Acute Effect of Evolocumab on Lipoprotein(a) Level and Inflammation in Patients with Coronary Artery Disease.. 2022, 9,	
666	Aggressive lipid-lowering therapy after percutaneous coronary intervention - for whom and how?: Aggressive lipid-lowering therapy after PCI.. 2022, 8, 24-31	
665	Lipid-Targeted Atherosclerotic Risk Reduction in Older Adults: A Review.. 2022, 7,	
664	Effect of Evolocumab on Coronary Plaque Phenotype and Burden in Statin-Treated Patients Following Myocardial Infarction.. 2022,	11
663	Biomedical consequences of elevated cholesterol-containing lipoproteins and apolipoproteins.	
662	Achievement of LDL-Cholesterol Goals after Acute Myocardial Infarction: Real-World Data from the City of Curitiba Public Health System.. 2022,	0
661	Exploring rates of PCSK9 inhibitor persistence and reasons for treatment non-persistence in an integrated specialty pharmacy model.. 2022,	0
660	Nitrates as a Marker of Multiple Co-morbidities and Increased Mortality in Patients Undergoing Percutaneous Coronary Intervention (PCI).. 2022, 14, e23520	0
659	Optimal low-density lipoprotein cholesterol target level in Korean acute myocardial infarction patients (. 2021,	1
658	Soluble lectin-like oxidized low-density lipoprotein receptor-1 predicts premature death in acute coronary syndromes.. 2022,	1
657	Differential cholesterol uptake in liver cells: A role for PCSK9.. 2022, 36, e22291	1
656	The LOX-1 receptor ectopically expressed in the liver alleviates atherosclerosis by clearing Ox-LDL from the circulation.. 2022, 28, 26	1
655	Effects of the Current Japanese Guideline for Dedicated, Intensive Lipid-lowering Therapy on Lipid Profile and Coronary Events in Patients After Acute Coronary Syndrome. 1,	
654	Real-world Insights into Evolocumab Use in Patients with Hyperlipidemia: Canadian Analysis from the ZERBINI Study. 2022,	0
653	Step-by-step diagnosis and management of the nocebo/drucebo effect in statin-associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP).	3
652	Effect of Alirocumab on Incidence of Atrial Fibrillation After Acute Coronary Syndromes: Insights from the ODYSSEY OUTCOMES Randomized Trial.. 2022,	
651	Cardiac Calcifications: Phenotypes, Mechanisms, Clinical and Prognostic Implications.. 2022, 11,	1

650	Drug Treatment of Hypercholesterolemia in Older Adults: Focus on Newer Agents.. 2022 , 39, 251	
649	Evidence for intensive LDL-C lowering for acute coronary syndrome: Recommendations from the Lipid Association of India.. 2022 ,	0
648	Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Beyond Lipids: The Role in Oxidative Stress and Thrombosis.. 2022 , 11,	2
647	Insight into the Evolving Role of PCSK9.. 2022 , 12,	3
646	Proprotein convertase subtilisin/kexin type 9 inhibitors in secondary prevention of vascular events in patients with stroke: Consensus document and practice guidance.. 2021 ,	
645	Effect of a PCSK9 inhibitor and a statin on cholesterol efflux capacity: A limitation of current cholesterol-lowering treatments?. 2022 , e13766	0
644	PCSK9 Inhibitors in Real-world Practice: Analysis of Data from 314 Patients and 2 Years of Experience in a Center of Preventive Cardiology.. 2022 , 1	1
643	Intracoronary Application of Super-Saturated Oxygen to Reduce Infarct Size Following Myocardial Infarction.. 2022 , 11,	1
642	ESC/EAS Guidelines for the detection, prevention, and treatment of individuals at risk of a first myocardial infarction: effect of 5 years of updates and the new SCORE2.. 2022 ,	1
641	Age- and sex-specific trends in the incidence of myocardial infarction in Denmark, 2005 to 2021.. 2022 , 346, 63-67	1
640	2022 focused update of the 2017 Taiwan lipid guidelines for high risk patients: Coronary artery disease, peripheral artery disease and ischemic stroke.. 2022 ,	1
639	Effect of Vupanorsen on Non-High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70.. 2022 ,	4
638	The Potential Clinical Benefit of Lowering Lipoprotein(a).. 2022 ,	0
637	Ten things to know about ten cardiovascular disease risk factors - 2022.. 2022 , 10, 100342	3
636	Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction: The PACMAN-AMI Randomized Clinical Trial.. 2022 ,	16
635	Metformin Ameliorates Hepatic Steatosis induced by olanzapine through inhibiting LXR/PCSK9 pathway.. 2022 , 12, 5639	0
634	Intravascular imaging assessment of pharmacotherapies targeting atherosclerosis: advantages and limitations in predicting their prognostic implications.. 2022 ,	0
633	Acute coronary syndromes.. 2022 , 399, 1347-1358	7

632 In Reply to Struikmans et al.. **2022**, 112, 1289-1290

631 [Modern lipid-lowering drugs-A means to counter the problem of undertreatment?]. **2022**,

630 Sex differences in low-density lipoprotein cholesterol reduction with PCSK9 inhibitors in real world patients: the LIPID-REAL Registry.. **2021**, 79, 1

629 Novel Pharmaceutical and Nutraceutical-Based Approaches for Cardiovascular Diseases Prevention Targeting Atherogenic Small Dense LDL.. **2022**, 14,

628 RSSDI consensus recommendations for dyslipidemia management in diabetes mellitus. 1 0

627 A proteomic surrogate for cardiovascular outcomes that is sensitive to multiple mechanisms of change in risk.. **2022**, 14, eabj9625 3

626 Efficacy and Safety of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors as Adjuvant Treatments for Patients with Hypercholesterolemia Treated with Statin: A Systematic Review and Network Meta-analysis.. **2022**, 13, 832614 1

625 Evaluation and management of blood lipids through a woman's life cycle.. **2022**, 10, 100333 0

624 Adoptive transfer of metabolically reprogrammed macrophages for atherosclerosis treatment in diabetic mice.. **2022**, 16, 82-94 0

623 Coronary Artery Calcium Measurement to Assist in Primary Prevention Decisions for Aspirin and Lipid-Lowering Therapies. **2021**, 14, 1

622 Warning: a short circuit has been detected in the prescription of PCSK9 inhibitors. **2021**, 33, 306-307

621 Kardiovaskuläre Hochrisikopatienten: Hilfe bei der LDL-C-Zielwerterreichung. **2021**, 21, 35-38

620 Consideration regarding the Analysis of Randomized Controlled Trials in the era of Evidence-Based Medicine.. **2021**, 0

619 Mechanism of Improving Aspirin Resistance: Blood-Activating Herbs Combined With Aspirin in Treating Atherosclerotic Cardiovascular Diseases.. **2021**, 12, 794417 0

618 Clonal hematopoiesis and atherosclerotic cardiovascular disease: A primer. **2021**, 1

617 Application of proprotein convertase subtilisin/kexin type 9 inhibitor, evolocumab, in patients with severe hypertriglyceridemia.. **2021**,

616 Trimming the fat: is there a health economic case for the use of new lipid-lowering drugs in chronic kidney disease? A scoping review.

615 Lipoprotein(a)-The Crossroads of Atherosclerosis, Atherothrombosis and Inflammation.. **2021**, 12, 5

614	Guideline based eligibility for primary prevention statin therapy - Insights from the North India ST-elevation myocardial infarction registry (NORIN-STEMI).. 2021,	0
613	Hyperglycaemic disorders associated with PCSK9 inhibitors: a real-world, pharmacovigilance study.. 2021,	0
612	Alirocumab after acute coronary syndrome in patients with a history of heart failure.. 2021,	4
611	The "real world" is relative-and biased.. 2021,	
610	Long-term hospital-based secondary prevention of coronary artery disease: a randomized controlled trial.. 2021, 21, 600	0
609	Use of negative control outcomes to assess the comparability of patients initiating lipid-lowering therapies. 2021,	0
608	2021 Clinical Practice Guidelines for Diabetes Mellitus in Korea. 2021, 22, 244-249	3
607	Risk of remnants and remnant risk in peripheral artery disease. 2021,	0
606	Pharmacotherapy in Familial Hypercholesterolemia- Current State and Emerging Paradigms.. 2021,	
605	Implicating genes, pleiotropy and sexual dimorphism at blood lipid loci through multi-ancestry meta-analysis.	1
604	High cardiovascular risk patient T focus on results. Treatment of dyslipidemia in the clinical practice of a cardiologist, pediatrician, neurologist and endocrinologist. 2022, 26, 4798	
603	Software Application Profile: SUMnlmr, an R package that facilitates flexible and reproducible non-linear Mendelian randomisation analyses.	0
602	Therapeutic application of genome editing in dyslipidemia.. 2021, 33,	1
601	Multifocal atherosclerosis: focus on the prevention of ischemic events. 2022, 26, 4808	0
600	Kardiovaskulärer Risikofaktor Dyslipidämie. 2022, 1-14	
599	Treatment goals in familial hypercholesterolemia - time to consider LDL-cholesterol burden.. 2021,	0
598	Lipid lowering therapy in primary and secondary prevention in Austria: are LDL-C goals achieved? : Results from the DA VINCI study. 2021, 1	
597	Hypolipidemic Pharmacotherapy from the Latest Recommendations. 2020, 97-107	

596 Topical issues concerning modern lipid-lowering therapy. **2022**, 24, 20-27

595 Effect of PCSK9 inhibition with evolocumab on lipoprotein subfractions in familial dysbetalipoproteinemia (type III hyperlipidemia).. **2022**, 17, e0265838 1

594 Residual Risk of Coronary Atherosclerotic Heart Disease and Severity of Coronary Atherosclerosis Assessed by ApoB and LDL-C in Participants With Statin Treatment: A Retrospective Cohort Study.. **2022**, 13, 865863 1

593 Approach to patients with elevated low-density lipoprotein cholesterol levels.. **2022**, 101658

592 Lipid-lowering therapy and risk-based LDL-C goal attainment in Belgium: DA VINCI observational study.. **2022**, 1-10 0

591 Guía ESC 2021 sobre la prevención de la enfermedad cardiovascular en la práctica clínica. **2022**, 1 1

590 Die polyvaskuläre Erkrankung – eine Übersicht über die Datenlage und Managementstrategien. **2022**, 11, 147-153

589 Poor achievement of lipid targets after acute coronary syndrome: what can we improve?. **2022**,

588 No association between APOE genotype and lipid lowering with cognitive function in a randomized controlled trial of evolocumab.. **2022**, 17, e0266615 0

587 Systematic comparison of Mendelian randomization studies and randomized controlled trials using electronic databases. 0

586 Genetically proxied PCSK9 inhibition provides indication of lower prostate cancer risk: a Mendelian randomization study. 1

585 Residual Inflammatory Risk and its Association With Events in East Asian Patients After Coronary Intervention. **2022**, 0

584 Compounding Benefits of Cholesterol-Lowering Therapy for the Reduction of Major Cardiovascular Events: Systematic Review and Meta-Analysis.. **2022**, 101161CIRCOUTCOMES121008552 1

583 A Systematic Review of Cost-Effectiveness of Non-Statins Lipid-Lowering Drugs for Primary and Secondary Prevention of Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus.. **2022**, 101211 1

582 Image_1.tif. **2021**,

581 Table_1.docx. **2021**,

580 Table_1.DOCX. **2019**,

579 Table_1.DOCX. **2020**,

578 [Update on PCSK9 inhibition].. **2022**, 1

577 [Cost-benefit analysis of new lipid-lowering agents].. **2022**, 1

576 Comparison of Evolocumab and Ezetimibe, Both Combined with Statin Therapy, for Patients with Recent Acute Coronary Syndrome: A Cost-Effectiveness Analysis from the Chinese Healthcare Perspective.. **2022**, 1 0

575 Combining evidence from Mendelian randomization and colocalization: Review and comparison of approaches.. **2022**, 2

574 Elevated lipoprotein (a) levels and risk of peripheral artery disease outcomes: A systematic review.. **2022**, 1358863X221091320 0

573 The Functional Role of Lipoproteins in Atherosclerosis: Novel Directions for Diagnosis and Targeting Therapy.. **2022**, 13, 491-520 0

572 OUP accepted manuscript. 1

571 Smoking and Diabetes Attenuate Beneficial Effects of PCSK9 Inhibitors on Arterial Wall Properties in Patients with Very High Lipoprotein (a) Levels.

570 Familial hypobetalipoproteinemia and abetalipoproteinemia. **2022**, 465-480

569 Clinical strategies for reducing cholesterol levels. **2022**, 853-901

568 Familial hypercholesterolemia. **2022**, 501-524

567 The First Report of a Real-World Experience with PCSK9-Inhibitor in a Large Familial Hyperlipidemia and Very-High Risk Middle Eastern Population.

566 Cholesterol and alcohol. **2022**, 747-767 1

565 Effect of PCSK9 Inhibitor on Blood Lipid Levels in Patients with High and Very-High CVD Risk: A Systematic Review and Meta-Analysis.. **2022**, 2022, 8729003 1

564 Low-Density Lipoprotein Cholesterol Levels in Coronary Artery Disease Patients: Opportunities for Improvement.. **2022**, 2022, 7537510 0

563 New Treatment Targets and Innovative Lipid-Lowering Therapies in Very-High-Risk Patients with Cardiovascular Disease. **2022**, 10, 970 1

562 Non-coding RNA-Associated Therapeutic Strategies in Atherosclerosis.. **2022**, 9, 889743 0

561 2022 Prevention of chronic non-communicable diseases in Of the Russian Federation. National guidelines. **2022**, 21, 3235 11

- 560 Di'ao Xinxuekang Capsule Improves the Anti-Atherosclerotic Effect of Atorvastatin by Downregulating the SREBP2/PCSK9 Signalling Pathway.. **2022**, 13, 857092
- 559 Dyslipidemia and PCSK9 inhibitors - practical focused update of indication and reimbursement criteria. **2022**, 68, 191-194
- 558 Undertreatment or Overtreatment With Statins: Where Are We?. **2022**, 9, 808712 1
- 557 [Novel options to maximize oral lipid lowering treatment : Role of bempedoic acid in combination treatment].. **2022**, 1
- 556 European Stroke Organisation (ESO) Guideline on pharmacological interventions for long-term secondary prevention after ischaemic stroke or transient ischaemic attack. 239698732211000 5
- 555 Transient injection site reaction to alirocumab during immune system activation: a case series.. **2022**, 6, ytac187
- 554 Proprotein convertase subtilisin/kexin type 9 (PCSK9) levels in primary antiphospholipid syndrome. The multicenter ATHERO-APS study.. **2022**, 129, 102832
- 553 Long-term secondary prevention of cardiovascular disease with a Mediterranean diet and a low-fat diet (CORDIOPREV): a randomised controlled trial.. **2022**, 9
- 552 Optical Coherence Tomography, Near-Infrared Spectroscopy, and Near-Infrared Fluorescence Molecular Imaging. **2022**, 107-125
- 551 IDOL deficiency inhibits cholesterol-rich diet-induced atherosclerosis in rabbits.
- 550 Attainment of low-density lipoprotein cholesterol goals in patients treated with combination therapy: A retrospective cohort study in primary care.. **2022**, 0
- 549 PCSK9 inhibitors and ezetimibe with or without statin therapy for cardiovascular risk reduction: a systematic review and network meta-analysis.. **2022**, 377, e069116 3
- 548 Effect of Early Initiation of Evolocumab on Lipoprotein(a) in Patients with Acute Myocardial Infarction: Sub-Analysis of a Randomized Controlled Trial. **2022**, 9, 153 0
- 547 Secondary Prevention of Atherosclerotic Cardiovascular Disease. **2022**, 475-482
- 546 Effect of PCSK9 Monoclonal Antibody Versus Placebo/Ezetimibe on Atrial Fibrillation in Patients at High Cardiovascular Risk: A Meta-Analysis of 26 Randomized Controlled Trials.. **2022**, 1
- 545 Effect of PCSK9 Inhibitors on Hemostasis in Patients with Isolated Hypercholesterolemia.. **2022**, 11, 1
- 544 Cardio-Obstetrics: the Next Frontier in Cardiovascular Disease Prevention.. **2022**,
- 543 Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial Infarction.. **2022**, 79, 1660-1671 7

542	Management of Dyslipidemia in Patients with Non-Alcoholic Fatty Liver Disease.. 2022 , 1	3
541	Cellular and Molecular Aspects of Managing Familial Hypercholesterolemia: Recent and Emerging Therapeutic Approaches.. 2022 ,	0
540	Early Initiation of Evolocumab Treatment in Chinese Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.. 2022 ,	0
539	Lipid-Modifying Therapies and Stroke Prevention.. 2022 , 1	
538	Implications of ACC/AHA Versus ESC/EAS LDL-C Recommendations for Residual Risk Reduction in ASCVD: A Simulation Study From DA VINCI.. 2022 ,	0
537	Carotid ultrasonography improves residual risk stratification in guidelines-defined high cardiovascular risk patients.. 2022 ,	2
536	2022 Guideline for the Management of Patients With Spontaneous Intracerebral Hemorrhage: A Guideline From the American Heart Association/American Stroke Association.. 2022 , 101161STR00000000000000407	15
535	The Management of Cardiovascular Disease Risk in Patients with Rheumatoid Arthritis.. 2022 ,	
534	Lipoprotein(a) and its Significance in Cardiovascular Disease: A Review.. 2022 ,	8
533	Innate immune cells in the pathophysiology of calcific aortic valve disease: lessons to be learned from atherosclerotic cardiovascular disease?. 2022 , 117, 28	1
532	PCSK9 inhibition in patients with acute stroke and symptomatic intracranial atherosclerosis: protocol for a prospective, randomised, open-label, blinded end-point trial with vessel-wall MR imaging.. 2022 , 12, e060068	
531	A Comprehensive Review of PCSK9 Inhibitors.. 2022 , 27, 10742484221100107	3
530	Precision Medicine for Diabetes and Dyslipidemia. 2022 , 65-87	
529	Precision Medicine Approaches for Management of Type 2 Diabetes. 2022 , 1-52	
528	Topical issues of adequate control of dyslipidemia in the prevention of acute and recurrent cerebral circulatory disorders of ischemic type. 2022 , 122, 7	0
527	Attainment of Lipid Targets Following Coronary Artery Bypass Graft Surgery: Can We Do Better?. 2022 , 11, 187	0
526	Alirocumab and Lipid Levels, Inflammatory Biomarkers, Metabolomics, and Safety in Maintenance Dialysis Patients: The ALIDIAL Study (A Phase III Trial to Evaluate the Efficacy and Safety of Biweekly Alirocumab in Patients on a Stable Dialysis Regimen). 2022 , 100483	1
525	Existing and emerging strategies to lower Lipoprotein(a). 2022 , 349, 110-122	9

- 524 Lipoprotein (a) and diabetes mellitus. **2022**, 349, 63-71 8
- 523 Estrategias de tratamiento de las dislipemias en prevenci3n primaria y secundaria. Registro de la Sociedad Espa3ola de Arteriosclerosis. **2022**,
- 522 Clinical opportunities and healthcare impact of optimal treatment in the post-ACS patient. **2022**, 9, 17-26
- 521 Multi-ancestry GWAS deciphers genetic architecture of abdominal aortic aneurysm and highlights PCSK9 as a therapeutic target. 0
- 520 LDL-C: The Only Causal Risk Factor for ASCVD. Why Is It Still Overlooked and Underestimated?. 0
- 519 Benefits and drawbacks of statins and non-statin lipid lowering agents in carotid artery disease. **2022**, 0
- 518 Cost-Effectiveness Analysis of Evolocumab in Adult Patients with Atherosclerotic Cardiovascular Disease in Canada. 0
- 517 Experiencia con inhibidores PCSK9 desde una consulta de Nefrolog3a. **2022**, 0
- 516 Targeting PCSK9 Ameliorates Graft Vascular Disease in Mice by Inhibiting NLRP3 Inflammasome Activation in Vascular Smooth Muscle Cells. 13, 1
- 515 Evolocumab administration prior to Coronary Artery Bypass Grafting in patients with multivessel coronary artery disease (EVOCABG): study protocol for a randomized controlled clinical trial. **2022**, 23,
- 514 Significance of superficial macrophage cluster in coronary atherosclerotic plaque. **2022**,
- 513 Synergistic effect of the commonest residual risk factors, remnant cholesterol, lipoprotein(a), and inflammation, on prognosis of statin-treated patients with chronic coronary syndrome. **2022**, 20, 0
- 512 The potential of polygenic scores to improve cost and efficiency of clinical trials. **2022**, 13, 0
- 511 Lowering LDL cholesterol: from mechanisms to therapies.
- 510 Actualit3 dans la physiopathologie de l'ath3roscl3rose. **2022**, 2022, 26-34
- 509 Lipid Testing Trends Before and After Hospitalization for Myocardial Infarction Among Adults in the United States, 2008-2019. Volume 14, 737-748
- 508 Towards more personalized low-density lipoprotein-cholesterol lowering strategies in patients with atherosclerotic cardiovascular disease.
- 507 Drugs for lipid disorders, antiplatelet drugs and fibrinolytics. **2022**,

- 506 Qing-Xin-Jie-Yu Granule alleviates atherosclerosis by reshaping gut microbiota and metabolic homeostasis of ApoE^{-/-} mice. **2022**, 103, 154220 1
- 505 Managing residual inflammatory risk in atherosclerotic cardiovascular disease: another piece of the puzzle?. **2022**, 7, 1-2 0
- 504 Association of PCSK9 with inflammation and platelet activation markers and recurrent cardiovascular risks in STEMI patients undergoing primary PCI with or without diabetes. **2022**, 21, 0
- 503 The Efficacy and Underlying Mechanism of Berberine against Atherosclerosis: a Meta-analysis in Preclinical Animal Studies. **2022**, Publish Ahead of Print, 0
- 502 Inclisiran: Small Interfering Ribonucleic Acid Injectable for the Treatment of Hyperlipidemia. **2022**, 30, 214-219 0
- 501 Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Use for Atherogenic Dyslipidemia in Solid Organ Transplant Patients. **2022**, 11, 3247 0
- 500 Implication of Lipids in Calcified Aortic Valve Pathogenesis: Why Did Statins Fail?. **2022**, 11, 3331 1
- 499 Lipid profile of patients treated with evolocumab in Spanish hospital nephrology units (RETOSS NEFRO). **2022**, 0
- 498 Use of Lipid-Lowering Drugs After Intracerebral Hemorrhage. 1
- 497 PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis. **2022**, 21, 2
- 496 PCSK9 and Other Metabolic Targets to Counteract Ischemia/Reperfusion Injury in Acute Myocardial Infarction and Visceral Vascular Surgery. **2022**, 11, 3638 0
- 495 Rationale, Criteria, and Impact of Identifying Extreme Risk in Patients with Atherosclerotic Cardiovascular Disease. **2022**, 2, 114-123 0
- 494 Considerations for routinely testing for high Lp(a). **2022**, 33, 213-218 0
- 493 Non-Lipid Effects of PCSK9 Monoclonal Antibodies on Vessel Wall. **2022**, 11, 3625 0
- 492 Achievement of ESC/EAS LDL-C treatment goals after an acute coronary syndrome with statin and alirocumab. 1
- 491 NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient. **2022**, 3
- 490 Optimal cardiovascular medical therapy: current guidelines and new developments. 1-7 0
- 489 Identification of Key Genes as Early Warning Signals of Acute Myocardial Infarction Based on Weighted Gene Correlation Network Analysis and Dynamic Network Biomarker Algorithm. 13, 0

- 488 Chasing LDL cholesterol to the bottom [PCSK9 in perspective. **2022**, 1, 554-561 2
- 487 Revascularization in stable coronary artery disease. e067085 0
- 486 Regulatory Non-Coding RNAs in Familial Hypercholesterolemia, Theranostic Applications. 10, 0
- 485 Proprotein convertase subtilisin/kexin type 9 inhibition after acute coronary syndrome or prior myocardial infarction. **2022**, 33, 147-159 0
- 484 Dynamics of Life Quality in Patients with Myocardial Infarction in Combination with Critical Ischemia of the Lower Extremities under the Influence of Complex Treatment Using Arginine-carnitine Mixture and Standard Protocol Treatment. **2022**, 1-2, 8-13
- 483 Shining a Light on Plaque Vulnerability and Treatment. **2022**,
- 482 The Role of MicroRNAs in Hyperlipidemia: From Pathogenesis to Therapeutical Application. **2022**, 2022, 1-10 1
- 481 Effects of blood lipids and lipid-modifying drugs on intracranial aneurysms. 0
- 480 PCSK9 Inhibition Following Myocardial Infarction: A Right Time to Act. **2022**,
- 479 Neues in der Prävention des Schlaganfalls. **2022**, 9, 145-159
- 478 THE ROLE OF INFLAMMATION AND THE POSSIBILITIES OF INFLAMMATION REDUCTION TO PREVENT CARDIOVASCULAR EVENTS. 2
- 477 Vasculome. **2022**, 441-451
- 476 Elevated plasma proprotein convertase subtilisin/kexin type-9 is associated with poor prognosis of acute myocardial infarction in hypertension patients. **2022**, 20, 1721727X2211072
- 475 RNA therapies for cardiovascular disease. **2022**, 413-425
- 474 Achilles Tendon Thickening as a Risk Factor of Cardiovascular Events after Percutaneous Coronary Intervention. **2022**, 0
- 473 SAMSON and the Nocebo Effect: Management of Statin Intolerance. 1
- 472 A systematic review of racial/ethnic disparities in pharmacotherapy and surgical treatment outcomes in peripheral arterial disease among African American/non-Hispanic Black, non-Hispanic White and Hispanic patients. **2022**, 18, 100179
- 471 New Strategies for Lowering Low-Density Lipoprotein Cholesterol for Cardiovascular Disease Prevention. 0

470	Lipid Management. 2022 , 407-417	
469	Gene Expression Profiling of Markers of Inflammation, Angiogenesis, Coagulation and Fibrinolysis in Patients with Coronary Artery Disease with Very High Lipoprotein(a) Levels Treated with PCSK9 Inhibitors. 2022 , 9, 211	1
468	Lipoprotein(a) When to Screen and How to Treat.	
467	Adverse event profiles of PCSK9 inhibitors alirocumab and evolocumab: data mining of the FDA Adverse Event Reporting System.	1
466	Polygenic Risk Scores for Cardiovascular Disease: A Scientific Statement From the American Heart Association.	1
465	The absolute cardiovascular benefits of PCSK9 inhibitors and ezetimibe added to maximally tolerated statin therapy depend on individual baseline cardiovascular risk.	
464	MHR and NHR but not LHR were associated with coronary artery disease in patients with chest pain with controlled LDL-C. jim-2021-002314	
463	Critical Limb Ischemia: Update for the Cardiovascular Anesthesiologist. 2022 ,	0
462	Safety of Statins and Nonstatins for Treatment of Dyslipidemia. 2022 ,	0
461	Tratamiento de la hipertrigliceridemia con icosapento de etilo en pacientes de alto/muy alto riesgo cardiovascular. Documento de consenso de la Sociedad Española de Cardiología y Sociedad Española de Diabetes. 2022 ,	0
460	Directly Measured vs. Calculated Low-Density Lipoprotein Cholesterol Does Not Identify Additional Individuals With Coronary Artery Disease and Diabetes at Higher Risk of Adverse Events: Insight From a Large Percutaneous Coronary Intervention Cohort in Asia. 9,	
459	Carotid Artery Stenting. 2022 , 80, 155-170	2
458	Evaluation of Subclinical Vascular Disease in Diabetic Kidney Disease: A Tool for Personalization of Management of a High-Risk Population. 2022 , 12, 1139	1
457	New Therapeutic Approaches in Treatment of Dyslipidaemia Narrative Review. 2022 , 15, 839	0
456	Relationship between PCSK9 and Endothelial Function in Patients with Acute Myocardial Infarction. 2022 ,	1
455	Lipids, Lipid-Lowering Therapy, and Neuropathy: A Narrative Review. 2022 ,	
454	Serial Changes in Coronary Plaque Formation Using CT Angiography in Patients Undergoing PCSK9-Inhibitor Therapy With 1-year Follow-up. Publish Ahead of Print,	
453	PCSK9 Modulates Macrophage Polarization-Mediated Ventricular Remodeling after Myocardial Infarction. 2022 , 2022, 1-18	0

452	Evaluation and Management of Lipids and Lipoproteins in Children and Adolescents. 2022,	0
451	Is Our Increasing Understanding of PCSK9 and Lp(a) Metabolism the Key to Unlocking the Paradox of Statins Ineffectiveness in Reducing Cardiovascular Events in Advanced CKD?. 2022, 4,	
450	Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy.	
449	The DA VINCI study: is Ireland achieving ESC/EAS guideline-directed LDL-C goals?.	0
448	Antisense Oligonucleotides and Small Interfering RNA for the Treatment of Dyslipidemias. 2022, 11, 3884	2
447	Effects of Lipid Lowering Therapy Optimization by PCSK9 Inhibitors on Circulating CD34+ Cells and Pulse Wave Velocity in Familial Hypercholesterolemia Subjects without Atherosclerotic Cardiovascular Disease: Real-World Data from Two Lipid Units. 2022, 10, 1715	1
446	Dyslipidemia in Transplant Patients: Which Therapy?. 2022, 11, 4080	0
445	Rationale and Design of a Pragmatic Trial Aimed at Improving Treatment of Hyperlipidemia in Outpatients with Very High Risk Atherosclerotic Cardiovascular Disease: A PRagmatic Trial Of Messaging to Providers about Treatment of HyperLIPIDemia (PROMPT-LIPID). 2022,	0
444	LDL Cholesterol How Low Can We Go?. 2022,	0
443	Secular Trends in Risk Profiles Among Adults With Cardiovascular Disease in the United States. 2022, 80, 126-137	0
442	Metabolic analysis as a driver for discovery, diagnosis, and therapy. 2022,	3
441	Decoding microRNA drivers in atherosclerosis. 2022, 42,	0
440	Intensive lipid lowering agents and coronary atherosclerosis: Insights from intravascular imaging. 2022, 11, 100366	1
439	Activation of circulating monocytes by low-density lipoprotein—risk factor for osteoarthritis?.	
438	Effects of PCSK9 inhibitors on HDL cholesterol efflux and serum cholesterol loading capacity in familial hypercholesterolemia subjects: a multi-lipid-center real-world evaluation. 9,	1
437	Familial Hypobetalipoproteinemia Caused by Homozygous Loss-of-function Mutations in PCSK9: A Case Report. 2022,	1
436	PCSK9 Inhibitors in the Management of Cardiovascular Risk: A Practical Guidance. Volume 18, 555-566	3
435	Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome: the dal-GenE trial.	0

- 434 Inter-Individual Variability in Lipid Response: A Narrative Review. **2022**,
- 433 From the garden to the clinic: how Mendelian randomization is shaping up atherosclerotic cardiovascular disease prevention strategies. 1
- 432 Reduction of cardiovascular events with the use of lipid-lowering medication in patients with familial hypercholesterolemia or severe primary hypercholesterolemia: A systematic review. **2022**,
- 431 Inclisiran: How Widely and When Should We Use It?. 4
- 430 Emerging roles of the RNA modifications N6-methyladenosine and adenosine-to-inosine in cardiovascular diseases. **2022**, 0
- 429 Racial and Ethnic Differences in Pharmacotherapy to Prevent Coronary Artery Disease and Thrombotic Events. 2
- 428 Epidemiology of heart failure hospitalization in patients with stable atherothrombotic disease: Insights from the TRA 2°P-TIMI 50 trial. 0
- 427 Discovery and SAR analysis of phenylbenzo[d][1,3]dioxole-based proprotein convertase subtilisin/kexin type 9 inhibitors. **2022**, 37, 2017-2035 0
- 426 Effect of Novel Stratified Lipid Risk by LDL-Window and Flow-Mediated Dilatation on the Prognosis of Coronary Artery Disease Using the FMD-J Study A Data. **2022**, 0
- 425 Exploring Contemporary Data on Lipid-Lowering Therapy Prescribing in Patients Following Discharge for Atherosclerotic Cardiovascular Disease in the South of Italy. **2022**, 11, 4344
- 424 Differences in Comorbidities Explain Black-White Disparities in Outcomes After Femoropopliteal Endovascular Intervention. **2022**, 146, 191-200 0
- 423 Combination therapy in the guidelines: from high-intensity statins to high-intensity lipid-lowering therapies: Combination therapy in the guideline. **2022**, 1, 25-29 0
- 422 Lipid-lowering for the prevention of cardiovascular disease in the new era: A practical approach to combination therapy: Lipid-lowering and combination therapy. **2022**, 1, 30-36 0
- 421 Cardiovascular Disease. **2021**, 435-451
- 420 The pharmacology of cholesterol-lowering drugs: The pharmacology of cholesterol-lowering drugs. **2022**, 1, 2-13
- 419 Atherosclerosis risk factor management - what's new for the neurologist?. **2022**, 80, 88-93
- 418 PCSK9 Monoclonal Antibodies: New Developments and Their Relevance in a Nucleic Acid-Based Therapy Era. 1
- 417 An intensive, structured, mobile devices-based healthcare intervention to optimize the lipid-lowering therapy improves lipid control after an acute coronary syndrome. 9,

416	Considerations for routinely testing for high lipoprotein(a). Publish Ahead of Print,	
415	Cognitive function with evolocumab in pediatric heterozygous familial hypercholesterolemia. 2022 ,	0
414	Application possibilities of PCSK9 inhibitors in patients with coronary heart disease in combination with type 2 diabetes mellitus. 2022 , 21, 16-25	
413	2022 Consensus statement on the management of familial hypercholesterolemia in Korea.	
412	The prevalence of hyperlipidemia and features of lipid-lowering therapy in patients with myocardial infarction according to the Russian register of acute myocardial infarction REGION-MI. 2022 , 62, 12-22	1
411	Management of Dyslipidemia after Stroke. 2022 , 40, 217-227	1
410	Information and consensus document for the detection and management of chronic kidney disease. 2022 ,	0
409	Inflammation drives residual risk in chronic kidney disease: a CANTOS substudy.	0
408	There Is Urgent Need to Treat Atherosclerotic Cardiovascular Disease Risk Earlier, More Intensively, and with Greater Precision. A Review of Current Practice and Recommendations for Improved Effectiveness.. 2022 , 100371	2
407	Evolocumab enables rapid LDL-C reduction and inflammatory modulation during in-hospital stage of acute coronary syndrome: A pilot study on Chinese patients. 9,	0
406	Newer and Emerging LDL-C Lowering Agents and Implications for ASCVD Residual Risk. 2022 , 11, 4611	1
405	Ocular disorders associated with PCSK9 inhibitors: A pharmacovigilance disproportionality analysis.	
404	mRNA Display Reaches for the Clinic with New PCSK9 Inhibitor.	0
403	Programmable Genome-Editing Technologies as Single-Course Therapeutics for Atherosclerotic Cardiovascular Disease.	
402	Global research trends in atherosclerosis: A bibliometric and visualized study. 9,	0
401	2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk. 2022 ,	4
400	Systematic single-variant and gene-based association testing of thousands of phenotypes in 394,841 UK Biobank exomes. 2022 , 100168	0
399	Therapieoptionen zur LDL-C-Senkung zusätzlich zu Statinen. 2022 , 147, 1001-1012	

- 398 Coronary Artery Calcium-Based Approach to Lipid Management.
- 397 Role of thermogenic adipose tissue in lipid metabolism and atherosclerotic cardiovascular disease: lessons from studies in mice and humans. 1
- 396 Extent of LDL-cholesterol Reduction and All-cause and Cardiovascular Mortality Benefit: a Systematic Review and Meta-analysis. **2022**, Publish Ahead of Print,
- 395 First clinical and efficacy data on evolocumab in routine clinical practice in endocrinology and nutrition services in Spain: A retrospective observational study (RETOSS-ENDO). **2022**,
- 394 Coronary Artery Calcium Score to Refine the Use of PCSK9i in Asymptomatic Individuals: A Multicohort Study. **2022**, 11, 0
- 393 Biomarker Prediction of Complex Coronary Revascularization Procedures in the FOURIER Trial. **2022**, 80, 887-897 0
- 392 Software Application Profile: SUMnlmr, an R package that facilitates flexible and reproducible non-linear Mendelian randomization analyses.
- 391 Eradicating Atherosclerosis: Should We Start Statins at Younger Ages and at Lower LDL-Cs. 1
- 390 A polygenic risk score predicts atrial fibrillation in cardiovascular disease. 0
- 389 Clinical study of Repatha: it does not affect patients' cognitive function and significantly reduce blood lipid and prevent coronary atherosclerosis. 8, 365-371
- 388 LDL-C target attainment in secondary prevention of ASCVD in the United States: barriers, consequences of nonachievement, and strategies to reach goals. 0
- 387 Comorbidities Associated With Residual Cardiovascular Risk in Patients With Chronic Coronary Syndrome Receiving Statin Therapy: Subanalysis of the REAL-CAD Trial **2022**,
- 386 Impact of Low Baseline Low-Density Lipoprotein Cholesterol on Long-Term Postdischarge Cardiovascular Outcomes in Patients With Acute Myocardial Infarction. 1
- 385 Genotype-driven NPC1L1 and PCSK9 inhibition and reduced risk of periodontitis. 0
- 384 Mendelian Randomization Study of PCSK9 and HMG-CoA Reductase Inhibition and Cognitive Function. **2022**, 80, 653-662 1
- 383 Glucose control independent mechanisms involved in the cardiovascular benefits of glucagon-like peptide-1 receptor agonists. **2022**, 153, 1135-17
- 382 How can we optimise health technology assessment and reimbursement decisions to accelerate access to new cardiovascular medicines?. **2022**, 365, 61-68
- 381 Low-density lipoprotein cholesterol goal attainment in Germany: Results from the DA VINCI study. **2022**, 50, 10-16

- 380 Blood lipid levels and treatment following an acute coronary syndrome or coronary intervention □
Journey from hospital to cardiac rehabilitation. **2022**, 15, 200145
- 379 Smoking and diabetes attenuate beneficial effects of PCSK9 inhibitors on arterial wall properties in patients with very high lipoprotein (a) levels. **2022**, 50, 1-9 1
- 378 Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab. **2022**, 146, 657-672 2
- 377 PCSK9 Inhibition: From Current Advances to Evolving Future. **2022**, 11, 2972 6
- 376 Micellar Curcumin: Pharmacokinetics and Effects on Inflammation Markers and PCSK-9 Concentrations in Healthy Subjects in a Double-Blind, Randomized, Active-Controlled, Crossover Trial. 2200139 0
- 375 Assessment and management of statin-associated muscle symptoms (SAMS): A clinical perspective from the National Lipid Association. **2022**, 0
- 374 The role of coronary artery calcium in allocating pharmacotherapy for primary prevention of cardiovascular disease: The ABCs of CAC. 0
- 373 PCSK9 is minimally associated with HDL but impairs the anti-atherosclerotic HDL effects on endothelial cell activation. **2022**, 63, 100272 0
- 372 Tackling inflammation in atherosclerosis: Are we there yet and what lies beyond?. **2022**, 66, 102283 0
- 371 Paediatric patients with heterozygous familial hypercholesterolaemia treated with evolocumab for 80 weeks (HAUSER-OLE): a single-arm, multicentre, open-label extension of HAUSER-RCT. **2022**, 10, 732-740 0
- 370 The relationship between pulse pressure with plasma PCSK9 and interleukin-6 among patients with acute ischemic stroke and dyslipidemia. **2022**, 1795, 148080 0
- 369 Risk stratification and lipid evaluation in mexican patients, evidence of lipid and cardiovascular analysis in REMECAR. The mexican registry of cardiovascular diseases (REMECAR group). **2022**, 50, 32-39 0
- 368 Functions and therapeutic interventions of non-coding RNAs associated with TLR signaling pathway in atherosclerosis. **2022**, 100, 110471 0
- 367 Bioactive lipids in cardiovascular disease. **2023**, 77-99 0
- 366 Therapie von Begleiterkrankungen: Diabetes mellitus und Dyslipoproteinämie. **2022**, 211-225 0
- 365 2022 Consensus Statement on the Management of Familial Hypercholesterolemia in Korea. **2022**, 11, 213 0
- 364 Mechanisms of Lipoproteins and Reverse Cholesterol Transport in Atherosclerotic Cardiovascular Disease. **2022**, 343-365 0
- 363 Effects of Loading-Dose Statins Combined with PCSK9 Inhibitor Pre-Treatment before Primary Percutaneous Coronary Intervention on the Short-Term Prognosis in Patients with ST-Segment Elevation Myocardial Infarction. **2022**, 0

362	Evaluaci3n econ3mica de evolocumab en pacientes con enfermedad cardiovascular de alto riesgo con hipercolesterolemia primaria y dislipidemia mixta no controlados. 2022 , 33, 52-63	0
361	Aortic valve stenosis: drivers of disease progression and drug targets for therapeutic opportunities. 2022 , 26, 633-644	1
360	Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association. 2022 ,	2
359	Long-Term Evolocumab in Patients with Established Atherosclerotic Cardiovascular Disease.	11
358	Endophenotype effect sizes support variant pathogenicity in monogenic disease susceptibility genes. 2022 , 13,	0
357	Prolonged and Pronounced LDL-C Lowering: The Gift That Keeps Giving.	0
356	Cancer therapy's impact on lipid metabolism: Mechanisms and future avenues. 9,	0
355	Impact of early PCSK9 inhibitor treatment on heart after percutaneous coronary intervention in patients with STEMI: Design and rationale of the PERFECT II trial. 9,	0
354	The Level of Remnant Cholesterol and Implications for Lipid-Lowering Strategy in Hospitalized Patients with Acute Coronary Syndrome in China: Findings from the Improving Care for Cardiovascular Disease in ChinaAcute Coronary Syndrome Project. 2022 , 12, 898	0
353	Modulation of vascular endothelial inflammatory response by proprotein convertase subtilisin-kexin type 9. 2022 ,	1
352	Sex difference in circulating PCSK9 and its clinical implications. 13,	1
351	Big Data: Using Databases and Registries. 2022 ,	0
350	Evolving concepts of the vulnerable atherosclerotic plaque and the vulnerable patient: implications for patient care and future research.	2
349	A Decade On: The Evolving Renaissance in Intracranial Atherosclerotic Disease.	0
348	Low-Density Lipoprotein Cholesterol Levels on Statins and Cardiovascular Event Risk in Stable Coronary Artery Disease [An Observation From the REAL-CAD Study] 2022 ,	0
347	Myeloid TM6SF2 Deficiency Inhibits Atherosclerosis. 2022 , 11, 2877	0
346	The Clinical Importance of Differentiating Monogenic Familial Hypercholesterolemia from Polygenic Hypercholesterolemia.	0
345	Platelet Redox Imbalance in Hypercholesterolemia: A Big Problem for a Small Cell. 2022 , 23, 11446	1

344	Novel Insights into the Management of Patients with Very High Cardiovascular Risk Eligible for PCSK9 Inhibitor Treatment: Baseline Findings from the PERI-DYS Study.	0
343	Genetic proxies for PCSK9 inhibition associate with lipoprotein(a): Effects on coronary artery disease and ischemic stroke. 2022,	0
342	Guidance for the diagnosis and treatment of hypolipidemia disorders. 2022,	1
341	The Egyptian Association of Vascular Biology and Atherosclerosis (EAVA) Perspectives on the Usage of Inclisiran.	0
340	RNA modification by M6A methylation in cardiovascular diseases: Current trends and future directions. 2022, 2, 158-177	0
339	Recent Advances on the Roles of PCSK-9 Inhibitors in the Management of Acute Ischemic Stroke Patients. 2022, 23, 10221	0
338	Low LDL-C level and intracranial haemorrhage risk after ischaemic stroke: a prospective cohort study. svn-2022-001612	0
337	Pathogenic gain-of-function mutations in the prodomain and C-terminal domain of PCSK9 inhibit LDL binding. 13,	0
336	Part I: Interactive case: Hyperlipidemia management for special populations. 2022, 5, 1011-1015	0
335	Projected impact of treatment intensification with statin, ezetimibe, and statin plus ezetimibe fixed-dose combination on MACE across six countries.	1
334	Stroke genetics informs drug discovery and risk prediction across ancestries.	5
333	Effect of PCSK9 inhibitors on remnant cholesterol and lipid residual risk: The LIPID-REAL registry.	1
332	The First Report of a Real-World Experience With a PCSK9 Inhibitor in a Large Familial Hyperlipidemia and Very-High-Risk Middle Eastern Population. 2022,	0
331	PCSK9 Inhibitor Wars: How Does Inclisiran Fit in with Current Monoclonal Antibody Inhibitor Therapy? Considerations for Patient Selection.	3
330	Cardiac Alarmins as Residual Risk Markers of Atherosclerosis under Hypolipidemic Therapy. 2022, 23, 11174	0
329	Consider old and new approaches when treating dyslipidaemia.	0
328	Association between remnant lipoprotein cholesterol, high-sensitivity C-reactive protein, and risk of atherosclerotic cardiovascular disease events in the Multi-Ethnic Study of Atherosclerosis (MESA). 2022,	0
327	Lp(a): a New Pathway to Target?. 2022, 24, 831-838	0

326	Pathway analysis identifies novel non-synonymous variants contributing to extreme vascular outcomes in Williams-Beuren syndrome.	0
325	Network Meta-Analysis of Randomized Trials Evaluating the Comparative Efficacy of Lipid-Lowering Therapies Added to Maximally Tolerated Statins for the Reduction of Low-Density Lipoprotein Cholesterol. 2022 , 11,	3
324	Contemporary National Patterns of Eligibility and Use of Novel Lipid-Lowering Therapies in the United States. 2022 , 11,	0
323	Reduction of C-reactive protein, low-density lipoprotein cholesterol, and its relationship with cardiovascular events of different lipid-lowering therapies: A systematic review and meta-analysis of randomized controlled trials. 2022 , 101, e30563	0
322	Dietary 7-ketocholesterol exacerbates myocardial ischemia-reperfusion injury in mice through monocyte/macrophage-mediated inflammation. 2022 , 12,	1
321	Cold shock domain-containing protein E1 is a posttranscriptional regulator of the LDL receptor. 2022 , 14,	0
320	Impact of conventional lipid-lowering therapy on circulating levels of PCSK9: protocol for a systematic review and meta-analysis of randomised controlled trials. 2022 , 12, e061884	0
319	Estimated number and percentage of US adults with atherosclerotic cardiovascular disease recommended add-on lipid-lowering therapy by the 2018 AHA/ACC multi-society cholesterol guideline. 2022 , 21, 100201	0
318	Therapeutic potential of the Proprotein Convertase Subtilisin/Kexin family in vascular disease. 13,	0
317	Medical treatment of dyslipidemia in the elderly. 2022 , 1, 65-72	0
316	Randomized, Placebo-Controlled Phase 2b Study to Evaluate the Safety and Efficacy of Recombinant Human Lecithin Cholesterol Acyltransferase in Acute ST-Segment Elevation Myocardial Infarction: Results of REAL-TIMI 63B. 2022 , 146, 907-916	2
315	Cholesterol not particle concentration mediates the atherogenic risk conferred by apolipoprotein B particles [A Mendelian randomization analysis].	1
314	Hypercholesterolemia diagnosis, treatment patterns and target achievement in patients with acute coronary syndromes in Germany.	0
313	Association of Low-Density Lipoprotein Cholesterol Levels During Statin Treatment With Cardiovascular and Renal Outcomes in Patients With Moderate Chronic Kidney Disease. 2022 , 11,	0
312	Predictive worth of estimated glucose disposal rate: evaluation in patients with non-ST-segment elevation acute coronary syndrome and non-diabetic patients after percutaneous coronary intervention. 2022 , 14,	0
311	Circulating levels of PCSK9, ANGPTL3 and Lp(a) in stage III breast cancers. 2022 , 22,	0
310	A case-study of model-informed drug development of a novel PCSK9 anti sense oligonucleotide. Part 1: First time in man to phase II.	0
309	Impact of psychological status on cardiovascular diseases: Is it time for upgrading risk score charts?. 2022 , 359, 42-43	0

- 308 A novel, orally bioavailable, small-molecule inhibitor of PCSK9 with significant cholesterol-lowering properties in vivo. **2022**, 100293 ○
- 307 Evolocumab for prevention of microvascular dysfunction in patients undergoing percutaneous coronary intervention: the randomised, open-label EVOCATION trial. **2022**, 18, e647-e655 ○
- 306 Cholesterol: how to measure and how to treat. **2022**, 33, 402-410 ○
- 305 Novel Therapeutic Strategies to Reduce Reperfusion Injury After Acute Myocardial Infarction. **2022**, 47, 101398 ○
- 304 Fenofibrate add-on to statin treatment is associated with low all-cause death and cardiovascular disease in the general population with high triglyceride levels. **2022**, 137, 155327 ○
- 303 Dislipidemia Aterogenik pada Pasien Diabetes Melitus Tipe 2: Patofisiologi dan Pilihan Terapi. **2021**, 34, 5-14 ○
- 302 Abordagem atual das dislipidemias. **2022**, 20-31 ○
- 301 Pathogenesis of Coronary Artery Disease in Chronic Kidney Disease: Strategies to Identify and Target Specific Populations. **2022**, 189-198 ○
- 300 Peripheral Arterial Atherogenesis. **2022**, 1-48 ○
- 299 Modulation of Plasma Lipidomic Profiles in Metastatic Castration-Resistant Prostate Cancer by Simvastatin. **2022**, 14, 4792 ○
- 298 Risk assessment of remotely fatal cardiovascular events after elective percutaneous coronary intervention. **2022**, 11, 40-50 ○
- 297 Electronic health record-based facilitation of familial hypercholesterolaemia detection Sensitivity of different algorithms in genetically confirmed patients. ○
- 296 Effect of evolocumab on fasting and post fat load lipids and lipoproteins in familial dysbetalipoproteinemia. **2022**, ○
- 295 Simulation study on LDL cholesterol target attainment, treatment costs, and ASCVD events with bempedoic acid in patients at high and very-high cardiovascular risk. **2022**, 17, e0276898 ○
- 294 Gaps and discontinuation of statin treatment in Norway: potential for optimizing management of lipid lowering drugs. ○
- 293 Therapeutic Inertia in Lipid-Lowering Treatment Intensification: Digital Tools and Performance Management to the Rescue?. ○
- 292 Potential Cardiovascular Events Avoided with Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared with Ezetimibe Alone in Patients with Atherosclerotic Cardiovascular Disease Taking Maximally Tolerated Statins. ○
- 291 Efficacy and Safety of an Investigational Single-course CRISPR Base Editing Therapy Targeting PCSK9 in Non-human Primate and Mouse Models. 3

290	Lipid-Lowering Therapy Use and Intensification Among United States Veterans Following Myocardial Infarction or Coronary Revascularization Between 2015 and 2019.	0
289	Achievement of low-density lipoprotein cholesterol targets in Chinese patients with atherosclerotic cardiovascular disease after receiving statins and ezetimibe. 9,	0
288	Growth differentiation factor 15 and cardiovascular risk: individual patient meta-analysis.	3
287	Dual Therapy for Dyslipidemia: When Two May Be Better Than One. 2022,	0
286	Considerations for Use of Pharmacodynamic Biomarkers to Support Biosimilar Development (I) A Randomized Trial with PCSK9 Inhibitors.	2
285	Prognostic Impacts of LL-37 in Relation to Lipid Profiles of Patients with Myocardial Infarction: A Prospective Cohort Study. 2022, 12, 1482	1
284	Patterns of Lipid Lowering Therapy Use Among Older Adults in a Managed Care Advantage Plan in the United States. 089719002211288	0
283	Triglyceride-glucose index and non-culprit coronary plaque characteristics assessed by optical coherence tomography in patients following acute coronary syndrome: A cross-sectional study. 9,	0
282	Comparison of Estimated LDL Cholesterol Equations with Direct Measurement in Patients with Angiographically Confirmed Coronary Artery Disease. 2022, 9, 342	1
281	Additive effects of ezetimibe, evolocumab, and alirocumab on plaque burden and lipid content as assessed by intravascular ultrasound: A PRISMA-compliant meta-analysis. 2022, 101, e31199	2
280	Proprotein Convertase Subtilisin/Kexin 9 Promotes Macrophage Activation via LDL Receptor-Independent Mechanisms.	1
279	Lipid management to mitigate poorer postkidney transplant outcomes. Publish Ahead of Print,	0
278	Antihyperlipidemic Treatment Options in Statin Resistance and Intolerance. Publish Ahead of Print,	0
277	2022 ACC Expert Consensus Decision Pathway for Integrating Atherosclerotic Cardiovascular Disease and Multimorbidity Treatment: A Framework for Pragmatic, Patient-Centered Care. 2022,	0
276	A stepwise approach to prescribing novel lipid-lowering medications. 2022,	0
275	A practical guideline of genomics-driven drug discovery in the era of global biobank meta-analysis. 2022, 2, 100190	0
274	A Systematic Review on Attenuation of PCSK9 in Relation to Atherogenesis Biomarkers Associated with Natural Products or Plant Bioactive Compounds in In Vitro Studies: A Critique on the Quality and Imprecision of Studies. 2022, 19, 12878	0
273	Comparing Simvastatin Monotherapy V/S Simvastatin-Ezetimibe Combination Therapy for the Treatment of Hyperlipidemia: A Meta-Analysis and Review. 2022,	0

272	Inclisiran and cardiovascular events: a patient-level analysis of phase III trials.	6
271	Cholesterol lowering with inclisiran: a new chapter in the PCSK9 story book.	1
270	Comparing the Relationships of Genetically Proxied PCSK9 Inhibition With Mood Disorders, Cognition, and Dementia Between Men and Women: A Drug-Target Mendelian Randomization Study. 2022 , 11,	0
269	Long-term Management of Patients with Myocardial Infarction: An Updated Review. Publish Ahead of Print,	0
268	Dyslipidemia treatment strategies in primary and secondary prevention. Dyslipemia Registry of the Spanish Arteriosclerosis Society. 2022 ,	0
267	Bending the Cardiovascular Event Curve by Evaluating the Potential Impact of Achieving Low-Density Lipoprotein Cholesterol Goal Across a Large Health System Among Secondary Prevention Patients. 2023 , 186, 91-99	0
266	The impact of the PCSK-9/VLDL-Receptor axis on inflammatory cell polarization. 2023 , 161, 156077	1
265	Session Three: Innovating Beyond Glucose Control in Diabetes Care. 56-69	0
264	Thoughts on secondary prevention after percutaneous coronary intervention in Japan. 2018 , 4, 67-70	0
263	Guidelines, Clinical Evidence, and Real-Life Practice: How to Find Your Way in Managing Hypercholesterolaemia. 38-46	0
262	Update on the Management of Diabetic Dyslipidaemia. 53-61	0
261	Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: Efficacy and Safety in the Treatment of Hypercholesterolaemia. 88-97	0
260	Silencing YY1 Alleviates Ox-LDL-Induced Inflammation and Lipid Accumulation in Macrophages through Regulation of PCSK9/ LDLR Signaling. 2022 ,	0
259	Healthcare resource utilization and costs of cardiovascular events in patients with atherosclerotic cardiovascular disease in Germany [results of a claims database study. 1-20	0
258	Magnetic Resonance Imaging of Intraplaque Hemorrhage and Plaque Lipid Content With Continued Lipid-Lowering Therapy: Results of a Magnetic Resonance Imaging Substudy in AIM-HIGH. 2022 , 15,	0
257	Highlights of Cardiovascular Disease Prevention Studies Presented at the 2022 European Society of Cardiology Congress.	0
256	PCSK9 inhibitors in a renal transplant patient complicated with hepatitis B: A case report and literature review. 9,	0
255	Inclisiran in primary prevention: reality or fiction?.	0

- 254 Cost-Effectiveness of Evolocumab in Adult Patients with Atherosclerotic Cardiovascular Disease from Chinese Healthcare Perspective. ○
- 253 National Institute for Health and Care Excellence guidelines for lipid management. *heartjnl-2022-321414* 1
- 252 Treatment of hypertriglyceridaemia with icosapent ethyl in patients with high/very high cardiovascular risk. Consensus document of the Sociedad Española de Cardiología [Spanish Society of Cardiology] and the Sociedad Española de Diabetes [Spanish Diabetes Society]. **2022**, ○
- 251 The Year in Cardiothoracic and Vascular Anesthesia: Selected Highlights from 2022. **2022**, ○
- 250 Guidelines for the management of hyperlipidemia: How can clinicians effectively implement them?. **2022**, ○
- 249 Quantification of Utilization Management Barriers for Patients Initiating Therapy to Lower Lipid Levels. **2022**, 5, e2240513 ○
- 248 Optimal target of LDL cholesterol level for statin treatment: challenges to monotonic relationship with cardiovascular events. **2022**, 20, ○
- 247 Identification of PCSK9-like human gene knockouts using metabolomics, proteomics, and whole-genome sequencing in a consanguineous population. **2022**, 100218 ○
- 246 Lipoprotein(a) and Cardiovascular Disease in Chinese Population. **2022**, 2, 653-665 ○
- 245 Increased residual cardiovascular risk in U.S. veterans with moderately-elevated baseline triglycerides and well-controlled LDL-C levels on statins. 9, ○
- 244 Reduction of cerebrovascular and peripheral events with PCSK9 inhibitors: Does it just depend on the lowering of the low-density lipoprotein?. **2022**, 24, 134-137 ○
- 243 Statin associated muscle symptoms: An update and review. **2022**, ○
- 242 Kommentar zu den neuen Leitlinien (2021) der Europäischen Gesellschaft für Kardiologie (ESC) zur kardiovaskulären Prävention. ○
- 241 PCSK9 Inhibition and Risk of Diabetes: Should We Worry?. ○
- 240 PCSK9 Pleiotropism: In the Same Vein as Statins. **2022**, 131, 890-892 ○
- 239 Recent lipoprotein(a) trials. **2022**, 33, 301-308 ○
- 238 Safety of PCSK9 inhibitors. **2022**, 156, 113957 ○
- 237 Mechanisms of unusual response to lipid-lowering therapy: PCSK9 inhibition. **2022**, ○

- 236 Dyslipidemia in Chronic Kidney Disease. **2022**, 549-572 ○
- 235 Primary Prevention of Ischemic Stroke. ○
- 234 Real-World Analyses of the Treatment Conditions in Patients Initiating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor in Taiwan. **2022**, ○
- 233 Sex disparities and dyslipidemic control in a coronary rehabilitation program. **2023**, 370, 72-74 ○
- 232 Update on management of paediatric dyslipidaemia. **2023**, 30, 52-64 ○
- 231 PD-1/PD-L1 Blockade Accelerates the Progression of Atherosclerosis in Cancer Patients. **2023**, 48, 101527 ○
- 230 Hypolipidemic agents in the secondary prevention of the stroke. **2022**, 1, 96-102 ○
- 229 Randomized Trials Fit for the 21st Century. A Joint Opinion from the European Society of Cardiology, American Heart Association, American College of Cardiology, and the World Heart Federation. **2022**, 17, ○
- 228 Economic evaluation of PCSK9 inhibitors inclusion in the list of medicines for outpatient preferential drug provision («23 INNs» list) for secondary prevention of cardiovascular events. **2022**, 51, ○
- 227 Safety, adherence and efficacy of PCSK9 inhibitors: a retrospective real-world study. **2022**, 31, 201010582211461 ○
- 226 European, Russian and American Clinical Guidelines on dyslipidemias management – where do we stand? European, Russian, and US guidelines on dyslipidemias. **2022**, 1, 48-53 ○
- 225 Recomendaciones preventivas cardiovasculares. Actualización PAPPS 2022. **2022**, 54, 102444 ○
- 224 Bi-atrial versus left atrial ablation for patients with rheumatic mitral valve disease and non-paroxysmal atrial fibrillation (ABLATION): rationale, design and study protocol for a multicentre randomised controlled trial. **2022**, 12, e064861 ○
- 223 Current development of bicyclic peptides. **2022**, 108026 ○
- 222 Revisiting secondary prevention in coronary heart disease. **2022**, 74, 431-440 ○
- 221 Unmet Need for Further LDL-C Lowering in India despite Statin Therapy: Lipid Association of India Recommendations for the Use of Bempedoic Acid. **2022**, 70, 67-75 ○
- 220 Step-wise lipid-lowering therapy: thinking beyond the guidelines. **2022**, Publish Ahead of Print, ○
- 219 Angina in 2022: Current Perspectives. **2022**, 11, 6891 ○

218	Real-world safety of PCSK9 inhibitors: A pharmacovigilance study based on spontaneous reports in FAERS. 13,	0
217	PCSK9 inhibitors for anti-inflammation in atherosclerosis: protocol for a systematic review and meta-analysis of randomised controlled trials. 2022 , 12, e062046	1
216	Cardiorenal diseases in type 2 diabetes mellitus: clinical trials and real-world practice.	0
215	Secondary Prevention in Lower Extremity Artery Disease Patients: Lipid-Lowering Therapy and Long-Term Guideline Adherence. 2022 , 11, 6838	0
214	Review of Recent Laboratory and Experimental Data on Cardiotoxicity of Statins. 2022 , 9, 403	0
213	Management of diabetic dyslipidemia in Indians: Expert consensus statement from the Lipid Association of India. 2022 ,	0
212	Cholesterol Management in Neurology: Time for Revised Strategies?. 2022 , 12, 1981	0
211	A cVLP-Based Vaccine Displaying Full-Length PCSK9 Elicits a Higher Reduction in Plasma PCSK9 Than Similar Peptide-Based cVLP Vaccines. 2023 , 11, 2	1
210	Heparin Does Not Regulate Circulating Human PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) in a General Population.	0
209	Lipid-lowering therapies and cardiovascular risk-stratification strategies in adults with type 1 diabetes. Publish Ahead of Print,	0
208	Association of low-density lipoprotein cholesterol levels with the risk of mortality and cardiovascular events: A meta-analysis of cohort studies with 1,232,694 participants. 2022 , 101, e32003	0
207	Sex differences in LDL-C response to PCSK9 inhibitors: A real world experience. 2022 ,	0
206	The German Lipoprotein Apheresis Registry Summary of the ninth annual report.	0
205	Lipid-Lowering Trials Are Not Representative of Patients Managed in Clinical Practice: A Systematic Review and Meta-Analysis of Exclusion Criteria.	0
204	Acute Coronary Syndrome: Unravelling the Biology to Identify New Therapies. 2022 , 11, 4136	0
203	Association of PCSK9 Loss-of-Function Variants With Risk of Heart Failure.	0
202	Is a PCSK9 Inhibitor Right for Your Patient? A Review of Treatment Data for Individualized Therapy. 2022 , 19, 16899	0
201	10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes 2023. 2023 , 46, S158-S190	7

200	Understanding patient preferences for handheld autoinjectors versus wearable large-volume injectors. 1-11	0
199	Clinical and Coronary Plaque Predictors of Atherosclerotic Nonresponse to Statin Therapy. 2022,	1
198	Randomized trials fit for the 21st century. A joint opinion from the European Society of Cardiology, American Heart Association, American College of Cardiology, and the World Heart Federation.	0
197	Therapeutics in Metabolic Diseases. 2023, 255-273	0
196	LDL delivery of microbial small RNAs drives atherosclerosis through macrophage TLR8. 2022, 24, 1701-1713	0
195	The Potential of Nanoliposome-Encapsulated PCSK9 Vaccine for Active Immunization Against Atherosclerosis: A Review. 2023, 293-300	0
194	PCSK9 in Liver Cancers at the Crossroads between Lipid Metabolism and Immunity. 2022, 11, 4132	1
193	Translating atherosclerosis research from bench to bedside: navigating the barriers for effective preclinical drug discovery. 2022, 136, 1731-1758	0
192	2022 Consensus Statement on the Management of Familial Hypercholesterolemia in Korea. 2022, 97, 339-352	0
191	Randomized Trials Fit for the 21st Century. 2022,	0
190	Drug-Drug Interaction between Antiplatelet Therapy and Lipid-Lowering Agents (Statins and PCSK9 Inhibitors).	0
189	New opportunities for lowering low-density lipoprotein cholesterol: comparative characteristics of PCSK9-targeted therapy. 2022, 27, 5271	0
188	Qualitative and quantitative effects of PCSK9 inhibitors in familial hypercholesterolemia: a synthetic review. 2022, 101550	0
187	Trends in Lipid-Lowering Prescriptions: Increasing Use of Guideline-Concordant Pharmacotherapies, U.S., 2017-2022. 2022,	0
186	Pharmaco-invasive therapy: Early implementation of statins and proprotein convertase subtilisin/kexin type 9 inhibitors after acute coronary syndrome. 9,	0
185	Lipoprotein(a) and Atherosclerotic Cardiovascular Disease, the Impact of Available Lipid-Lowering Medications on Lp(a): An Update on New Therapies. 2022,	0
184	Effects of routine early treatment with PCSK9 inhibitors in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a randomised, double-blind, sham-controlled trial ; 2022, 18, e888-e896	0
183	Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on the number needed to treat. 9,	0

182	Atherosclerosis With Immune Checkpoint Inhibitor Therapy. 2022 , 4, 598-615	1
181	Targeting PCSK9 With Antibodies and Gene Silencing to Reduce LDL Cholesterol.	0
180	Effects of PCSK9 Inhibition on Coronary Atherosclerosis Regression of Nontarget Lesions after Primary Percutaneous Coronary Intervention in Acute Coronary Syndrome Patients. 2022 , 2022, 1-5	1
179	Fundamental Pathobiology of Coronary Atherosclerosis and Clinical Implications for Chronic Ischemic Heart Disease Management The Plaque Hypothesis.	2
178	Therapieoptionen zur LDL-C-Senkung zusätzlich zu Statinen. 2022 , 20, 376-385	0
177	Efficacy and Safety of Inclisiran in Patients with Polyvascular Disease: Pooled, Post Hoc Analysis of the ORION-9, ORION-10, and ORION-11 Phase 3 Randomized Controlled Trials.	5
176	An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors. 2023 , 2023, 1-11	0
175	Effect of evolocumab on the progression of intraplaque neovascularization of the carotid based on contrast-enhanced ultrasonography (EPIC study): A prospective single-arm, open-label study. 13,	1
174	Evolocumab como tratamiento de la dislipemia secundaria a lorlatinib. 2023 ,	0
173	Efficacy and safety of the use of alirocumab in real clinical practice. 2023 , 94, 1401-1406	0
172	Gene editing for dyslipidemias: New tools to cut lipids. 2023 ,	0
171	PCSK9 facilitates melanoma pathogenesis via a network regulating tumor immunity. 2023 , 42,	0
170	Peripheral Artery Disease (PAD). 2023 , 183-191	0
169	PCSK9 deficiency alters brain lipid composition without affecting brain development and function. 15,	0
168	Safety and Effectiveness of Alirocumab, a Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor, in Patients With Familial or Non-Familial Hypercholesterolemia A Post-Marketing Survey (J-POSSIBLE) 2023 ,	0
167	Association between genetically proxied PCSK9 inhibition and prostate cancer risk: A Mendelian randomisation study. 2023 , 20, e1003988	0
166	Atherosclerotic Cardiovascular Disease Prevention in the Older Adult: Part 2. 2023 , 67-138	0
165	Continuous Improvement of Antiplatelet Therapy in Cardiovascular Disease.	0

164	Oxidized low-density lipoprotein associates with cardiovascular disease by a vicious cycle of atherosclerosis and inflammation: A systematic review and meta-analysis. 9,	0
163	Efficacy, safety, adherence and persistence of PCSK9 inhibitors in clinical practice: A single country, multicenter, observational study (AT-TARGET-IT). 2023,	0
162	Highlights of Cardiovascular Disease Prevention Studies Presented at the 2022 American Heart Association Scientific Sessions. 2023, 25, 31-41	0
161	PCSK9 inhibition reduces low-density lipoprotein cholesterol and stabilizes the plaque in ischemic stroke patients with severe intracranial atherosclerotic stenosis.	0
160	Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial. 2023,	4
159	ORION-3: delivering lipid lowering treatment for longer. 2023,	0
158	Long-term persistence with evolocumab treatment and sustained reductions in LDL-cholesterol levels over 30 months: Final results from the European observational HEYMANS study. 2023,	0
157	Intensive lipid-lowering therapy for early achievement of guideline-recommended LDL-cholesterol levels in patients with ST-elevation myocardial infarction (Dena auf Ziel)	0
156	The Role of Monoclonal Antibodies in the Treatment of Atherosclerosis. 2023, 101585	0
155	The effect of the 2019 ESC/EAS dyslipidaemia guidelines on low-density lipoprotein cholesterol goal achievement in patients with acute coronary syndromes: The ACS EuroPath IV project. 2023, 148, 107141	0
154	Preclinical toxicity assessment of a peptide-based antiPCSK9 vaccine in healthy mice. 2023, 158, 114170	1
153	Imaging subclinical coronary atherosclerosis to guide lipid management, are we there yet?. 2023, 13, 100451	0
152	Validation of a predictive model for coronary artery disease in patients with diabetes. 2023, 24, 36-43	0
151	Restoring mortality data in the FOURIER cardiovascular outcomes trial of evolocumab in patients with cardiovascular disease: a reanalysis based on regulatory data. 2022, 12, e060172	3
150	Implicating genes, pleiotropy, and sexual dimorphism at blood lipid loci through multi-ancestry meta-analysis. 2022, 23,	0
149	Protein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies (PCSK9mab) in Clinical Practice at Secondary Care [Real World Multicentre Experience. 2022,	0
148	Acute LDL-C reduction post ACS: strike early and strike strong: from evidence to clinical practice. A clinical consensus statement of the Association for Acute CardioVascular Care (ACVC), in collaboration with the European Association of Preventive Cardiology (EAPC) and the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. 2022, 11, 939-949	3
147	Biomedical consequences of elevated cholesterol-containing lipoproteins and apolipoproteins on cardiovascular and non-cardiovascular outcomes. 2023, 3,	1

- 146 Rationale and design of a randomised double-blind 2x2 factorial trial comparing the effect of a 3-month intensive statin and antiplatelet therapy for patients with acute mild ischaemic stroke or high-risk TIA with intracranial or extracranial atherosclerosis (INSPIRES). svn-2022-002084 ○
- 145 ST-segment elevation myocardial infarction. **2023**, 13-33 ○
- 144 New Therapeutic Approaches to the Treatment of Dyslipidemia 1: ApoC-III and ANGPTL3. **2023**, 12, 23 ○
- 143 Targeting lipid metabolism in metastatic prostate cancer. **2023**, 15, 175883592311528 1
- 142 Real-World Use of Alirocumab: Experience from a Large Healthcare Provider. **2023**, 12, 1084 ○
- 141 Lipid Management in Korean People With Type 2 Diabetes Mellitus: Korean Diabetes Association and Korean Society of Lipid and Atherosclerosis Consensus Statement. **2023**, 12, 12 ○
- 140 Effect of Triglyceride-Glucose Indices and Circulating PCSK9-Associated Cardiovascular Risk in STEMI Patients with Primary Percutaneous Coronary Artery Disease: A Prospective Cohort Study. Volume 16, 269-282 ○
- 139 Multizonal observational study conducted by clinical practitioners on evolocumab use in subjects with hyperlipidemia in Saudi Arabia and Kuwait: Results from the ZERBINI study. **2023**, 18, e0278821 ○
- 138 Association between Low-density Lipoprotein Cholesterol and Sudden Cardiac Arrest in People with Diabetes Mellitus. ○
- 137 Association between Low-Density Lipoprotein Cholesterol Level and Cardiovascular Outcomes in Korean Adults: A Nationwide Cohort Study. **2023**, 47, 59-71 ○
- 136 Inclisiran Safety and Effectiveness of Small Interfering RNA in Inhibition of PCSK-9. **2023**, 15, 323 ○
- 135 From genetic variation to precision medicine. **2023**, 1, ○
- 134 Guideline LDL-C Threshold Achievement in Acute Myocardial Infarction Patients: A Real-World Evidence Study Demonstrating the Impact of Treatment Intensification with PCSK9i. ○
- 133 Introduction to polymeric nanomaterials. **2023**, 3-25 ○
- 132 Effect of Early Use of Envolocumab on Cardiovascular Events in Patients with Extremely-High-Risk Atherosclerotic Cardiovascular Disease after Percutaneous Coronary Intervention. **2023**, 13, 1346-1355 ○
- 131 Lipid Management in Korean People with Type 2 Diabetes Mellitus: Korean Diabetes Association and Korean Society of Lipid and Atherosclerosis Consensus Statement. **2023**, 47, 1-9 ○
- 130 Cardiovascular Outcomes according to Comorbidities and Low-Density Lipoprotein Cholesterol in Korean People with Type 2 Diabetes Mellitus. **2023**, 47, 45-58 ○
- 129 Optimal Low-Density Lipoprotein Cholesterol Level for Primary Prevention in Koreans with Type 2 Diabetes Mellitus. **2023**, 47, 42-44 ○

- 128 Lipid-Lowering Efficacy of Combined Lipid-Lowering Therapy and Its Effect on Glucose Metabolism. **2023**, 13, 1567-1573 ○
- 127 Tradeoffs in Approach to PAD Revascularization. **2023**, 81, 371-373 ○
- 126 Clinical potential of inclisiran for patients with a high risk of atherosclerotic cardiovascular disease. **2023**, 22, ○
- 125 Monoclonal Antibodies, Gene Silencing and Gene Editing (CRISPR) Therapies for the Treatment of Hyperlipidemia—The Future Is Here. **2023**, 15, 459 1
- 124 Efficacy of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Treatment for Repeated In-stent Restenosis in a Coronary Artery. **2023**, ○
- 123 Contemporary Aspects of Lp(a) Metabolism and Therapies Based on Tracer Kinetic Studies in Humans. **2023**, 91-111 ○
- 122 Lectin-Like Oxidized Low-Density Lipoprotein Receptor 1 Inhibition in Type 2 Diabetes: Phase 1 Results. **2023**, 12, ○
- 121 Residual risks and evolving atherosclerotic plaques. ○
- 120 Non-esterified fatty acids: Another piece in the puzzle of PAD risk stratification?. **2023**, 370, 1-2 ○
- 119 Combination Moderate-Intensity Statin and Ezetimibe Therapy for Elderly Patients With Atherosclerosis. **2023**, 81, 1339-1349 ○
- 118 Proprotein convertase subtilisin/kexin type 9 (PCSK9) in the central nervous system. **2023**, 105155 ○
- 117 The changing landscape of drug clinical trials on cardiometabolic diseases in China, 2009–2021. **2023**, 15, ○
- 116 Grado de consecución de los objetivos lipídicos a largo plazo en una cohorte de pacientes con síndrome coronario agudo en práctica clínica real. **2023**, 223, 223-230 ○
- 115 Inclisiran—A Revolutionary Addition to a Cholesterol-Lowering Therapy. **2023**, 24, 6858 ○
- 114 The evolving landscape of PCSK9 inhibition in cancer. **2023**, 949, 175721 ○
- 113 Two decades of vaccine development against atherosclerosis. **2023**, 50, 101822 ○
- 112 A double-edged sword of platelet-derived extracellular vesicles in tissues, injury or repair: The current research overview. **2023**, 82, 102066 ○
- 111 Disparities in statin prescription among patients with severe hypercholesterolemia in an integrated healthcare system. **2023**, 14, 100492 ○

- 110 How Low Can You Go? New Evidence Supports No Lower Bound to Low-Density Lipoprotein Cholesterol Level in Secondary Prevention. **2023**, 147, 1204-1207 ○
- 109 Impact of lipid lowering on coronary atherosclerosis moving from the lumen to the artery wall. **2023**, 367, 8-14 ○
- 108 Advances in the available pharmacotherapy for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. **2023**, 24, 453-471 ○
- 107 Vaccine Formulation Strategies and Challenges Involved in RNA Delivery for Modulating Biomarkers of Cardiovascular Diseases: A Race from Laboratory to Market. **2023**, 11, 241 ○
- 106 Secondary prevention after intracerebral haemorrhage. ○
- 105 New Drug Developments for Stroke: from Basics to Clinics. ○
- 104 Long-term cardiometabolic health in people born after assisted reproductive technology: a multi-cohort analysis. **2023**, 44, 1464-1473 ○
- 103 Remnant cholesterol, low-density lipoprotein cholesterol, and incident cardiovascular disease among Koreans: a national population-based study. ○
- 102 Pharmacometabolomics for the Study of Lipid-Lowering Therapies: Opportunities and Challenges. **2023**, 24, 3291 ○
- 101 Unexploited potential of risk factor treatment in patients with atherosclerotic cardiovascular disease. ○
- 100 Subclinical atherosclerosis burden in non-diabetic hypertensives treated in primary care center: the IMTABI study. **2023**, 24, ○
- 99 Awareness Among Primary Care Physicians in Canada of Guideline Recommendations for Lowering LDL-Cholesterol in High-Risk Patients. **2023**, ○
- 98 Association Between Achieved Low-Density Lipoprotein Cholesterol Levels and Long-Term Cardiovascular and Safety Outcomes: An Analysis of FOURIER-OLE. **2023**, 147, 1192-1203 1
- 97 Trends in LDL-C following coronary angiography involving assessment by fractional flow reserve in obstructive vs non-obstructive coronary artery disease. **2023**, 13, 100473 ○
- 96 Exploring the Active Compounds of Traditional Mongolian Medicine Baolier Capsule (BLEC) in Patients with Coronary Artery Disease (CAD) Based on Network Pharmacology Analysis, Molecular Docking and Experimental Validation. Volume 17, 459-476 ○
- 95 Therapeutic Strategies and Future Directions of Management for Patients with a History of Coronary Artery Bypass Grafting Who Require Secondary Coronary Revascularization. **2023**, 29, 1-7 ○
- 94 Statins and diabetes: What are the connections?. **2023**, 37, 101749 ○
- 93 High triglyceride-glucose index is associated with poor cardiovascular outcomes in Chinese acute coronary syndrome patients without diabetes mellitus who underwent emergency percutaneous coronary intervention with drug-eluting stents. 14, ○

92	A Web-based Application for Risk Stratification and Optimization in Patients with Cardiovascular Disease (STOP-CVD): Pilot Study (Preprint).	○
91	Real-World Outcomes of Proprotein Convertase Subtilisin Kexin-9 Inhibitors Use. 2023 , Publish Ahead of Print,	○
90	PCSK9 Inhibitor Use and Outcomes by Concomitant Lipid-lowering Therapies in the Veterans Health Administration. 2023 , 100035	○
89	Dyslipidemia Treatment and Lipid Control in US Adults with Diabetes by Sociodemographic and Cardiovascular Risk Groups in the NIH Precision Medicine Initiative All of Us Research Program. 2023 , 12, 1668	○
88	Association between low-density lipoprotein cholesterol and sudden cardiac arrest in people with diabetes mellitus. 2023 , 22,	○
87	Antithrombotic therapy and bleeding risk in the era of aggressive lipid-lowering: current evidence, clinical implications, and future perspectives. 2023 , 136, 645-652	○
86	Clonal hematopoiesis and atherosclerotic cardiovascular disease: A primer. 2023 , 35, 35-41	○
85	A Systematic Review of Lipid Management in Secondary Prevention and Comparison of International Lipid Management Pathways. 2023 ,	○
84	The importance of low-density lipoprotein cholesterol measurement and control as performance measures: A joint clinical perspective from the National Lipid Association and the American Society for Preventive Cardiology. 2023 , 13, 100472	○
83	Safety and Effectiveness of Evolocumab During Acute and Sub-acute Phases of Acute Coronary Syndrome (ACS): A Systematic Review and Meta-analysis. 2023 ,	○
82	Systolic blood pressure, low-density lipoprotein cholesterol levels, and adverse kidney outcome: results from KNOW-CKD.	○
81	The importance of low-density lipoprotein cholesterol measurement and control as performance measures: A joint Clinical Perspective from the National Lipid Association and the American Society for Preventive Cardiology. 2023 , 17, 208-218	○
80	Treatment with PCSK9 Inhibitor Evolocumab Improves Vascular Oxidative Stress and Arterial Stiffness in Hypercholesterolemic Patients with High Cardiovascular Risk. 2023 , 12, 578	○
79	Trends in Prevalence, Risk-Factors Controls and Medications in ASCVD Among US Adults, 1999-2018.	○
78	Therapy of Elevated Lipoprotein(a). 2023 , 347-357	○
77	Benefits of Bempedoic Acid [Clearer Now. 2023 , 388, 1425-1426	○
76	Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. 2023 , 388, 1353-1364	4
75	PCSK9 inhibitor, ezetimibe, and bempedoic acid: Evidence-based therapies for statin-intolerant patients. 2023 ,	○

- 74 Baseline inflammatory status affects the prognostic impact of statins in patients with peripheral arterial disease. ○
- 73 Colesterol remanente, riesgo vascular y prevención de la arteriosclerosis. **2023**, ○
- 72 Transient very low LDL-C levels: a legacy effect for cardiovascular prevention?. **2023**, 44, 1418-1420 ○
- 71 Lipid-lowering Efficacy and Safety of High Doses of Atorvastatin and Rosuvastatin. **2023**, 63, 59-67 ○
- 70 Medical Therapy After CABG: the Known Knowns, the Known Unknowns, and the Unknown Unknowns. ○
- 69 Lipid management in ischaemic stroke or transient ischaemic attack in China: result from China National Stroke Registry III. **2023**, 13, e069465 ○
- 68 PCSK9 Inhibitors Reduce PCSK9 and Early Atherogenic Biomarkers in Stimulated Human Coronary Artery Endothelial Cells. **2023**, 24, 5098 ○
- 67 Effect of PCSK9 inhibition in combination with statin therapy on intracranial atherosclerotic stenosis: A high-resolution MRI study. 15, ○
- 66 Analysis of The Use of PCSK9 Inhibitors in Clinical Practice. **2023**, 19, 43-49 ○
- 65 Inflammatory Activity in Patients with Obstructive and Non-obstructive Coronary Artery Disease. **2023**, 19, 26-33 ○
- 64 The Role of the Meaning of Life and its Relationship with the Attitude towards Death in Patients with Myocardial Infarction in the Intensive Care Unit. **2022**, 8, 382-389 ○
- 63 Genetics, Safety, Cost-Effectiveness, and Accessibility of Injectable Lipid-Lowering Agents: A Narrative Review. **2023**, 2023, 1-9 ○
- 62 Effect of PCSK9 on atherosclerotic cardiovascular diseases and its mechanisms: Focus on immune regulation. 10, ○
- 61 Secondary Cardiovascular Prevention after Acute Coronary Syndrome: Emerging Risk Factors and Novel Therapeutic Targets. **2023**, 12, 2161 ○
- 60 The Association Between PCSK9 Inhibitor Use and Sepsis: A Systematic Review and Meta-Analysis of 20 Double-Blind, Randomized, Placebo-Controlled Trials. **2023**, ○
- 59 Macrophage-Targeted Nanomedicines. **2023**, 193-240 ○
- 58 Statin Treatment and the Alterations in the Platelet Lipidome: What Is the Impact of Lipid Profile on Thrombosis?. ○
- 57 Role of percutaneous coronary intervention in the modern-day management of chronic coronary syndrome. heartjnl-2022-321870 ○

- 56 Achievement Rates for Low-Density Lipoprotein Cholesterol Goals in Patients at High Risk of Atherosclerotic Cardiovascular Disease in a Real-World Setting in Japan. **2023**, ○
- 55 Inclisiran: present and future perspectives of a new effective LDL cholesterol-lowering agent. Publish Ahead of Print, ○
- 54 Achievement of long-term lipid targets in a cohort of patients with acute coronary syndrome in real-world clinical practice. **2023**, 223, 223-230 ○
- 53 Effect of rosuvastatin 20 mg versus rosuvastatin 5 mg plus ezetimibe on statin side-effects in elderly patients with atherosclerotic cardiovascular disease: Rationale and design of a randomized, controlled SaveSAMS trial. **2023**, 261, 45-50 ○
- 52 Role of plaque imaging for identification of vulnerable patients beyond the stage of myocardial ischemia. 10, ○
- 51 Attainment of the low-density lipoprotein cholesterol treatment target and prognosis of heterozygous familial hypercholesterolemia. **2023**, 371, 61-66 ○
- 50 Proline/serine-rich coiled-coil protein 1 inhibits macrophage inflammation and delays atherosclerotic progression by binding to Annexin A2. **2023**, 13, ○
- 49 Lipid lowering combination therapy: From prevention to atherosclerosis plaque treatment. **2023**, 190, 106738 ○
- 48 Baseline Lipoprotein(a) Levels and Long-Term Cardiovascular Outcomes After Acute Myocardial Infarction. **2023**, 38, ○
- 47 Anti-Inflammatory Effects of Lipid-Lowering Drugs and SupplementsA Narrative Review. **2023**, 15, 1517 ○
- 46 Recent Trials on the Cardioprotective Effects of New Generation Anti-diabetic and Lipid-Lowering Agents. **2023**, 117-167 ○
- 45 Challenges with PCSK9 Inhibitors Use in Asia Given Real-World Data Implications. **2023**, ○
- 44 Uptake of non-statin lipid-lowering therapies for secondary prevention in community practice. **2023**, ○
- 43 Management of Statin Intolerant Patients in the Era of Novel Lipid Lowering Therapies: A Critical Approach in Clinical Practice. **2023**, 12, 2444 ○
- 42 Small Interfering Ribonucleic Acid as Lipid-Lowering Therapy: Inclisiran in Focus. **2023**, 24, 6012 ○
- 41 Exploring the common pathogenesis of calcific aortic valve disease and atherosclerotic cardiovascular disease through bioinformatics analysis. ○
- 40 Disparities in PCSK9 Initiation Among US Veterans with Peripheral Arterial Disease or Cerebrovascular Disease. ○
- 39 Effect of in-hospital evolocumab therapy on lipoprotein(a) in patients with acute myocardial infarction: a retrospective cohort study and a propensity score matching analysis. Publish Ahead of Print, ○

- 38 Association between lipid levels and all-cause and cause-specific mortality in critically ill patients. **2023**, 13, ○
- 37 Lipidmanagement 2022 Von der Tradition zur Innovation. **2023**, 12, 132-136 ○
- 36 Genetic association of lipids and lipid-lowering drug target genes with non-alcoholic fatty liver disease. **2023**, 90, 104543 ○
- 35 Proprotein convertase subtilisin kexin type 9 inhibitors and other novel lipid-modifying drugs: broadening the perspective of cardiovascular disease prevention. **2023**, 427-440 ○
- 34 Lipids, atherosclerosis, and microvascular disease: Translating basic science into pharmacotherapeutics. **2023**, 97-135 ○
- 33 Gene transfer and genome editing for familial hypercholesterolemia. 3, ○
- 32 Evolving Diagnostic and Management Advances in Coronary Heart Disease. **2023**, 13, 951 ○
- 31 Efficacy and safety of moderate-intensity statin with ezetimibe combination therapy in patients after percutaneous coronary intervention: a post-hoc analysis of the RACING trial. **2023**, 58, 101933 ○
- 30 Modern possibilities of intensive treatment of dyslipidemia and gaps in its control: literature review. **2023**, 13, 168-175 ○
- 29 A review on the efficacy and safety of lipid-lowering drugs in neurodegenerative disease. **2023**, ○
- 28 Moderate-Intensity Rosuvastatin Plus Ezetimibe Versus High-Intensity Rosuvastatin for Target Low-Density Lipoprotein Cholesterol Goal Achievement in Patients With Recent Ischemic Stroke: A Randomized Controlled Trial. ○
- 27 Untargeted Lipidomic Profiling Reveals Lysophosphatidylcholine and Ceramide as Atherosclerotic Risk Factors in apolipoprotein E Knockout Mice. **2023**, 24, 6956 ○
- 26 Diagnosis and Management of Large Artery Atherosclerosis. **2023**, 29, 486-500 ○
- 25 The Efficacy of PCSK9 Inhibitors in Treating Hypercholesterolemia Caused by Lorlatinib: A Report of Two Cases.. **2023**, ○
- 24 Ischemic stroke caused by large-artery atherosclerosis: a red flag for subclinical coronary artery disease. 14, ○
- 23 Revascularization and Medical Therapy for Chronic Coronary Syndromes: Lessons Learnt from Recent Trials, a Literature Review. **2023**, 12, 2833 ○
- 22 Recurrent Atherosclerotic Cardiovascular Disease Events Potentially Prevented with Guideline-Recommended Cholesterol-Lowering Therapy following Myocardial Infarction. ○
- 21 Person-Centered Cardiology. **2023**, 501-538 ○

- 20 The Cardio-Kidney Patient: Epidemiology, Clinical Characteristics and Therapy. **2023**, 132, 902-914 ○
- 19 Lipid-lowering therapy in patients with coronary artery disease undergoing percutaneous coronary interventions in Italy: an expert opinion paper of Interventional Cardiology Working Group of Italian Society of Cardiology. **2023**, 24, e86-e94 ○
- 18 Patients with higher-atherothrombotic risk vs. lower-atherothrombotic risk undergoing coronary intervention with newer-generation drug-eluting stents: an analysis from the randomized BIOFLOW trials. ○
- 17 Response by O'Donoghue et al to Letter Regarding Article, Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease. **2023**, 147, 1258-1259 ○
- 16 Letter by Zhou et al Regarding Article, Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease. **2023**, 147, 1256-1257 ○
- 15 Geographic and ethnic variations in response to lipid-lowering therapies: why do they matter?. ○
- 14 Medical Management of Dyslipidemia for Secondary Stroke Prevention: Narrative Review. **2023**, 59, 776 ○
- 13 Familial Hypercholesterolemia: Challenges for a High-Risk Population. **2023**, 81, 1621-1632 ○
- 12 PCSK9 Inhibitors and Coronary Atherosclerosis: Insights From Recent Intravascular Imaging Clinical Trials. 3, ○
- 11 Evincumab-dgnb (Evkeeza-REGN1500), A Novel Lipid-Lowering Therapy for Homozygous Familial Hypercholesterolemia. Publish Ahead of Print, ○
- 10 Soluble PCSK9 Inhibition: Indications, Clinical Impact, New Molecular Insights and Practical Approach. Where Do We Stand?. **2023**, 12, 2922 ○
- 9 A bibliometric analysis and visualization of literature on non-fasting lipid research from 2012 to 2022. 14, ○
- 8 Updated guidelines for the management of dyslipidemia and the prevention of cardiovascular disease in adults by pharmacists. 171516352311649 ○
- 7 Understanding the molecular mechanisms of statin pleiotropic effects. ○
- 6 PCSK9 Inhibition Regulates Infarction-Induced Cardiac Myofibroblast Transdifferentiation via Notch1 Signaling. ○
- 5 Acute coronary syndromes: hospital management of dyslipidaemia with proprotein convertase subtilisin/kexin 9 inhibitors: time to act. **2023**, 25, B114-B118 ○
- 4 Lipid treatment status and goal attainment among patients with premature acute coronary syndrome in Israel. **2023**, ○
- 3 Lipide: Diagnostik und Therapie bei Diabetes mellitus (Update 2023). **2023**, 135, 157-160 ○

- 2 The addition of evolocumab to maximal tolerated statin therapy improves walking performance in patients with peripheral arterial disease and intermittent claudication (Evol-PAD study). **2023**, ○
- 1 Hallmarks of cardiovascular ageing. ○